var title_f30_15_30960="Polypectomy short stalk Endosc";
var content_f30_15_30960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Resection of a pedunculated colonic polyp with a short stalk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 126px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) 2 cm polyp in the descending colon, note the short stalk; (B) prophylactic injection of epinephrine solution 1:20.000; (C) polypectomy in toto; (D) resection site after polypectomy: a non-bleeding vessel is visible; (E) prophylactic placement of hemoclips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Uwe Seitz, MD, Sabine Bohnacker, MD, and Nib Soehendra, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30960=[""].join("\n");
var outline_f30_15_30960=null;
var title_f30_15_30961="Laparoscopic cystectomy a";
var content_f30_15_30961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Laparoscopic ovarian cystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ovarian cortex is incised in the direction of the ovarian axis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30961=[""].join("\n");
var outline_f30_15_30961=null;
var title_f30_15_30962="Retrorectal avascular space";
var content_f30_15_30962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Retrorectal avascular space for posterior mobilization of the rectum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 505px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the dissection of the rectum in the retrorectal avascular space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30962=[""].join("\n");
var outline_f30_15_30962=null;
var title_f30_15_30963="Genetic testing for breast and ovarian cancer";
var content_f30_15_30963=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/15/30963/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30963/contributors\" id=\"au5650\">",
"       Beth N Peshkin, MS, CGC",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30963/contributors\" id=\"au4183\">",
"       Suzanne W Fletcher, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30963/contributors\" id=\"au5575\">",
"       Claudine Isaacs, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/15/30963/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30963/contributors\" id=\"se4959\">",
"       Daniel F Hayes, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30963/contributors\" id=\"se2252\">",
"       Benjamin A Raby, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/15/30963/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30963/contributors\" id=\"de3439\">",
"       Rosemary B Duda, MD, MPH, FACS",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/15/30963?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Having a strong family history of breast or ovarian cancer can increase your risk of developing these cancers. A strong family history means that: &nbsp;",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Multiple family members have breast or ovarian cancer, or",
"      </li>",
"      <li>",
"       A family member has both breast and ovarian cancer, or",
"      </li>",
"      <li>",
"       More than one generation of your family has breast or ovarian cancer",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In many instances, women with breast or ovarian cancer were diagnosed before age 50. &nbsp;",
"    </p>",
"    <p>",
"     Genetic testing can tell if you have inherited an abnormal gene that increases the risk of breast and ovarian cancer. If you test positive for a gene alteration (or mutation), there are things you can do to decrease your risks.",
"    </p>",
"    <p>",
"     However, genetic testing is not perfect. Most women with breast cancer",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a family history of breast cancer do",
"     <strong>",
"      not",
"     </strong>",
"     have an abnormal gene, and not all women who have inherited one of these genes will develop cancer.",
"    </p>",
"    <p>",
"     This article will discuss who should consider genetic testing, issues to consider before you have testing, and what you can do after testing to reduce your risk. More detailed information about genetic testing is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"      \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS GENETIC TESTING?",
"     </span>",
"    </p>",
"    <p>",
"     Cancer develops because of mutations in one or more genes. Genes hold information about how you look and how your body works, and genes are passed from parents to children. If there is an abnormality in a gene, this is called a genetic mutation.",
"    </p>",
"    <p>",
"     There are two types of genetic mutations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Germline mutations are inherited, passed from parent to child. Between 5 and 10 percent of breast cancers are caused by germline mutations, such as those in BRCA1 and BRCA2. These mutations increase the risk of developing breast and ovarian cancer.",
"       <br/>",
"       <br/>",
"       Most genetic testing for breast and ovarian cancer analyzes these two genes for mutations. The test is done on a mouthwash sample (to obtain cheek cells) or a sample of blood.",
"      </li>",
"      <li>",
"       Acquired mutations are not inherited, but instead develop during your lifetime. Acquired mutations can be caused by exposure to environmental agents such as radiation, chemicals (including those found in tobacco smoke), or viruses; they can also develop without a known cause. Most cancers, including breast cancer, are caused by acquired mutations.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WHO SHOULD CONSIDER GENETIC TESTING?",
"     </span>",
"    </p>",
"    <p>",
"     Genetic counseling and testing should be considered for women who have:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Multiple close family members affected with breast or ovarian cancer, particularly if the relative was diagnosed with cancer at an early age (less than 50 years old). Close family members include your mother, sister, or daughter; close family members can include men with breast cancer.",
"      </li>",
"      <li>",
"       A close family member with more than one cancer, such as breast cancer involving both breasts or breast and ovarian cancer",
"      </li>",
"      <li>",
"       Multiple generations of close family with cancer (eg, grandmother, mother, sister). Family history on the father's side is as important as the mother's side. It is also important to know the cancer history of your cousins on both sides of your family.",
"      </li>",
"      <li>",
"       Other cancers in addition to breast and ovarian cancer in women can be suggestive of hereditary cancer. For example, it is important to know if there are relatives with pancreatic, prostate, colon, or male breast cancer. &nbsp;",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     BRCA testing should be initiated with an individual who has cancer, whenever possible. Usually this would mean testing a woman with ovarian cancer or breast cancer diagnosed at the youngest age within the family. If a mutation is not found, it is often not helpful to test family members without cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      GENETIC TESTING",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Pretest counseling",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before you have genetic testing, you must think about the medical, emotional, practical, and financial effects of testing on both you and your family. You should discuss these issues with a certified genetic counselor, if possible, to understand what is involved in genetic testing. A list of certified genetics counselors and their phone numbers is available through the National Cancer Institute (",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/genetics/directory\">",
"      www.cancer.gov/cancertopics/genetics/directory",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Costs and insurance coverage",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because the BRCA genes are large and include hundreds of different mutations, testing can be expensive. In the United States, most health insurance companies will cover most of the costs. Your doctor or genetic counselor might need to write a letter to explain why testing is needed.",
"    </p>",
"    <p>",
"     Many people are worried about how the results of genetic testing will affect the chance of getting health or life insurance in the future. In the United States, a federal law known as the",
"     <a class=\"external\" href=\"file://www.genome.gov/10002328\">",
"      Genetic Information Nondiscrimination Act (GINA)",
"     </a>",
"     prohibits health insurers and employers from using your genetic information. This law is intended to encourage Americans to take advantage of genetic testing if needed. In general, the law means that:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Employers cannot deny you a job or fire you because of the results of genetic testing.",
"      </li>",
"      <li>",
"       Health insurers cannot use genetic testing results to deny you coverage or set your insurance rates.",
"      </li>",
"      <li>",
"       Employers and insurers cannot require you to have genetic testing.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The law does not have provisions for disability, life insurance, or long term care insurance. In addition, GINA does not apply to individuals in the military State laws may provide additional coverage.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Posttest counseling",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most doctors and genetic counselors prefer to discuss the results of genetic testing in person. During this meeting, you can discuss your test results, ask questions about what the results mean, and ask what you can do to decrease your risk of cancer.",
"    </p>",
"    <p>",
"     If you test positive for a BRCA1 or BRCA2 mutation, talk to your family about the results. Some family members will want to talk to their doctor or nurse about having genetic testing.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      INTERPRETING THE RESULTS",
"     </span>",
"    </p>",
"    <p>",
"     It is not always easy to interpret the results of genetic tests. The results may be:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Positive for a BRCA1 or BRCA2 mutation. This means that a mutation was identified that is known to be associated with increased risks for cancer.",
"      </li>",
"      <li>",
"       Negative, meaning that you do not have a BRCA mutation. This result does not rule out the possibility that you may have a hereditary risk for cancer. &nbsp; Not every mutation is detected by BRCA testing. In addition, there are many unknown genetic mutations that have not yet been discovered.",
"      </li>",
"      <li>",
"       A &ldquo;true&rdquo; negative result means that a BRCA1 or BRCA2 mutation present in one or more of your family members was ruled out in you. This result usually means that your cancer risks are about the same as other women in the general population.",
"      </li>",
"      <li>",
"       Positive for a genetic mutation with \"unknown significance.\" This means that you have a genetic mutation, but it is not clear if the mutation increases your risk of breast or ovarian cancer.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A negative result does not mean that you will not develop cancer and a positive result does not mean that you will develop cancer.",
"    </p>",
"    <p>",
"     If you test positive for a BRCA mutation:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Your lifetime risk of breast cancer is between 55 and 85 percent for BRCA1 and 50 to 85 percent for BRCA2. This means that in a group of 100 women with BRCA1, between 55 and 85 of the women will develop breast cancer in their lifetime.",
"      </li>",
"      <li>",
"       The lifetime risk of ovarian cancer is 35 to 46 percent for BRCA1 and 13 to 23 percent for BRCA2 [",
"       <a class=\"abstract\" href=\"mobipreview.htm?30/15/30963/abstract/1\">",
"        1",
"       </a>",
"       ] &nbsp;",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Test result interpretation can be complex. Sometimes &ldquo;negative&rdquo; results are more difficult to interpret than &ldquo;positive&rdquo; results. It is important to discuss what test results mean with a genetic counselor and your doctor.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      REDUCING YOUR RISK OF CANCER",
"     </span>",
"    </p>",
"    <p>",
"     If you test positive for a BRCA mutation, there are several ways to screen for cancer and to reduce your risk of developing cancer: &nbsp;",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Have more frequent screening for breast and ovarian cancer",
"      </li>",
"      <li>",
"       Have surgery to reduce your risk",
"      </li>",
"      <li>",
"       Take a medicine to reduce your risk",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The best strategy might include a combination of these methods (",
"     <a class=\"graphic graphic_table graphicRef69530 \" href=\"mobipreview.htm?19/43/20155\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     If you test negative for a BRCA mutation but have a strong family history of breast or ovarian cancer, talk to your doctor or nurse about ways to reduce your risk of developing cancer. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"      \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Breast cancer screening",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have inherited a BRCA mutation are usually advised to have more frequent screening for breast cancer. This includes:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A monthly breast self-exam (BSE) beginning at age 18. You should learn how to perform BSE; instructions are provided in the table (",
"       <a class=\"graphic graphic_table graphicRef53792 \" href=\"mobipreview.htm?36/43/37563\">",
"        table 2",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       A breast exam, performed by your doctor or nurse, every six months beginning at age 25.",
"      </li>",
"      <li>",
"       A mammogram once per year, beginning at age 25 (or individualized based on family history).",
"      </li>",
"      <li>",
"       A breast MRI, which is typically done alternating with a mammogram every six months, beginning at age 25 or individualized based on family history.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Ovarian cancer screening",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have inherited a BRCA mutation have an increased risk of developing ovarian cancer. However, screening tests for ovarian cancer are not very accurate in detecting the disease. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/15/6386?source=see_link\">",
"      \"Patient information: Ovarian cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     However, ovarian cancer screening is an option if you have a BRCA mutation. Screening includes a combination of a blood test and a pelvic ultrasound. Some experts recommend this combination of tests every six months, beginning at age 35 or 5 to 10 years before the youngest relative was diagnosed with breast or ovarian cancer. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/15/6386?source=see_link\">",
"      \"Patient information: Ovarian cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;An alternative to frequent cancer screening is surgery to reduce the risk of developing cancer. This is called preventive surgery, and it can significantly decrease your risk of cancer and may help you to feel less anxious. Talk to your doctor about the potential risks and benefits of preventive surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Mastectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have both breasts removed (called prophylactic bilateral mastectomy) reduce their chance of developing breast cancer by at least 90 percent.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Removal of the ovaries",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having the ovaries and fallopian tubes removed (termed a prophylactic bilateral salpingo-oophorectomy, or BSO) has been shown to reduce the risk of ovarian and fallopian tube cancer by 80 to 90 percent and breast cancer by 50 to 60 percent (for premenopausal women). The benefits of this surgery are greatest in women who have surgery before menopause, particularly before age 40, after you finish having children. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34202?source=see_link\">",
"      \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Medicines to reduce the risk of cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;A medicine called tamoxifen can reduce the risk of breast cancer in women who have BRCA mutations, although the degree of reduction is not clear for women without a history of breast cancer (see",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/31/499?source=see_link\">",
"      \"Patient information: Medications for the prevention of breast cancer (Beyond the Basics)\"",
"     </a>",
"     ). However, the amount of risk reduction is unclear for women without a history of breast cancer. &nbsp;",
"    </p>",
"    <p>",
"     Hormonal birth control (pill, skin patch, vaginal ring, shot, implant) can decrease the risk of ovarian cancer. Data suggest that this is also true for women with a BRCA mutation. In addition, there is a concern that hormonal birth control may increase the risk of breast cancer, particularly in BRCA1 mutation carriers. If you have a BRCA mutation, talk to your doctor or nurse about the risks and benefits of hormonal birth control.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413417581\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H256645\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/26/27043?source=see_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/1/11283?source=see_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/14/27874?source=see_link\">",
"      Patient information: Ovarian cancer screening (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H256652\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/15/6386?source=see_link\">",
"      Patient information: Ovarian cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/31/499?source=see_link\">",
"      Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5064?source=see_link\">",
"      Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"       <br/>",
"       <br/>",
"       <a class=\"external\" href=\"file://cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional\">",
"        (cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Society of Clinical Oncology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cancer.net/patient/All+About+Cancer/Genetics/Genetic+Testing\">",
"        www.cancer.net/patient/All+About+Cancer/Genetics/Genetic+Testing",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Facing Our Risk of Cancer Empowered (FORCE)",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.facingourrisk.com/\">",
"        www.facingourrisk.com",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/15/30963?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30963/abstract/1\">",
"      Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_15_30963=[""].join("\n");
var outline_f30_15_30963=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS GENETIC TESTING?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WHO SHOULD CONSIDER GENETIC TESTING?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           GENETIC TESTING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           INTERPRETING THE RESULTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           REDUCING YOUR RISK OF CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/43/20155\" title=\"table 1\">",
"           Options breast ovar ca PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/43/37563\" title=\"table 2\">",
"           Breast self-exam PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_15_30964="H pylori on crypt cells Light";
var content_f30_15_30964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Helicobacter pylori adherence on gastric surface cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of surface and foveolar epithelium shows numerous",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    organisms lining the surface of the cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30964=[""].join("\n");
var outline_f30_15_30964=null;
var title_f30_15_30965="Urethral anatomy";
var content_f30_15_30965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Urethral anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The male urethra is divided into two major segments: the anterior urethra and the posterior urethra. From proximal to distal, the urethra is initially eccentrically placed toward the dorsum of the penis becoming centrally located at the fossa navicularis.",
"    <ul>",
"     <li>",
"      The anterior urethra begins at the meatus of the penis and includes the fossa navicularis, the pendulous urethra and the bulbar urethra. The pendulous urethra is delineated from the bulbar urethra at the suspensory ligament of the penis.",
"     </li>",
"     <li>",
"      The posterior urethra includes the membranous urethra, prostatic urethra and the bladder neck.",
"     </li>",
"    </ul>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30965=[""].join("\n");
var outline_f30_15_30965=null;
var title_f30_15_30966="Survivor bias";
var content_f30_15_30966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Survivor bias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this case-control study, cases are drawn from a hospital population. Out of all those with disease in the hospital (16 blue circles), 4 cases agree to be part of the study (shaded square). These 4 may represent a biased sample in that those with severe disease or those who die before being approached for participation are not represented. Out of all those with no disease in the general population, 4 controls agree to be part of the study. By comparing these 4 cases and 4 controls, any genes found to be selectively enriched (or depleted) in the cases may be linked to occurrence of the disease but may also be linked to severity or survival.",
"    <br>",
"     In a prospective study, blood is taken at baseline so that even if someone develops disease and dies before recruitment into a case-control study could happen they are still represented in the cohort study, ie, the cases are more representative.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30966=[""].join("\n");
var outline_f30_15_30966=null;
var title_f30_15_30967="Origin of dyspnea sensation";
var content_f30_15_30967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Efferent and afferent signals that contribute to the sensation of dyspnea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 647px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKHAfEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiub+I95rlh4K1S48Jx20uuqiraJcMApYuq9yAWwTtBOC2B3ryXSfi3e6JZajDqra7qWuC8s7BNN1XTktpLeWYSEOWtkYvGwTICoX+XAzuGAD36ivJIvilr9y2gafb+DXj1zVXvohBfXMloi/ZlRvMXzIQ5R1kyMqpGMH1GU/xznbS9B1JfD8dpp2oWi3Et5fXEqwJIZWjMIkjhcA5XO6TYMEUAe4UV5Vb/FeeTXkifRY10abVLrR4LgXZM5ngVmLNFswqEqQDuJHUjmoLP4v3aeFND8Ua54bTTfD2p3EUJuhqIlMCurfvGURj5QyheSPvA+1AHrlFYPgTXLjxN4R0vW7vTzp0l/CJ1tjL5pRGJKEttXkrtbGOM4561vUAfP/AIp+N+t6Hq3jfTRpNpNcafI8ejMI32zGJVkuPOO/nZGwfjbwDXTR/GKK10DTry90i6u5I9Gs9W1eWzKLHZrcKMbVdtzc7jtGSAOpNdq/gjQXt9ehey3LrbSveFnJZjJH5T7T1TKDHy4rOvfhd4TvYrCK40+UxWlpDYCNbqVFngix5ccyqwEqggHD5oA52L4szWl745l1rRJ49G8PSpHDcwPGzTF9gjQrvzucyAqcAAfeIPFW7j4t21lvttQ0DVY9Zi1SDSZdNiaKSQSTRNLEytvCMrKvqOevrW1e+CfCV7rmtpdxLJea3aj7dYm8cLPGpVRL5IbAIKoBIACD0IJOX2nw48N2yW222uZZoNRj1X7RPdyyzSXMaFEd5GYswCkgKTj2oA6jT55Lqwtria2ltZZYlke3lILxEgEo2CRkdDgkcVYoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKWtaVYa5pk+navZwXtjOAJIJ0DI+CCMg+hAI9wKxoPAPhSDR7rSo/D+nf2fdMHniaEN5rD7rMTySOxzkdsV01Q3sUk9ncRQymGWSNlSVRkoSMBh9OtAGDpPhLwxpM1rJpumWVvLprSvEyfehMqgSEnPVgqgk9gKqR/DjwWwsHTw9prpaIq2/7vcoQMXUejAMxIznrXlNv8KtbTwvaaX/AMI3oEV7YvC95eJeEnXlSdZHil/d5CuFyS+7BwBxmr9j8J9SnXQINWsrFdJTXb3UptMinJisraaIqkCEBcgNyQoA+Y9qAPSdN0TwbdeKdVv7DT9NfXbZzHezJGPMjd0BOfRmUjJHJHU1F4n8CaR4j+H48J2jLY6IxiG21AYeWkgfapPTJXr1Feaa18INTe88f2+g2GmWMeteTJZX6TbWCK0TS2zrsJCuUYk8gnGQcmqy/CrX/wDhHTYaZaDRNRm1RbyG/a/iY6diPbI0SW8MKrvACbAMEZJxxQB9BwRRwQxwwoqRRqERFGAoAwAKfXO/DvS5NF8E6Pps2mwaZNawLFJbQSeYisOrBu+45bJ5555roqAPFH8O+KP+El8SPNp+rza3dXV0+ka2mpBbO0t2hZYUaLzM/K2AV8s5J3Zrmh4S8eDwprUOlWWuaY8mn6fA8E+piWa4v0uUa4uInErbVMYbJyu707V7T46uJ4V0CK2mkia41e2jby2IZlBLsvHYhDn2zW9Pf20LFZJV3jqq/M35Dmi9gSvsePax8P7/AE34n2Go6JbavdW50Wezhv5NSeQ2140pdJJt8m5owCeMMCcfKcAjnPCXhTxfYaRrq6xZeKJLybSDBJDHeIqz3okUpNHN9pdt/wB4ltqLjII6A+/f2ta56zf9+X/wpkmqx4PkxSv7kbB+vP6UuZFckuxyPwd07xHpumapF41NzPrzXZeW9aYSQ3CbRsMIGNiqOCuByCec16BWR/ak/wDz7Rj6yn/4mm/2lc5z5cOPTcf50udD9nI2aKyP7Vn/AOfaP/v6f/iacmqvn97bkD1Rwf5gUc6D2cjVoqpbX8E7hAxSTsjjBP09fwq3VXuS1bcKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyln440268cXHhhI5xdRK2JyB5Ujqqs0anOSwDgkY4wa6s5xx1rzaz+F/2S503UE126bWLbUHv5bhkJjmLk+Yoj3fLuXapOTwtRPm05Trw0aDUvbO2mnr39P8AMs2HxMtb2PUpotIvha2EdxJJKZIefJViwC793O3A4xzUY+KNqPD76xJo98lrmFYx5sLNJ5udvAc7en8WP51Z0r4cafYeHdZsM2smoait0n9o/Y1EsazAjGc5IGem4Z9qh1L4Z2E/gi20Gwaysp0FuZ7xLFSbloh96RQRuySTyT949c1H7yx23y/mt0uu+3V/19xauvH629vpJ/sS+e61OSWOG3SaAn92ASS2/bjGe/aq1x8T9OXTfD15aaffXI1tZzBHmONl8ogOGLsAO+OecfSodQ+GMGrWOjWerXVm1rYSTs8NnYLbJKJVxgKrYQg855yar3vwwu7zTfDVtPrdnO2hrNHEbnS1mjljcKqh4y+CVC9e/B6jJTdT+vkOEcv05n3v8X963/tv/B6bd58QdOsfEOl6Pf29xb3GoWaXaOxUohbdiNmBxuJQjjIJxg1RuviXHDpui38egapPa6s0cVs6GLmVywWM5fr8p9vepdX+HcOsSyPf3iHfo8elhYbYRiORHLrMgDfLg9EHTGM1L/wgf/FNeFNI/tL/AJAV9Be+b5H+v8ot8uN3y53dcnGOhp/vDNfUUot79d7bPVfOyNHxJ4ug8O+HrPU9Ts7iKS6ljgS2ZkDLI+cK7E7FAwcsTgYrN1Lx6+m6HDqd3oN75clyLXEU8EgJbbsZWD4ZWLYyOhU5xW/4r0ibW9MW0guLaAeYGkFzaLcxSqAfkZGI4yQcgg8VxT/C2WPw0NJsdZit1kv/AO0Zm+xZTeNu1Y0Eg2KNvTJJ9acue+hGHWEcV7XR31+Lb5f8E35/GUz6vcaZpWhX2oXdlFHJeqksSC3LjcI9zNhnx2HHvVXUPiTpWn63qOlXdtdxXNnYm9w4UCTEXmGMc/f2g8H+6eao+KPhm2tzahIurRwDU0hN8j2QlVpY12iWL5wY2wSOrde9O1v4XWurW+txz37Kb+K0SBxD81s0CMm773zbgxBHHBIpP2nQ1hHAac76dL3vpfy76Lou5o678RNK0ZdAa6huSurRpMCgBFtGxQB5OeFy4GfrW1a+ILe58V32grFKLm0t47h5DjYQ5wAOc5rkNR+FcGqR3S6lrF05bTodOtxEpjWJI1HLDcd4MgD44xgD3q5aeCtasvEEerWviWIXDWkFpc+Zp+/zhH1bPmfKW/GmnO+qIlTwThaM/es972vpbp0V0WtD8eQ63rMtnpmnTzW0Vw1tJP58QZGXgsYt28Jnvj8K7OuBT4eGXxXZ63f6hbSSWs5uEa3sEt55DzgSyq3zgZ/ujNd9VQ5vtHNi1QTXsNra77/Pf7kFFFFWcgUUUUAFFFFABWR4p0ix1zR5rPUmaKPIkjnjbZJbyKcrIjfwsp5B/wD1VZvtQW3by418yYjO3OAvuT2rKkLzPvuH8xgcgYwq/Qf5NS5JFxg3qZPhjxddPNLoetRq+u2ibjKo8uK8hzhZ0B6Z6Mo+63HQqT0B1G6I4EKn6Fv6iub8U6ENZtoZLab7Jqtm/nWV2BkxSYwQR/EjD5WXuD2IBDPDGvjVbWaO+iFlqtmwivbVm/1b9ip/iRhyrdx6EEDNyZqoJaFfxpLPda34PgnmLK+qszIqgDC2ly2fXGQo69/eukRFRQqKFUdgMCuG8Qa9YS+NPDEUUrS+S9zM3lrkZERTqeCPn7e1dFNrXzKILdju4zKwTJ9B1zUykluVG3Q2aK5ebV7sXBS5cWYPKBFDbh9SOv4Cpp7m8hUSG9do8cgRKT9elZ+1QzoqK5tdTfGV1FSfR0X+gFOttbmlB5tdwJXGSM+9HtIgdFSVkW2tI5PnxGMKdrOrblB9+4/KtSOWOUZjkRx/stmrUk9gHOiupV1DD0IqSGe4gP7udiv92T5h+fX9abRTvYGk9y9BqoBxdJsH99Tlfx7itNGDqGUgg8gjvXO063mltGzBzH/FETwfp6H9P51an3MpU+x0NFQWtzFcx7omz6g8EH0IqetTHY5nxT4th8P6hY2TWVxdT3iu6CN0UALjOS7Ad6qXvjmK31ldMTS7uW58mOZgJIlCh+gyzjJHtmn+M/B7eI9U069S7tYms0kTyrmyFyj78clSwHGKfb+DLM+I31bUltL5jbRQJFJaLtjZP41yTjPoBx611x9goJy3t573/wAjJ899CG08dwXWq39nDpt2Usp5oJZjJEBuiBLYXduI49O/1qC0+IdtP4evdZOmXkdnbRLLkvEWcMwXAAYkde+KuaT4JsrF9ankFtPfahdXFxHdNbKJLdZRjYGySQMnuM5PArGsvhvJbeF9Q0U6lZ7LqFIvPi01Y5PlcNl2D5f05PerX1Z/h3+Yv3hp/wDCe2iaZrV1c2F7BLpIiNxbtsLYkxt2lWKng+vFMvviBa6foMerX2m3kUEl0tqEVo5G5Qvu+ViMAA8darf8K7WHRdd0ix1IQabqZR1iNvuMEgK7iDuGQdv3e3HPrZtvBDJp+nWk93ZbLTUUv8W2nrAsgVCpVlDYJOfve2MUWw2/n57WX63D94T3Xje3S21O4srC7voNPYGaSBkxsMfmeYMsMrj8a0tE8QLqWgvq09jdWNqIvPXztrF49u7eApPbt1rH0bwHDpOjeI9Ntb1vI1YSLHujz9nVkKgdfmxn26V0Wmaa+n+HLTS4rk+Zb2iWy3AQZyqBQ+05HbOOayqextaH67W/zKjzdTn9J8bnVLCa+tNHuZbVYTMjR3EDMQOoYB/kbHOD6EdaIfHUVzp+lTW2lXsl3qjN9ktd0e50UZaQndhVHvz7VUtPh/Jb3t3fJqFpFezWzWytbaeIY8MfmZ0V/nbHuB3xSw+AZY9I0i3/ALVQ3umCSKGf7JlHhdcNHJGXO7PrkVq1hr6P8+z/AFsT+8L2r+N4NETTTrenXlk95M0JDFGEW3GXJBwVwc5HoeKluPGtjBompakYLh0sr1rARIAXmkDhfkGeck/lWbpfw7t7ODSYJ7tbiCzkunli8jaswnQoVA3fKBn3qDTfhstpY2Ni+sXD2dtfSX2ETy5HcqAnzhuCuCc45z2pWw3f8+7/AOB94XqG7F4wsZrbw9PDHM8etPshxj922MkNz2wRxnkVHrfjCHT9e/se2s5Lu+EQmZfOjhG0nAC72G5vYVjR/Dy4tLWyg07XPJWwvpLy082183y1cf6s/OM4OTnjqeKteI/BN34hhSPU9Us5v3QjeRtNUyKe5jbdlM+h3UKOHUlrpr376fh5jvO2x2sL+ZFG5Rk3KG2uMFc9j70+obSBbW0gt0ZmSJFjUucsQBjk9zxU1cT8jUKKKKACiiigAooooAKKKKACiiigAooooAKKKKACimSyJDG0krqkajJZjgAfWqFxrul2+s22kz39umpXC74rYv8AO455A/4CfypXSKjCUvhVzSormIPHOg3P9vfZrmWV9EVmvUELhk27twAIGcbG6VT1L4hafZ+FbXXodO1a7tLmUwpHDb/vAQGOWViML8p557UuePc2WErt25H2+9XX4HZ0VyV/45srPxvpfhl7a5a61CATxTDbsVTv685z8h7VBp3j+11CTxOkGm6gToXmeZ8g/flC4Ij55PyHg4o547D+p1rc3LpZP5N2X4naUVwt18RYbfwfZ+IP7D1d4rm4Nv8AZliHnIRu5K56fKfzFal54tjtfFmmaEdNv3kvoBOLlYwYo87vlY54PyfqKOeIPB1lvHv+G/3HTUVyFl43hupfEsY0rUk/sNZGcvGALnZv/wBVzznZx9RVW6+IkFv4OtPEJ0XVnjuLg24tViHnIRu+YjPT5P1FLniNYOu3bl7Lp1V1+B3NFczeeLY7XxZpmhHTb95L6ATi5WMGKPO75WOeD8n6iq1l43hupfEsY0rUk/sNZGcvGALnZv8A9VzznZx9RT50T9Vq2vy+f3u35nX0Vw118RILfwdaeITourPHcXBtxarEPOQjd8xGenyfqK07zxbHa+LNM0I6bfvJfQCYXKxjyo87vlY54PyfqKOeI3hKy3j3/Df7jpjwKx7zUGm+S0banQy+v+7/AI/lXL3HjiPUJfENqmmX8cejeZ5xeMf6TsLDEfPIO39RWXceOoYPClrrh0jU2SecwC2WIeav3vmIz0+X9RWcqq6GtPA1r6x7firo7BECjjPXJJOST70O6ojM7BVUZJJwAK5rVfF8Gna/Y6XLYXztdwiVZ0QGNM7vlJz1+X9RXMzeMH1WTWYpLO5SPTAzPCRgTBS2dp/iPy/TkVlKokafVqtr28/xt+Z2Fzq7TuI7FginjzHHX/dB/rXEeLdFMuu2Ortcym5iHksVAJkj5Oxhjlc8juD06nKt4otLPwrDrcWjXatNMbdIVQGRThvmI7D5f1Fcn4+8Saj4W8SRCzlaZbm2V5YblNyDJx8pzlTxyBgdOtYSqNnVhcDWqVVBKz1/Dc6MQJ52+4tnIjz5Umz5kBxkA9R0H5CtSJXPlXFtM0pQ7hvYkVzXhjxdeapEqzaBqBz/AMtYgCh/Fto/Wum+zTQSGS1woflkbsfwrop1oyXLUIxmXzpSbjv2ujTTWE8xZLqybzFGAy4NFnex6rdvLFcRQtGpUITyfrWTLLdxfNLEjp32HmuU1LRreKeG40vSLW6tVXMiyTMvPp1zWsaNCSb5n8lf9UeZV9rS+KJ6aLwou2aKB3HGRIuDRFLY3sTo/lIw4KsRkV50nhq8voFubTw1pKIOoF2/6gnNMh8M393Owt/DOmKY+GH2p8Z/Os3DDrRyl9y/+SI9rP8Al/P/ACPQ5EtrCymMUsbyMMnc4JY1R09laKIpLAUHAYNtda4c+FdRlujAPD+mo6jJAum5H50288LX8E8at4f05GboPtbEGjlw380vuX/yQe1n/L+f+R6taaz5MZW7Ik2nAkR1JI9xnrWpBqFpcRCSK5iZT/tAfmK8W/s2KxmP9r+D38llzutLgylQOp25zWhpGkeG9QtZru0toLiCHB5ZwT/ssM8GtFLDreUvuX/yRUakpO1lf5/5Hr32q3/57xf99ij7Vb/894v++xXJWHg/wleKTHpKK6/eRncEf+PVb/4QHwx/0CYv+/j/APxVapYd/af3L/Mq9Tsvv/4B0K3cUUqyxTwiRf8AbGGHofaty01O0uIg6zxDsVLjKn0NcF/wgPhj/oExf9/H/wDiqIvAnhaO4jMujwmJjtbMj8Z6H73+c1UfYL7T+5f5kTjN62X3/wDAPSI5EkXdGyuvqpyKdXFSfC/wg7bl0oxP2aO4lUj6fNimH4ex22G0bxDr2nsOirdGSP8AFW6/nWvJRe0n81/k2YXl2O4orhWi8eaMd0Vxp3iK3HVJE+yzn6EfL+dTaf8AELTjdLZa/b3WhX54Ed8u1G/3ZOhHucUPDyavD3vT/Lf8A5110O0opEZXVWRgysMgg5BFLWBYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFMmljhieWZ1jjQFmdzgKB1JPYVz9xqWo3+v3+iQade2dolqf8Aib5UKJGA2iNTndjJ57EYI70m7Fwpud7dC34h8SaT4e+yDV7xLdruUQwKQWLsSBwADwMjJ7VWS48QXet6nZyWMNhpKQlbW/WYSSvIQMMExgAZPDdx3Bqtb2aeF/DRgjN14g1Oxje6jSaRXuZWYnJBPIBJI4zxkcnikh0WTWLnQ9f19rqxvbKEu1hHdfuI5CDlmx1IBI9MHHNRds6owpxTfTVXffdWjo/m7rU5GOwTxh4J1DSrSeXxFfWF8Ct1rMckELy8q23ZglVBb5fXg8EVsa9peg6bqPhrXvF2pra6pZRJbReVIUilk7kLgsRlj7AHmt+bVry78QX+hWen31qiWpf+1ii+UkjD5dgPDkZJ+owRUug+HY7DSrK21O5k1m6tZGmW7vVDyB2JJK/3epA54HGalRubyxLj8Tst7J62ktdbWV+1uuxn6fDdReKdZt7Lw5baZaSRs51hDHvuJ2wQSmMkDcck55FN/wCENOq+GxpXjHUptbY3H2hpVX7NnjATCH7oyfzrr6K05F1ON4qad4aPTXrp1u9V8nYojSdPFzb3JsbZrq3jEUU7xhpEQdAHPOOT371eooqrGDk3uwooooEFFFFABRRRQAVBe3AtrZ5SMkDgf3j2H51PWFqE32i6wDmOEkD3bufw6fnUydkVCPMyvGuxAM5Pcnue5pZGVEZ3OFUZJ9BTq5bxReieX7HE2UQZl2nv3H4D+ftXPKXKrnUTNcG4JuZ1Z8cxQj+Edjj1p0emvcypPeRRLGgJEY5/Oki06SdoLiGTyCEwcDJPtTm1VLVpLK7mQ3WMogPzOvqF61hvuS2U1tY2knmiUKkDKVUcAkHJpJ7DQ5NWbVpLJLnUZFVUeVd+3A4CbuF79PU1l2ms3V5pDTaXpNxOy3G1I7n9x5ue4J7DP6Vo6mdbubjSrdYrC1jdVe7EhZnUjG5YyOPXBPtSCNZx1g3r2Fn0W+mme4hKQ7+Sh55rHNxdR3c1uqx3EsBxKsTZKfUdq2tOvNXi1yaC/vIjbMhSCBYeQePnLdxwePevMPG+naxL4ihC3BuNRiISXUI0FtGCcbUznG4c5Oc/MB2oG8bUpJWVzsIr6Se7WNUI67wR0pnywamuBhJchh2z2plh4b8S6XFFJqWs2sgc8xiDzD+L/Kf50/VRhk/vblx9c1dNuM0zuUvrNFtqxu2sotpARwjfKfpW14cVdl02OfMP9K5a9mWK1y5wMVb8Oa00JMUsT7pTvHqa6MTDVSR5dN6WLetxNBqkMqOY8naWHvVzWoVksNzfMQMg0zxWFew3H7xHH17Uai6WXhqeaXeyQRNIRnJIAya5DYzYEnvRHOJGiSNMBsDLHuee1cX4jt5NN1BtXslV5UXN3Eg2ieLPO4dMjrn29qo2/wAVYbrwbc6iNJvobO0gSYuXiYuhcJwA5IPP8WKhvPHkFnptvI2kX+b+c2scLzWz7yU3HLCTCjB7kU+SRE7SVjvNJ1JJbaKS3lIfbvgk/vr2Hv7iuz0vUItQthJGCrD7yN1U14ZYeJ4oLaHTtL0PUruextTdXUIniLW8ZPHz7sMxAyFXtV3UPi3p2mT2dzpdjeX0TaaNTkkj8tQtuZDGQwZgdwYdBnn8auClFlKWmp7nTXUMpVuQRg15rqHxWS1vtMt4PDOsXY1MZspImhCznyxIwAZwQVDc5A6V6VYxXN9bwuIJbcSKGbzRgpkcjHc/pW9rhzI2tMlaWxhdzltuCfUjj+lWqjgiSCJI4xhVGAKkrdHM9wqrqOn2ep2rW2oWsNzA3WOVAw+vPf3q1RTTad0I4CXwnq/hl2ufA96Wts7m0i8ctE3tGx5Q/j9TWx4W8Y2etzvY3MUmnazF/rbC54ce6n+Ie4/KunrA8V+FtP8AEtugu1eG8h5t7yE7ZYW7EH0z2/rzW6qxqaVfv6/Pv+ZnyuPwm/RXBaP4l1DQNSi0PxqV3SHbZ6qo2xXA9H7K/wDj+J72s6lN03r9/cqMlIKKKKzKCiiigAooooAKKKKACiiigAooooAKKKKACiiigApksscKhpZEjUkKCxwMk4A+pJAp9cVHZx+OwX8Q6LeWdppuoFrSOaUqLnZld7p6ZzgH88E5TdtjWlTUryk7RW//AA11cfNYXHjWHVtO8T6TLZaRDdqLYC4Ie6VDyXC/wE9Oeh9QDWp4mvr3SNDZfDemLqF9GY4YrVXCrGDwGbnhR7foMkSeL9cfw/ozXkOn3WozmRIYra3XLO7HAycHaPc/1pND8O2Wl6pqmqwi4N9qjrJO08m8pgYCL6KOeOfyAxNui3N+f3VOa91bR6N6X63Wm7DS/DthZ61d659mC6vfRos8hkaQKAB8iE9FyB2GcVj3dtL44j1rR9b0y/07Sbe5SOKUT+W14F5bgf8ALM8euQexHEeonT/H9xqOiCTU4LfSL2L7TJEfLjuXHJi3dTg4zjH8JB6V24GBihJP0CU5UmpSfv6W393Zq2vb7kMgiSCGOGJdscahFHoAMCn0UVZxhRRRQAUUUUAFFFFABRRRQAUUUUAVdSnNvaMyf6xvlX6n/OaxY1CKFGcD1q5q8m+6jjz/AKtd5HueB/I/nVWspvU6KasinqlwbezdkYLI2EU+hNZdlpMIDkjeXOQT24xRq0kd3dNBMw8iMhQufvP/APWrHuX1OaBNP0m9hgvY50LvKfmEGeWC9/T8+9cs3dlSdlcVHuNW06+sfDerRpLbXKxSXDxEhB1YIejEf09wavpYQG7bU/scEmsRhYpJtvLADHHpkH8uKlljjtxmKcuscoeRVAUZJyScDrk5p9wZPNv/ALKT5vlq647nn/CoJUerFmuJmvrRbuMRKGLAhsgnFTatHYkm8vbpYoYhks0mxV9yawvFer22lxwtqKPcyum2C2QfNNKTgAD+vv8ASsfSvCq6rO934unzKp3JpyMRFAD6/wB4/p9aBSnryx3JbTxcLzWbh9B0q81l0GxGjHlxD1y7dPyrN8Vz+JLu3un1W10mztlhfdDI7ysc8BRt4LEkAe5rp7dY9FmE+m4Onk7XRBwvuK2kME9zHdo4J24HPHNAnTlJayPFNE0/xpaWUTK89nY5G1bw/KPohBIH4CuvaHUFt1lv5beeRCG/cRlenXqTn8hXYa9fiRRZwhXll45GcD1Nc4Fe0uZLK4JOOUY9xRezujrwNJRi4Nv7/wBB0saX0UMivwpDCn3MaSwZU4ZeQy9QazJGmtbkQwkCOYnk/wAJ71Z065syZrO2uVnmQF3Cndtye5HAOe1elCamrnHWpujPlZrxtqOp2EFx5cbogzjdySPb61p3dvD4i0G4sjI0DSxNE2OqEjHI/pVDwxdTQ6ZIkUXmiOVgy5wcdePzrXFsl8iXdo7wO65LL3HuK86S5ZNGqd0eSD4PXOleDNV0VdW0+SG7tkgaeDSVhlAVw+5mEhMh4xyRWj4p+HuhouhXcVtYW2lafP8Aarq2WzTyrj5NpLLwPxINdxc3FyFuoZ723hiiUFppBgYPqScCuUur278YK2j6YQNHjYfar9VIV1H/ACzTPUn1/p1fPJsibUVbqZ134Ji1Bv7b8G6l/YMWo2awS2y2alGjXO0qoK7GAJ55HtXM3vwi0/Uoo0juWT7Hpi6dboY8tFKJTIJ92RnqwK45DHkV6rpZtbS0+aTPkZiRS3CqOBj8MVBEF812kJ2z9McYAFCnJFqOmpR03wtc6r4h8OX17qivcaCzTSlLbaLl3j8snG75OgPf8K9j0Z91iqHrETH+A6fpiuL8JrtEvqY4y3rnmuu0RsTXSdvlf8Tkf+yiuii9ETUWhq0UUV0HOFFFFABRRRQBQ1vSbLW9NmsNTgWe2lGCp6g9iD2I9a4vRNVvfBmpweH/ABLM0+lzHZpupv8ApFKexHY/06eh1n67pFnrulT6fqUQltphgjoQexB7EVtSqJLknrF/h5r+tSJR6rc0KK4Twdqt5ourHwl4jlMlwiltPvW/5eoh/Cf9tf8APqe7qalN03b+mOMuZBRRRWZQUUUUAFFFFABRRRQAUUUUAFFFFABRRWB4um1OWwksPDF5Yw644R1Fw4JjiLYaQJg57jkY/lSbsrl04c8lG9jJu5bLx1ezWVhqOo20OiagguzANiXLqM+WHHPysBnHp05U11Wq6ha6Tptzf38ohtbdDJI57Afz+lTW0IhjxhPMb5pGVQu9sYLEe+KwdZTU7/xHa6XJpdnceGZbZ3vZbkB975G2NVz1HByQQRnHIqdlfqb3jVko7RXmvn6t9BPDdpNc6teeIRrE95p+pQxGztihjjhjxnO08liTnOAefym8YTXsmlTadoV/ZWmu3UZ+yfaXwcAjeyjkkgH0IBIzW6qhVCqAFAwABgCuR8Nyab4k8Q3mvLp1xFe6bJLpcU8zHa6AglkXPGc9cA84yaGrK3cIS55Oq1pG3RfJPb5nU2cUkNrFHNKZ5lRRJKVCmRgACxA4GfQVNRRVnM3fUKKKKBBRRRQAUUUUAFFFFABRRRQAVFd3EVpazXNw2yCFGkkbBOFAyTgc9KlqjrtrJfaJqNpDt82e3kiTccDLKQM/nQB5vD8UvCOoWeqazb6nMdNtVWWS4axuEUISEBGYxu+bsM9ahuPir4RhsEu31C5WKSTyY92nXIZ327sBTHk8d8Yrz3R/hh4mg+GOu+GJoLSO7uLdII5jqk00buk2T+7ZdsYwD93rW54t+FpnsfD0Gn3F21rY3L3V40+oTNKB5W3ETkkjkdARWLsdCcrFm88ceFvsUDvd3c07QtdHybKZ5IkDYaWRQmUXOeWAqCfxn4O0e/TVNRv3fU7qxS5Ro4JZU+zbiqyAopCqSOcn0rMvPB+p+H/EV1c+FJLO7g1exWxkj1K6k3ROoIWTftYuuDyDg571zWt/B/VZrjT9O03U4wlt4fFh5hkZBPMJ2lZHUf8ALJt2OuRxxxXOlDuDu+h6HqfxD8P6JqIt9Qv2M9yqN5EVjPIsisgcFHVCr/KwJwa6W0dJJftWkyKIPKEjNLkBgeRnPIwPWuc8Q6Jqdxrnw/1Ka3s7WDRjJ9rghclYt0QQCPjlQR3xxWl49u4LHwlq81jKplulWEKhH8RCn9CaiSWlgcnFOTKHg6SbXvFC+I9Rj/dSB4rBD0RFOCw9yc/rXZa7bRfarSaSNWQSYbI7EY/niseHZYaLpQjhkjFoqx4I7AYOf51t6qzXVpHFChdpSMN2XvmpuEI8q13JNahiXSpV3CNSvBHY9q5ey0oT2oNpeSpNjLKH6H0x2ruTErxIsgDY9azJrcDWIGRNqBG3MB16YptalJnJ20N5pVw7yx+fn+P+L9aZqt9FehWSR4ZsbScAMPQgEEV2l09qXKu6ZPbNZOp6BBewsYxz2I7UGtOfLJM8o8RaBf3YLJq08yn/AJZy8L/47x+lU/DumalYST2puriylJDgxIsiOOnJ/wAa7a+0zUbJWwolUevBqtHp+oRILhESUOAcA4x7VrRcU/eMsVhqUmqlN6+rK2lWmtxi9Fr4ikhPGQ1oj7yeB16VszaRq9pYxpJ4rvcEBRHDAiEn0B61Q0uVobwG6BjLtkqfbpz+NdG8kb3C3DvkKPlHp71NRrmfKRGira3+9mdbeCNO+zm61mW61G66g3U5YA/QYz+Na9rJNJpMNrYwi3jCbd2AAB7AVm3eqG6l8slkthwzAHn2zWpa38X+riIwq9ugrMuNNR2Rn2McbXDpcRRqYRj1LH1qK8LTNJIgHkp8hP164+lRsVvdVYqshjHDMpwO9b2m6amoOI9hFjEeSpxvb0B/nTSvoizU8MweXayzf89pCw/3RwP5V0mkELdyDuyfyP8A9eqUaKiKqKFVRgAdAKktX8q+gfsSUP4//XArqguWxE1dM6Ciiiug5QooooAKKKKACiiigDn/ABr4cj8R6T5SyG3v7dhNZ3K8NDKOQc+nr/8AWFQeA/EUmuadLBqMYg1qwfyL2Dphx0Yf7LYyPxrp68x+IUM3hLxLZ+NNORmt2K22pwr/ABocBX+vQfUL7100f3q9i9+nr2+f5mcvdfN956dRUNncw3lpDc2sgkgmQSRuvRlIyDU1c2xoFFFFABRRRQAUUUUAFFFFABRRRQBDd3CWlpNcSBykSNIwRSzEAZOAOSfYVzPg22s9XkTxi+mT2WqajbLEUuJN5SIE42joobg8Y7cZzmfxCb7UdW06x0PWLW0ltbhLjUItwaZoMHChcHhj3NdLU7s6L+yp2W8vXbs/XR/IyfE2v2HhrSX1HVZGS3V1T5F3MzMQAAOpP9Aah8IeH4fDmly20Fzc3Tz3El1LPcH53dzkkjgDt0A9cc1FfDVLvxZb2cmn2knh1bYzSTzqHY3Ab5VQZ4I4OSPpXQ0LV3CT5Kagnvq9fu+a1/Aoa6b3+xr0aSYl1EwutsZThRIQdpPB74p2iJex6PYpq0iy6gIUFw6ABWkwN2AOMZzWB8QINI1KLSdH1q8nt/tl6hgSJSfOdPm2NwcL+XbmusoW4pLlpR823t8t+vUKKKKowCiiigAooooAKKKKACiiigAooooAKKKKAObH+sn/AOu0n/oZpSAQQRxRjEs47+bJ/wChGlrnZ1rY4620+J7Upki5U8s33lYVR8NRaja6ckQu7fUpY2ZHufNLMTuJ2k88jOMV2F9psN0xky0U2P8AWIcE/X1rzi4uf+Ee1q+0jT1l8xn+1yGQYVy/UryeO3QVzyhykv4kX9Q8UaZpPirS9D1nUZF1PUPmihVMx8khQzdslSB6kVzeta/o2o6tqukzR31tPpri+ndbIsoijBY4ORw2OD3rjPEvg7W9e1XU9VfVVgvZp4ZbVFQMkYh/1eSV3AglyQp6nvWhbadrUfiDxDqOqT2C22qaY9i8ilz5fyMFY4X1PPtTtDuKSbTT2PT/AAp8QdA8Xzvp+nrcx3JthdpFdQNH5kJO3epPBGSBVSXxPHpV7rNi14d+kWR1C4TyiwWHBPynPJwDxXD/AA58FS+HNSh1Cx1e0urSXTYoLklmd45FH/LIkZEZ67TjB+gFHir4cxeIdf1zUrvULSRrvTxb2mXZTHKFIDMB1HI9fpQ1G/kNXsdra/EeCWG8lTdJHaaWmsS4Ugi3dN4Iz3x2qEfE/T7vU9L03zHtLjU7FdQtjMmA8TBiMf7RCtwa5CLwLrVtYzRWGoaZm90GLQ7zzw5CBE2eZGV68Z4OPrS+I/h+uoXFrbW90jJbaDb6VaS4IljngkLLNxwBjGcHuRTtDuHvdjptM8ceHprOx8q3v9TvtUVp7e2trffMYx1dhkBRn1IpW+Jdpo1zaWk1lrE01zG80cCWTtMqKxVt6DkEEVzafDrUNC0vSbiw1CyGo2+lNpN6kjyoksRk8wMkiEOjBu/fpWTN8Mdbv4NCuLq70/UprK1kgl/tCSceYWYkNlDu4B7mjlh3C8j0XxT8UdB0qeWz1CC/WWKCO4mZbVmWFH+6XI6eldGsi2mgq3ymVhlB169B+teO+Lvhvquvaxd6iby1ikNtbRxKXYxM0RyRIhGGQ+hz0Hvn0q1EtxFE9zPH9uQAlYiSitjnGeSPrUytZWGr9S74gsI2053KDdsJ6d65ea3uYLgoHZ7fAbGcEA/zro7i6kmX7PeKU3/KGU5BqB9q3E4k4+RVQY+916VBaFihljhVJLOVUI4ZV3KR7MODU0Gm3dxB5FlA0QIwZJAUH8ua67RYXt9KtYpRh1QZHp7VdrZU0K5z2l+HRCii7ZSi9I4ycH3J6n/PWt+ONI41SNQqqMAAYAp9FaKKWwBUcxwqkdQykfmKkpYIjPdQxDpnex9lIP8APFUhN2R0NFFFbnIFFFFABRRRQAUUUUAFVNVsINU026sbxd9vcRmNx7EY496t0U02ndAeU/B3Vp9L1DUvBmrP/pNhIzWxP8aZ+YD25DD2Y+lerV4t8Z7W48P+LtF8V6YuJSwjkxwGdegP+8mV+i167o+o2+raXa6hZtut7mMSIe4BHQ+46H6V2YuKko147S39eplTdrwfQuUUUVxGoUUUUAFFFFABRRRQAVFdzpa2s1xLuMcSNI20ZOAMnA71LWD4sXV54bO28PXlta3bXMTztKQWFuG+cqpByeg5x35pN2RdOPPJRbsU/AsVhqFvJ4pt9Nmsb7WkR51ncs+FyF69ARg8Y4xxXQanfW2l6dc319IIrW2jaWVyM7VAyeB1+lWq5zxpczLDp1gmi/2vbajdLbXSOpMcUJzukbg4wcdaXwo1v7etrt67JdLvstEL4I02Cy024u7bULjUI9UuG1BZpgV+WTBUKp6ADtgda6KmQxpDEkUSBI0UKqqMAAcACn00rKxlUm6k3J9TnNamY+LvD1qdD+2RsJ5DqDRkiyIQYw2DgtyOo/GujrD1CDVX8V6TNaX0EelRxzC7tWPzysR8hUY6A9eR+NblJdS6tuWFu36v+tPzCiiiqMQooooAKKKKACiiigAooooAKKKKACiiigDCvozDfSH+GUB1+uMEfoD+NRVe1sYa2f8A2in5jP8ASqNYyVmdMHeIV5545iv5dZRrFot6tHuSQffj5yM/n+teh1ja/pbXqrLb7fPQY2t0cen+fWsqibWhTV1Y4pEW4TzLR45oicZT5xxx2/wz71FPbCRWjmCgsMcnqPTPX86qS20mmoE0fTIsvPunhklMZGRg7Rnjt/hWgl9b3dzNaR3atNF9+LcCV6eucDkc59utcxKl0lucr4fWfTryfS3LpcWxLxE/8tIieD/j/wDWrpl1ElVFzaxuo5445/lVDX9F+0LDcWty0WoQc27np7gj+6fSqen6tHJcC11RpLLUFwHjkxh/dGx0PYZ7+1BMZez9yXyN64vNMNs7DfDJjgDI5/CtDR0iSBpInikJGQynJPsTXM6ukFrbtcSy7VRcszfN+OPftXO2Gtx2+Jri0vYbaVvluNhCe3P/AOuhFyqRhpJnfalLM5VrjYiBhhC3Le3FWEupApW4jaDHZgRVjwx4fN1JBqF2cwDEkSk5L9wfYd/eu4xnrWsabauy7nnNyt3dhEhgnW3b/lqIyQfpxVixsJrYkQ288nHGYSDn64rvqWq9khXONg0XUryVGu/LgjBB25yf0/8ArV0dhpcFo3mf62f/AJ6OOR7D0FX6KuMEgCiiiqEFFFFABUllL5N9GW+44KZ9CcY/lj8ajprqHUg9DTWgNXVjpKKo6VcmeEpIwM0fDe47H8f55q9Wydzlas7BRRRTEFFFFABRRRQAUUUUAcp8UNLbVPBWoLEP9JtlF3CQMkPH83HuQCPxrnPg5qYiF1ojHELRrqVgM9IZOWQf7j5H1Jr01lDqVcAqRgg8g14ZY7vDQhvVyG8NatJY3HfNlMcgn1wWJH1rvw/72jKk/l/Xrp8zGfuyUj3SikBDAEEEHkEUtcBsFFFFABRRRQAUUUUAFchoX9jeIPGOoa5Zm7e+0vfo7mTHlAhgzFB65OM+/TpXS6pJcQ6bdy2EP2i7SF2hhyB5jhTtXJ4GTgc1U8Lref2DZy6tbW9tqc0Yluo4E2qJCOe556AnJ6VL1aRvTfJTlJPV6b/fp2NWueiivLnxvLdQ6vC2l21p9nl0+N8ss5bcHcdvl6d66E8DJrkvh4+j6jZX3iDQorpE1e5aWRrnGXZCUyOThcg45oe6QUlaE5/Lbv8AlomdbRRRVGByuow6OfiLpEtxcXC62tnMLeFR+7aLI3EnHUfUV1VYGpySR+MNGWPRI7lJoplk1PaC1qAAQucZAY8dRW/Ux6m9Ztxh6fq/u+YUVQ1jV9O0a1Nxq19bWcP96aQID7DPU+wri3+J0GoyNF4Q0PVdfYcedFEYbfPoZHHH5UOajuFLC1ay5oR077L73oeh0V4r4k8feKLFzHqN94b0GQ8C0RnvrwE9BtTK/nisGWT4ma5C01pqGsQ2mNzXd7HDpsaD12jLEe+f51m6y2SPQp5RUa5pzjFeb/J2s/kz6Ior5YkGqtcG0n+IWsatek5NpoZnvM/RiyJ+Wcelaln4F8famB9km12xjPSbUdW2Z9zGoLD6VPt29om0smhBXnWS9U1+dr/I+k6K8O074Q+LH2nUfHd5D6rBJNJ+pdf5VvWvwjlXH2vxp4ml6Z8q5Kfz3VanN/ZOSeEwsP8Al+n6RZ6nRXnkXwrskB3eJfFkmf72pdPyUVJ/wq+w/wChg8U/+DNv8Krml2MfY4b/AJ+/+S/8E7+iuA/4VfYf9DB4p/8ABm3+FNb4W6e6lX1/xQyngg6kxB/Si8uwexw3/Px/+A/8E9Borzj/AIVDo3/QX8Rf+B5/+Jo/4VDo3/QX8Rf+B5/+Jpc0+34j9jhf+fr/APAf+CdzrKbrB2HWMiT8jz+mayhzXNH4Q6MQQdX8REe9/wD/AGNY3/CrdLRnR9U10MjFT/pv5Hp6YqJuW9janSw23tX/AOA/8E7+krgv+FXaT/0FNd/8Df8A61Ry/DXRIiBLrOtIT0DX+P6VF5djX2OHf/Lx/wDgP/BO3vLC2vEK3ESsSMbhww+hrnNQ8HRu0sljMI5ZUMbMyDfjHZwM1kf8K60D/oOav/4MB/hR/wAKx0G5BT+1tYmxzt+3Bv6VLV90DoYfrUf/AID/AME53xNBqHg60s4pr/y4p5WH22cNKueuxyBuGe3HY1MbCbxDIkdtHpmo6fjDXCzbih5ztAxjt71x2taBod5qyaHY3tzpeoxTMlydXuf3YA4HlkDDE5yM44+tdx4R+FGhw28V3dXV3dzdQ0cvlIfcbeR/31WD30OrEZfhKNGLnOSk/Ldel7fic9qfgXVU0vUSkNxGsJDQQi5EizKCc4XqDjnr7VNrHiSz1nR/7M02xuJNQnURC1Ef+rb/AOt/nFejaqiwWYsLUTlXHlJmVmYZ4HzMSe9VrP4eWcPzvqmr/aCMM8d0Vz7dM10UacJ/HK3yufPzouN/Z7M6Xw1ZS6b4f02yuGDTW9vHE5BzyFAOPatOuR/4QW0/6C+u/wDgaf8ACj/hBbT/AKC+u/8Agaf8K6/Z0f5/w/4JonNK3L+J11Fcj/wgtp/0F9d/8DT/AIUf8ILaf9BfXf8AwNP+FHs6P8/4f8EfNP8Al/E66iuR/wCEFtP+gvrv/gaf8KP+EFtP+gvrv/gaf8KPZ0f5/wAP+CHNP+X8TrqK5H/hBbT/AKC+u/8Agaf8KP8AhBbT/oL67/4Gn/Cj2dH+f8P+CHNP+X8TrqK5H/hBbT/oL67/AOBp/wAKP+EFtP8AoL67/wCBp/wo9nR/n/D/AIIc0/5fxOuorkf+EFtP+gvrv/gaf8KP+EFthymta+jdmW+OR+lHs6P8/wCH/BDmn/L+J1qs8MqTRffXt/eHcVv28yXEKyRnKtXmLeDbpARb+KdfXP8Az1uBJ/QVBbeFPFySSR6X4ymyoD7Z4eCTxycn09K0p0qbdvaL7n/kZ1HK1+X8j1mivH7uH4s6UCY7q11SNef3axE/qqsf1qlb/E7xTYXAt9d0zT7ebOAlyktszf8AAmyv48V0rAzkrwkpejOf2yW6aPbaK4G2+IVwkKzap4Y1SG3bkXFkVvIceu9OMfStjR/HXhrVmCWmr26ynjypyYnz6YbGT9Kwlh6sdbfdr+RSnF9TpqKAQQCDkGisSwooooAK821HTIpviJ4g0efC2+v6SsuewkjOwfiB81ek1w/jcfYvGvgzUxwDcyWLn181MKPzBrowzak0uqf4ar8URUWhc+F+pSaj4OtEusi8si1lcKeoeM7effG0/jXWVwnh/wD4k3xO1/TD8sGpwpqUI7bh8sn4k8/hXd1OISU7rZ6/eEHpYKKKKxLCiiigAooooA5fx1DBqcFhora0+lXV7cK8Rjz5kwjIdkUgjHbnP511Fcs01nqXxCS2m0p2utJtTPDqDMQqGX5WRR0JK9+a6mpWrbN6t4whDyv06/8AAtuUddmvYNFv5dKgFxqCQO1vESAHk2naDkjjOO9JoAuf7EsDfwQ2160KPcQwrtRJCMuAMnjcT3NZXxAgF74cexGt/wBiS3c0UUV2G2tv3hginIOW2kdfzrpAMDFHUTsqS82+/S3yCiiuI8XeODZaiNC8M2n9r+JJBxAh/d24/vyt/CBkcfyyKcpKOrFRozrS5YL/AIHm+yOl8Qa7pnh7T2vdZvYbS3HG6Q8sfRQOWPsAa4Ya/wCL/GfHhWyGg6O3TVNRTdNIPWOL+p4PqKtaN4HgtrlvEPjq/TVtWQGQyTnFrZjriNDwAPU+meDVK48Qa549uZLLwWz6boSsUn1yRCGl55WBT/6F/LvlKTe/3dT0aNKlC7p2lbeUvhXour9d/wCUyNT0/wAH+FNUQaoL3xh4ulxsgmJuZS3X7n3UXuMgkDpmtpNA8W+KolbxFqI8OaRjjTNLb96V9JJu30Xj2FdP4X8K6J4NsJmsYlRipe5vbht0sncs7nt37CuOefUfindyw2M0+neCYmKSXCZSbUiOCqn+GP8An+irlto/uNVXdVuUXpHectbf4Y7LyS180VNPvtH0q9k0j4VeHbfVNVj+WfUX5hhP+3MeWP8Asg49PStyD4cy6xMt3491i51qYHctnGxhtIj7IME/U4z3Fdvo+lWOi6fFY6VaxWtpEMLHGMD6n1PueTV2rVP+b/gHLVx8r3o3X956yfz6ei/Ep6ZpljpVsLfTLO3tIB/yzgjCD8hVyiitDz23J3YUUUUCCiiigAooooAKjuJ4raCSa4lSKGNSzySMFVQO5J6Ci4mit4JJ55FjhjUu7ucBVAyST2GK8esZrj4v6/cGR5YPA+nShREuVa/kHPzHrt6HHYEdzkRKVtFudWGw3tk5ydoR3f6Lu30N6f4gahr1zLafD7Rm1MI2x9SuiYrRD3weC/0GPxFZ974T8V31ykniLxbLB5wJMOkRiFVIxwJD8x49R2r1G0toLO2it7SGOC3iUKkcahVUDsAOlMv7YXUBTO1x8yN6GpdNyXvM1WMjTdqEEl3er+9/okeW/wDCsNAl/wCQhJqeoHubq9di31xipY/hh4Ojzt0VDn+9PK382rslJ+YMNrqdrKexp1Zckexv9exL/wCXj+9nk+rWXwp0jWn0nUo7S3v0MavG5nwhf7m5vujOe5rpJfhj4Odfn0aMAf3Z5V/k1ee/ET4b+JNc8b6/f6XBF5N+LP7NcSXxjjheHGWlh2kSjg4BBx1reuPh9fS33jzUvs2nzatqIKaZNc5ZMNbiJwydBu5HIP4iq9nHsQsdir/xJfeznZ/hbZxM+o6jO8VnPOIoLLSke58rd93fIc4A43MRgeor0fwx4O0Xw3Ej2IuEuWGfmun+b1+QHafyryvR/hp4hsr4CSztraCbWdL1AQpPEVVYPM89tscaICdy4AUZ9TitOy+G17pmp6Vqi2lrHqcWv3N5PcpJ87Wkm/aue/3h8vufesZU4p6F18zxWIXLOTt2/rf5npiMj6zaq7qvzbhuOMkdAPfOK2rHVbG/lvYrO5jleyl8i4Cn/VPgHaffBBrxr4heAtb8U+IIdQ0izsptkAtRJfPFJCnz7n3QvEx6EfOjBu3pRqvwt1iU+M4dPtNNt31S7S8hvElCmaPcjPbMpRtqkqzc7lzjIIJrWnFKJxNvse4LIjxiRXVoyM7geMfWhJY3ICOjEqGABByD0P0rxLT/AIXXr2GkWd3psa6fHrp1C6tLi6ilXyjCVbasUUaKC2PkAx1PfFW/hp8N9S8Maz4Zvpbe3hkt7W9t9Rkjly0geXMC/wC0AgA9sVdkF32PZaKKKkoKKKKACiiigAooooAKa7bFJwT7CnVHOpaJwv3iDj60ATi2uycC1cZ7s64/QmtPTrT7MjF2DSv94joPQD2qxbyrPAkqfddQRUlbKKWpzym3owqG7tYLyBoLuCKeFuGjlQMp+oPFTUVWxBw178P4rSdrzwhqFxoV6TuKREvbyH/ajPH9B6Vj3mpWn2qPTvidoNlFLIdkOppHugl/4H96M/j+Qr1Gq+oWVtqNnLa30Edxbyja8ci5BFdMMS/+Xmvn1+//ADM3TXQ4oeA5NNAm8Ha/faYCMrA7faLcj2Vv55NIfFXiHw8MeLtE8+0XrqGlkyIB6sh5A9T+Qqmftvw2uUy8974OlbB3ZeTTyTx7mP8Az1+96NBLHcQRzQOskUihkdTkMDyCDWlSbVnP3ovrs/v7+txRXbRlHQ9d0zXrX7RpF7DdRjG7Y3zJnsy9QfrWlXI6/wCBdPv7o6hpckuj6uOVu7P5dx/216MPXoT61n23izVPDlzHY+OrdFhc7ItXtl/cSHt5g/gP6e2Oay9jGetJ38uv/B/rQrma+I76uI+L/wC58KQ6h306+t7oH0w4X/2au0ikSaJJIXWSNwGVlOQwPQg1zXxPt/tPgDXExnFsZP8Avkhv6VOHdqsb90E9YszviD/xLfEXhPXRwsN4bKYjp5cwxk+wIz+NdzXC+MLc638JJZE+aQ2EV2jDrlVWTIx7A9PWur8P341TQtPv+P8ASbeOU47FlBIqqivTi+za/X9WEfiZfooornLCiiigAooqC+uobGxuLu6fZb28bSyNjO1VBJP5CgaTbsjL8Ox64t3rDa5LC1u1232BIwPlgwMZIA5PPXNbdc38O9NsNL8IWEOkXct7ZShriO5lUq8okYuCRgY4IHQdK6Spjsa4i3tJJdNNrbabdDlPGdxpDax4Y0/VrOa6nnvxPZ7HKiKWJdwdsEZAB6HPXpXV1i6hNrS+J9JisreJtFZJjfTMRuRgP3YHzA8n0B/CuY8da/qGo6ung/wjJs1WZd97eryLCE9T/vkHgdeR6ghOXLdm0KMq3JCL6Nt30Wr1fb066dxninxNqOt63J4V8EyKLxONR1PGUsUPVV9ZPbt9cldzQND0PwD4fuJFdYYlHnXl9cHMkzd2dup5JwPfjrV3wv4f0zwjoS2OnqIreIGSWaQjdI2PmkdvXj8PoK4W2jl+KmuC7uVZfBGny/6PEwI/tGVeN7D+4PTv+eI1Wr3Z0LkqRcIPlpR3fWT6fN9Fst+7C1tL/wCKdyt7qgmsfBcb7ray5STUMdHkIPCZ5A//AF16hbW8NpbxW9rFHDBEoRI41CqoHQADoKeiqiKiKFRRgKBgAelZfivWYvD3hvUdWnwUtIWkCn+Jv4V/E4H41aioq7OWrWliJRpwVo7Jf1u31ZxXjKWfxr4rXwbYSvHpVqFn1qeM4JB5SAH1PU//AFiD6LZ2sFlaQ2tpEkNvCgjjjQYCqBgAVyXwo0OXSPCkdxfkvq2qOb+9kb7xkk5wfoCB9c12dEF9p7srF1EmqFP4Y/i+r+fTysFFFFWcYUUUUAFFFNkdI0LyMqIOSzHAFADqKhlu7eFUaW4iRXGVLOAG+nrQLu3MwiE8Pmnom8bjxnp9KAJqKbJKkQBkdUBO0bjjJ9KY1zArFWmiDBgpBYcE9B9aAPKfjrq9xdWjeGdNkKE2cuo6hIv8FvGCQn/A2AH5djXXfCfSo9I+HehW6KA0lstw/qWkG85/76x+Fc3P4Xvbiz+Id5qL2o1TVQ9tajzlISFY8RKScbdx6g46A13fheOSz8O6XZXeyO8trOFJ4w4bYwQAjI7ZB5rGKbm5M9XE1YRwscPTa0d35u2/yvb5GtRVS31KxuYpJLe9tpY4jiRo5VYIfQkHin/bbUxGQXMHlg7S/mDGfTNbHlFDWYVSWGdRhmPlt78Ej8sfrVSrusSJLBbGNldWkyGU5BAU1SrGe50U/hCiiipLIygMm88kDAqKe3Ep5qzVa5mEbhScHGaTS6jSuSwRLDGEToKkqrJOsccZJ5YZqyOgz1phYWiiigQUUUUAFFFFABRRRQAUUUUAFNchVJY4A5JNOpIwv2u3Z1DLvAwRnr0/XFCB6GtpEbR2Q3gqWJcKewJq7RRW6Vjlbu7hRRRTEFFFFAEdzBFc28kFxGssMqlHRxkMpGCCPSuC8KPL4Q8Tt4Vu5GfS7oNPpMrknaOrQk+3Uf8A18V6DXJfEzSJNT8MyXFlldS01he2jr1DpyQPqMjHrit6Ek37OWz/AAfR/wBdCJr7S6HW1DeW0F5ayW13DHNBINrxyKGVh6EGqfhzVYtc0Kx1ODAS5iWTH9091/A5H4VpVi04uz3RW6PN7iy1H4eStd6Qs2oeFi26exyXlswerxnuo7j/APWOo1a8tNe8D6lPp0yXNrc2MwRkPXKMMex+vSug69a8w8S2cvgWe81DTkdvDOoBkvbRBkWkjDAlQdgT1H/1sdcJe3av8f5/8H8zNrkXkdT4D2X3w80aOU7o3sUhbjHAXaR+lUfhBMzeBrW2lOZrKWW1f6q5x+hFU/Bup3OnfB/T9RtbZbmS1ti5hyRvRXO7B9doJ781zPwv8aLca5e6TpdjK/8AaOpzX2+UhVt4GAJzjPPBAHTJHNaSoylGrZaJ/lf/ADJUknG/Y9mooorzzcKKKKACsPxvfNp3hTUrlNLfVtsW1rFVLeerEKy4APGCc8HjNblYfi6HV57C1TQb2CzuftcRkklPWIHLqAQckjtx9aUtjWhb2kb7X/rbU1NPhS20+2gigS2jiiVFhT7sYAACj2HT8KsUVDeXMNlaTXV1IsVvCjSSSN0VQMkn8KexnrJnMfEbxRJ4c0qKHTYvtOu6g/2fT7YclpD/ABH/AGVyCfwHGc1N4B8Kx+F9IZJZPtWq3TeffXbctNKeTz/dGcAfj1Jrnfh1azeJ9buvHWqxsomBt9Jgf/ljbAkF8f3mOefQnsRXTeP/ABInhbwzc6gE826OIbWEDJlmbhVx355PsDWSd/fZ6NSDhbB0vib97zfb0X53fY5jxzcz+MPEieCdKlaOzjCz61cxnlIv4YQf7zd/b15Feh2Fpb2FlBaWUKQ20KCOONBgKo6AVzfw48NP4a8Phb1/O1e8c3V/OeS8zckZ9B0/M966uqgvtPdmGKqR0o037sfxfV/Pp5BXnnxhH9oReG/D45TVdViSZf70KfM/H/fNeh15/wCLR53xc8CxPjZFFfSgY6t5YH6UVPhsPAaVub+VSfzSbX4noA4GBRRRVnGFFFFABRRRQAV5d8eLPVtf0zRvC+kaTc6hb6peLJqBRjFGLaHEjRtNgiMuQoBPXBxmvUaKAPlbVtN1a4+F/hHQfEnhHVb3WPD2uras6aTLdBrGJhuZXVCDGyFFwPv+X0OKj+IHhHWbz4k+KdXtPDF1LoS3uiyedb6c/wBuSFYRuNmccbSoV1UEj5c42mvq2igDy34/abqet+FvD0egwXMl0Nds5g8dq0pgUFv3jpwdq5BOce5FeYar4R8WJqPi26vrO91ae28R6TqL3FvYND9shiRt7Qx5O8ruAIUnpX1DXGfE3V77TLbQYNKnaC61DV7e03KoJ2MSW4IPGBSk+VXNaNJ1pqEep434m8Nat4k0b4i3yaHq62Wu6zpv2aGW1eO4kijZFkfyiN6qASckDgE9qoS+DPHjWfxI0iS3vbm6isbGytLzaY/7TtYpGO1ZOhcwkKwBPOQetfU1cl498O6hqq2OpeH702muaa7SW29j5UoIw0br0wR37UN2V0KlCM5qMpWT6nhviGw1LVvCXj2y0PwF/ZtgdOt4rA2+hzWd3N+/QmF1JPmlQMllGOpov/C19d/CbTtN0nQ5pLs+JbSWWKbw1JYps2AFpYckyRj+J8gEHHGK9n8MfEKyvroaV4gibQ/EKYWSzujtVz6xv0YHt3+vWu4ojJS1Q61CpRly1Fb+unc8S+B2n3mkaDqWmarplzpmow6ncz3EBgMdqDIw2/ZeMGHanGCcHPqK9LpHk86eabs7cfQcD+WfxpaxbuzWKsrBRRRSGIa4PxNrqJqdwscmViAj49R1/U4rqvEmrW+iaLdX91NHEsSHYZGADPg4UepJ7V4Hcaxb3VqxtblZ5FUswBwSf51lUlbQ9TL8K6t6jWiPXG1NbvxZFYRHcsTCM4/2Rlv1GKzY/EOt6p461+ws9S03S9P0KW2jeG6g3vdeYoYsW3DYCDtXAOT1z0rH+FRkvPFFxcTks6wO5b/aZhz+prY8TeIPh5/aVlqupLouo3sF3FZ/a1EMjWjMW2s7E/KilW55wQcc5q6burnLjYKnNQXRGZN8YYoX1snSfOtbGxlv7e4gnk2XSRzLEwBeJMHLDld68EZrS8QfEa80SW6S70AD+z7RL6/U3o3RxPM0aeWAhEjYXcRlQM4yTVhovhrb2I1Ejw1FZ6uskIuMxKlypcF1z0I3AEjoD1q54i1HwFLrMY8Q3nhx9UtASou5YTLCFAfnccjHDYP1rTQ49e5zmm+OdbuIUfUreG1B8UHR0a2cPvQSSKVYMvGNq/MOTn+GrPgnx1qXijxlYD7NFZ6He6RcX1tF5okkk2XEcau/yjYcM3yAsOeua2JJ/AVrNb37z+H4ZNTmS+im3xr9okUkLKD3ILn5vVvU1LYnwLomo6heWMnh+xvrdXW7khkiSSNS67w+DkfPtyD3I7mgNe519FYVx4v8OW2n2t/Prmmx2d1u8iZrlAkm372DnnHf074qU+JtCF7eWbaxp63VnG0tzEbhA0KKMszDPAA6k9O9TYq5sUVyepfEPwpp8MMs2u6e8Ut0tnvjuEZUdhnLHPC45J6CtQ+JtCGptpx1jTxfIhdoDcJvAC7iSM/3fm+nPSnYLo2KK5+bxp4YhtUuJPEWkC3diiyC8jKkhVYjIPZWUn0DA9xXQUgGSsUjZhyQOM1rWenLC4klbzJR0OMBfoKyJ13wyL/eUj9K6K3fzIIn/vKG/MVcEmZ1W0iSiiitTAKKKKACiiigAo69aKKAOF+Fo+wLr+g8hdM1BxEPSKT5k/8AZq7quH0cfZvi34hiGcXdhb3B9Mp8ldxW+J1nzd0n961/EiG1gqrqsUc+mXcUyLJE8TqyMMhgQeCKtVn+IZBFoGpyNnCWsrHHshrKPxIp7HmfwS1qaPToPD+rKDHPA11YM3IkiLEOn1BBOPTPbFT/AAe8Mpo/iHxXMYziC6NlAx6hAdx/MGOoZNNnj+FHhvW7FR/aWixpex4/ij6yIT6FeT9K9N0aS0urJdQsABFfhbksP4sooBPvgD8q9DE1bc7jtJ2fqn+q/UxhHa/QvUUUV5puFFFFABXKeMYNHvNb8L22rXFxFdi9NzYpEPlkkjXJDnBwMH1FdXXO6tOw8ZaDbnRFu42jncakYt32MhRwG2nbv6dRnHeplsb4a6nddE/Lo/6/I6KvOPibLN4i1nSvBFi7Kt4Rd6m6HmO1RumexZhj8B2Neg3lxFZ2k1zcuI4IUaSRz0VQMk/kK4L4SWsuopqvjDUEK3muTFoVbrFbIdsa/pn34qZ62j3NsJ+6UsQ/s7f4nt92r+SO/toIra3igt0WOGJQiIowFUDAA/CvOiv/AAmHxZ5+fSPC6jj+GS8f+ewD8CPeuz8V6zF4f8N6jq02CtpC0gB/ib+FfxOB+NYnwn0aXR/Bdo15k6jflr+7dvvNLJ83PuBtH4US1aiOg/ZUp13u/dXz3f3afM7GiiitDhCvP/Fh8n4u+BXf7ssV9Ep9xGDzXoFeefF0/wBnyeFdeziPTdVjEzZxtikG1z/L86ip8NzswGtbl7qS++LS/E9DoooqzjCiiigAooooAKKKKACiiigArz/x/wD6R8QPh9ZHkPd3Nx+MUQP9a9Arz/xAPN+M/hRTgeTY3coPqSAtRU2+78zswOlRy7Rl/wCks9AoooqzjMrxD4d0jxFafZtb0+C8iH3fMX5l/wB1hyv4EVxF14Dv/D9uz+FPFurafECAlrcbbqIEnACq2MD869MrF1aXzbtIx92Ebj/vEcfkM/8AfVZzitzqoYmrT9yL93s9V9zujz5Lb4hWaBIbzw5eooxmeKWNiB/u8Zp32n4hf8+Hhz/v9LXb0Vjy+Z2fWr7wj93+RxH2n4hf8+Hhz/v9LR9p+IX/AD4eHP8Av9LXb0UcvmH1pf8APuP3P/M8C+JUms3Gv6TF41Szt7UQyvAtq7GJ5B/e3d/uj8R6muT8Rw2kOo6ebFY47hmAZYgACvqQK+jfGOk6bq2gXUer20c8MUbSqW4KMFPKkcg/SvA7fQreK8trXTof9LnZYwzEk5Y4/DrXPUi0z6DL8bCdLa3LpZba3/pnqfwk0rbpN7ezKQLo+UnY7Fzkj8SfyqC38C3Fjp+gaTda1FLp2i3cF1aBdP2vsiLfJI3mHcTuA3BQBjJBzXoenWkVhYwWluuIoUCKPYCi9gM0R2HEq8off0+ldUFyqx8xiantqjmeYXfwiiuYITDq0bOGvQ4lt3MMkVzN5hQqkqH5emd2D3XtWvB8N1h1CG6GpA+XrEGrBfs//PO28jy87u/3t3bpjvXUWN3tjEqj903LoTjae/8A9f8AOrEWqRS/dBYdtrA1bUjnTizzr/hUbx6Omn2+uqiS6c+lXbNZbjJC07zZjG/924LsMncOnHArTu/hlb3Gg6vp/wBvZJr3Vv7ViuFiIaJgyMqNhgXA2dcqeeMEZrvYZ45gfLJJHUEEEfgafJIkYzI6qOmWOKm7LUUedad8OLrSZ7W90jVrO21GOO5hlZrB5YXSZ1diEeYsH3IDuLtnJyCOKzNX+FMkUHiOfTbuO5lu7fUWtYJY3EiS3MbgoJDLsC7m/wCeYPTLGvV0k8xA0cczoeQyxMQfoQKGkC/fV0/30K/zFF2HKjzK1+Gt/JbR3t1rEEeuefYXKstkTBH9lRlSNk8zLffbLBxnjGAMVavPhrJdX1wX1gCwlv5dVEItf3guZIDET5m/mP5idu3PbdivQluIWOFljJ9AwqSi4cqPNNW+F7XeheHLCx1ZLCfSLNbQX0Nu6TsQqKZEZJV2k7Ojb19jjNelKNqgEliBjJ6mhmCDLEKPU0REznFujS+6j5fz6UbjskJKGdCkf+sf5V+pro41CRqi/dUACqOn2Hkt505DTYwAOiD2/wAa0K0grGFSXM9AoooqzMKKKKACiiigAooooA4gAD41nAxnw/k+/wDpNdvXEWH7/wCMOqyDkWulRQE+m59+K7et6/2V5IiHX1Cue+IdwLbwLr0h4zZyIPqylf610NcR8YGaTweNPjOJdSu4LNMdSWcHA/BTSw65qsV5oc3aLL9nc22gfD3T31GGWS0t7GGOcRpvIXYAxI7j1xXEfCrxlCJLHwpZBrrZc3CpctkKLZQzq3POSeMEDAr1wxRmExFFMRXaUIyCMYxivIfB/hZPC/xkureNG+xS2Uk9oT/CCygr+HzD6YNdNCVOdOop77r+vmZzUlKNj2GiiiuA2CiiigArDuYNWfxhZzQ30EejJauJbXP7ySUn5WxjoB3z+FblcrLDo8nxPhka4uf7ei0lisAH7r7OZcFidv3t3HXp2qZG1Bay9H0v/wAN69DJ+MdzNcaPp/hyycrea9dpaZHVYQQ0jfQDAPsa7mytYbGyt7S1QR28EaxRoOiqowB+QrgbBf7f+NF/dEbrXw7ZLbRnt582WYj6LlTXotTHVuRvif3dOnR8uZ+sv+BY87+LmdUuPDHhdeRq2oK869d0EI3uP5H8K9EHAwK88ixqvxxuHPMWi6UqAf3Zpmzn/vjivQ6cNW2GK9ynTpdlf5y1/KwUUUVZxBWJ410NPEnhTVNIfAN1CVQnorjlCfowU1t0UmrqzKhN05Kcd1qcl8LtfbxB4OtJbncNRtc2d4jfeWaPhs+54P411teY+I9/gDxo3iWJT/wjurlYdVRFz9nm6LPgdj0P1PUkV6XFIk0SSwurxuoZWU5DA9CD3FTB/Ze6OrGU1zKtT+GWq8n1Xy/KzH0UUVZxhRRRQAUUUUAFFFFABXn918/x2sVXlo9Bd29gZ8A/nXoFcB/zXz/uWf8A26qJ9PU7MH9t/wB1nf0UUjMEUsxAAGST2qzjIby4W2t2lbnHQdyewrCXcctIcuxLMfc1LdXBvJgwGIU/1YPf/a/w/wDr0ysZSudFONkFFFFSWFFFJQByvxHv/sugG3U/vLtxEP8Ad6t+gx+NcT8NdO+3+LHu3GYrJC+f9tsqo/Lcfwq38TdS8/Wvs6HKWUWD/vvgn9Nv610fwrsfsvhoXDJiW7kaQk9So4X8OCfxrH4p+h66/cYPzl+v/AOzqK5lEEDyHnaOB6nsKlrE1qc/aY0B+WJgzj1zkD8uPzrdK7PHk7K5Qe3c221mJDOGYDpnv+FM8gqcg807S783FuqXKss2CSQpwR61cmZETccYx1rc5ibTpikse/o/yE+/b+o/GtZwzbUjOHchFPoT3/Dr+FZ2l2fyCeYHc3zIp/hHr9f5Vq2rAapaK2OSxH1Cn+maylZs3jdRN+JFjjVEACqAAB2FOoorU5xrxpIMOisPcZqA6fZk5Npbk/8AXNf8Ks0UWC9iCOytYzmO2hQ+qxgVPiiigAooooAKKKKACiiigAooooAKKKxfGWtJ4f8ADOoakxG+GI+UD/FIeEH5kVUYuTUVuxN2V2YHw+P2/wASeMdY6pNfLaI3qsK7cj25rua534faO+h+EdOs5wftOzzZ93XzHO5gfoTj8K6KtK8lKo7bbfdoKCtHUK4XxZ/xM/iJ4V0ocpaeZqcw9Ao2xn/vrNd1061wXw/P9t+I/EPic8wTSixsm9YY+rD2ZsH6g1VD3VKp2X4vT/ginrZHe1Xls4Jb6C8dAbiBXSN/RWxuH47R+VWK5L4lajd6To9he2U7wiLUIPP2/wAURbDKfY5FZU4uclFdRydldnW0UUVBQUUUUAFUJre3g1GTU5YLRXS2MbXRjHnBAdxXdjOzvj1q/XIfFvUf7L+HGvzhtrPbGBcdcyER8f8AfVTJ2VzahB1KkacftNL7zO+CkUk3hW51u4XFzrd9PfPnqAWKqv0wuR9a9ArL8K6cNI8M6VpwABtbWOI+5CgE/nmtSiCtFIrF1VVrTmtm9PTp+B598NB9r8U+PdTOSZNVFnk/9MEC4/8AHq9Brz/4K/vPDmq3XBN1q93MSOhJfHXv0r0ClT+E0x/+8Sj2svuSX6BRRRVnGFFFFAEF7awX1pNa3kSTW0yGOSNxkMp4IIrzCKTUfhVcNDOlxqPgiR8xyrl5tNyejDq0fv2+vB9WpHUOrK6hlYYIIyCKmUb6rc6aGI9knCSvF7r9V2fn+hW0zULTVLGK8065iubWUZSWJtyn/PpVqvPNQ+H1xpd7JqXgDUv7FupDulsnG+znPun8B9x07AUxfiDqOhHyvHXh2709V639kpuLVvckcp9Dk1PPb4jV4NVdcNLm8tpfd1+V/kejUVi6H4q0LXVU6Rq1ndFv4ElG8fVT8w/EVtVaaexxzhKD5Zqz8wooopkhRRQaACuA/wCa+f8Acs/+3VdhPqcEZKxZmcdk5A+p6CvOLm5ml+Nkcjkw+Z4fMY8s9cXGSM9fx4rKpJKx3YKDfP8A4WemXN9Bbttdt0n9xeW/+t+NZV1cS3Zw4CQg8Rg5z9T/AEqJEVBhRjPP1p1JybMYwUQoooqSwooooAKiup47W1muJjtiiQyOfQAZNS1zXxCufs/hi4TPzXDLCPfJyf0BpN2VzSlDnmo9zyW8afU71F/5er+4yR6MzdPpzXvFlbR2dnBbQjEcKLGv0AxXkXgO1F941hJGY7ONpfxHA/U5/CvR9e8WaH4fuY7fWNQS1mkTeqsrHK5IzwD3BrKlom2elj+apONGmr2WyNW+uBbWzyEruxhAxwC3YVi7RKGWbcZvvMH4bkdQfTgeo4rHg8aaJr2sRW2mahHLMgby0KsBJxknJHHA4zV+7mSQeSilXXkoeGQ+o9P5Guqna10eNiITpy5Zpr10FNwyHaEJEZG141+ZfT5e/wCHWtO3tPtUqzSqY1By0e0gMfXnoP8ACk0Wx2xxXEzb3xlflwRnuffFX1v7Rr02a3MTXYUuYVYFlXjkjt1HWhu+xMY2WpZqvdZWS3lQ7WjkBDehIIH6kVYproroVYZU9azNTZsbxLkED5ZV+8h6j/Ee9W65sr8ysrFXXlWHUVoW2p4O28AX0kH3T9fStYz7mEqdtUalFIpDDIIINLVmYUUUUAFFFFABRRRQAUUUUAFFVLnUbK2u4LW4uoY7qc4ihLje/wBF6n61Ld3MFnbvPdzRwQoMtJIwVVHuTTswuTV57eSf8Jt42hsoDv0HQ5BNcuPuz3I+7H7hep/H2puo+IdQ8ZzSaX4MLw6fnZd6yylVUd1i7s3v/LrXZeH9GsvD+kQafp0fl28I6n7zHuzHuTXSl7BXl8T2Xbzfn2+8zvz6LY0qKxbTxPpF7rI0uwvY7u8Cl3WD51jUdSzDgc4GM5yaz/E3jWx0mYWNiraprUh2xWNsdzZ/2yPuD68+1YqjNvlS1Kckle5V+JOsTxWUGg6Qd2tauTBCB/yzj/jkPoAM/wA+1dLoGlQaJo1nptmMQ20YjBxyx7sfcnJ/GsDwZ4burO7udb8QypceILwYcpylvH2iT29T/Pqeuq6slGKpw2W/m/8AgdBRTb5mFcb8YITN8OtX25DxiORSByNsinP5A12Vc78RIvO8Ca8uM4s5X6/3VLf0qaDtVi/NDnrFm7azC4tYZlxiRA4x7jNS1leE5fP8LaNNknzLKF8nvlAa1aiSs2hp3QUUUVIwrz34x/6VZeG9JB41HWraJx/0zBLMf0FehV5943/0n4m+AbPqqyXdy/tsiG39aip8NjswGldS7Jv7k3+h6DRRRVnGcB8DP+Se2/8A19XP/o1q7+vP/gj8ng+5tuf9G1G6hweoxITg+/NegVFP4EdmYf71U9WFFFFWcYUUUUAFFFFABQeRg0UUAcrrfw98Ka0xe/0S0Mp6yQqYXJ9SUwT+NY4+GUdpg6J4o8S6aB0iS83xD/gLD+tehVSuNRhicouZZB1VOcfU9B9OtQ4R3aOuGMxEVyxm2uz1X3M4v/hEvGkAP2P4gzFR0W40uGQn6tnNRXGl+OrcfvfHFgp9P7LQk/QA5NdRNd3M5O5/KT+7Gefxb/DFQJGqZ2gDPU+tZu3S/wB7Nliar+JR/wDAY/5HJfZvH7P8ni202f3m0tBn6DP88VDPpHju4J83xfasp/h/s5Qv5ZrtaWpt5/iaLFSX2Y/+Ax/yOHGieNwMDxZZgD/qGp/jXK61pnimz8feH2n8Q27Xt7FPbxXS2KhYwo3lWXPOe1exVwvxYH2Oy0TWx00vUoZZD/0yY7W/mtRKKSudWDxU51VC0dU18Meq06dx/wDYvjj/AKG2z/8ABan+NH9i+OP+hts//Ban+NdsCCAQcimyyLFGzucKoyTVcqOb65P+WP8A4DH/ACOIk0nxrEu5/F1mB/2DU/xqEaf40P8AzNloP+4an+NdFeTn5ppztAB2qT9wf41gP4mSDLWcInnPR34RB7DufenGnzOyFHF1Ju0Yx/8AAY/5Ei6N44IyfFdoPrpqf407+xfHH/Q22f8A4LU/xrIn8U61ksJ0UeixL/WpdM8c3sM4Gook8JPJVdrD+hrT6u/6Zt7aqvsx/wDAY/5Gl/Yvjj/obbP/AMFqf41x3j218UQy2drqHiG3uuswCWSptxwCcHnqa9hs7mK9tY7i3cPFINykV5T8QbnzvEl4QflgjWIflk/q1c9RWR0YCvOpW1jHT+7H/IzPhtpPiS7m1K40zW7e0ZSsbO9msm/OTgZPHQfnTPEby6J8StIl8bajaalD9jfEjWgVEB3AZUZzg813fwit/K8LyTY5nuXcH2AC/wA1NaWq2Vjqt6093ZwymEeXG8kSyZwTnIIzjPpThT5krBWzH2defOtNVokntbex5lHf6FcfFXSpPCxtfsqWciu0aFFZ9rdeBg9K9G060N/cnfG0ZQE5ZQwXIOMHoee351l3Flp9vODaWNpbSrlkkiiUc45wwHIPcVyPib4k6l4bvPG2m2tjaibRUtpUmDE7/NiDEEe3Y10Qi1ddWeXia0MROPInaKtq7vqzp/FOgeKbhZFtvEjFCPlh8vyMj03J1rm/Auj69puoXtqdQk0WZwGMjWaXCygH++TxjPQetYN/8S5YRMb6TU38hIJLp4gDHCJRlSeRx9Bmuj0T4oafPqUWm3tveiVr7+zRdCNfK87jCk7s85ABAx64ru+t1YU3Tsmn5L/Kz+45KmGipKaf4s7gaF4qIyPGXH/YLi/xpf7F8WJyni2OX2fTY1x+RrjdO+NfhqKW4jAvpLRIZZ4pURGEix/e2APuA7gMF9uK9J8Ma7B4i0tdQtLa8gt3bEf2qExM4wCGAP8ACc9fY1zfWZ9l/wCAx/yKUIvZv73/AJmR/ZPi/wD6GW1/8AF/xo/snxf/ANDLa/8AgAv+NddRS+sy7L/wFf5D9ku7+9nJW+meMbc/ufE9sq/3fsC7fyzU8UXjMvtn8VWsXPDHTkK/nnj8a6akprFTXRf+Ar/IToRff72ZS6Z45UAxeJtMnU93sQMfTBp39nePf+g9pH/gGf8AGtKPfA263cxk8kAZU/UVoQaoAALpCh/vpyv+I/zzVrFN7pfcjKVC2zZzv9nePf8AoPaR/wCAZ/xo/s7x7/0HtI/8Az/jXaI6ugZGDKeQQcg06r+sPsvuRnyLuzif7O8e/wDQe0j/AMAz/jSfY/iCnC6poEo/vPbyKfyFdvRR7d/yr7kHJ5sqaYt6unQLqbwPe7f3rQAhC3sDziuR8VeHPFuoeYdK8WfZ0OdsP2YR4/7aLlv0ruaKiFVwlzK33IbimrM+fPDPgvxRpfjRRqV1dWElyrIupxRC6DMexY/cyAeTg9u9emwfDnTZZ1n1+91HXJlOVF9OTGp9kGBj2Oa7aiuirjalR329P6uRGlGJFFbxQ2y29uiwwquxFiAUIPYDpXBeK/hqddWTHiPWELf8s55fOiH/AADj+dehUVhTrTpPmg9S5RUlZniHhP4WXum67Na66biXTZ0ws9hclEJHO2ReGwRn2B+tes6B4d0jw/CYtHsIbUEYZlGXb6seT+JrWoq6+KqV/iYoU4w2CiiiucsKyfF6LJ4T1pG5VrKcH6eW1a1Utc/5Amof9e8n/oJqoO0kxPYzPh65fwLoBY5Isoh+Sgf0roK5f4Xf8k/0P/r3H8zXUVdZWqS9WKHwoKKKKyKCvPtVHnfG/Q0IH+j6RPMCeeWfbx6V6DXn7fN8e0DchPDZZR6E3WCfyqJ9PU7MHo5v+7L8rHoFFFFWcZ598KD9mv8Axrpx6wa5NMo9EkAKj9DXoNee6ERpvxo8S2ZJA1Swt79B2/d5iOPfJzXoVRT2sdmO1q8/8yi/wV/xuFFFFWcYUUUUAFFFFABUF1cxWybpWxngDqSfQCq19qAhJigAebvn7qfX/D+VZeGZy8rF5D1Y/wAh6ColK2xpGnfVk1zdz3XBzFEf4VPJ+p/oKhVVVQFACjoB0FOorNu5uklsFFFFIAooooAKy/E+lprfh7UNNfA+0wtGpP8AC2PlP4HBrUqnf3RhUJHgyt09FHqaGVGbg1Jbo5XwJ4lF14NsjcgtqNsDaXER6rJH8p3emQAfxq1Zz3Gqai0k7/uYPmCDhd3b/GuI1Hd4Z8bSvIxGm618xYnhLkdc/wC9+pPtXeeFgr6SZl/5auxz9OP6VEHfTsaY2K5/aQ+GWq/VfJ6GX4snfy0t1P8ArSd30HasW3twF5rZ1+MvqK56BePzqqFCLXbRVolUElAz7qJQuK569GxyBXRXZyDzWHerurU6DsPhvrcMVjcWd5MkSo++NnOBg9RntyM/jXEa7dG5lvLk5zNIz8+hJIp2jRzzXkkFsvmO8bEJ3bAyQPfANU9TYNasynIPNebirqVmd+BpxTc1uz1fwUwsPAenOAMlCwB7lnJH86sOqxW+5Q0UnUtG25WPup/pWX4aukn8IaHFuQR+WQ24AglG245/OrOqbBGI1XYezQNj/wAdORW9Je7c+fxbbrSv3Y7RYGu70s6IVQhmYHrzxkH6V5n4p8Iabr/ijWby6ku0N3L5VzHDNsS4WM4QOPYADjHFdrqGsf2bbR2VtLuu5wDM4G3ykycD/eP+e1eL6tomvXfxCGo2tkyQx6pDJ58MyKrW4ID7gW3ZwD8oAHXqaqnNObRvToOFNTkr3NQ+ELPWdZ1XUHuZG0m6NvGlrEWjDeSCpWRSBlcgYxUGmeEzY63cajd3DysNTbULeFXPlq3G1mXHLAg+3SodK8LavPe6SmtR3QsojetPtvCv3pQ0Wdj5Ix27d6ytW8N+LIbi/bTgzxWc0v8AZ6m4UedHPu3Zy3GzIxnHTit/kHS7ietWXw60OXSZY7W41OHTryGRfsaXP7qISA7goIzxk4BJAPatTwrq39jXT6OGJFriPY5+8oA2t+WOa8s1vwT4rkttPXSrCSX7Ha2q2d7BcojllkzJ5hdwQcEkbRznk9qyPFFtdWHxh1NLS7Z7S2lGoFd5OySVB8je2csB6EVxVPd1uc0FeXKj6wt5kniEkZyp/T2qWuI8Ha4t7YRXcZJB4ljHJ/8A1iu1jdZEV0IZSMgjvSTvqWn0Y6iiimAUUUUANj3Qvvt3MbE5IH3T9R/k1oQaoAdt0gQdnXlfx9Ko0lNSaFKKludCjq6BkYMp5BByDTq5yMyQHdbyGM5zjqp+o/8A1GtK11NHYJcL5Uh6HOVb6H+h/WtVNMwlTaNGijNFUQFFFFABRRRQAUUUUAFFFFABVbUVWTTrpGGVaJgR7YNWaraiyx6ddOxwqxMSfbBprcTOa+ErF/h1ohY5PlMPwDsBXXVyPwlUp8OtEDDB8pj+BdiK66tcR/Fn6v8AMmHwoKKKKxLCvPydvx7XdwG8NYXPc/as4FegV5/qn7n436I56T6RPEM8cq+78aifT1OzB7zX92X5XPQKKKKs4zzv4hH+x/HXgzxB92E3D6ZcN/szL8mfYMCa9Erl/iZobeIfBGqWMIY3Xledb7Tg+ah3Lg+5GPxqz4D11PEvhHS9VUgvPCPNA/hkX5XH/fQNQtJNdztq/vMNCf8ALeL/ADX6/cb9FFFWcQUUUUAFZWoXxYtBbNgjh5B/D7D3/lUuqXZiAhhOJnGSf7g9fr6f/WrLRQigKMAVnKXRGtOF9WCoqABRgCnUUVmbBRRRQAUUUUAFFFJQA2V1ijaRzhVBYn2FZC5ctLIP3j8n29B+FReINWSKNreIBySBI3ZRnkfWrAGV/Cgzm+hxfxIsY9R0b7LJgF3G1scqwBIIpnwt10yWUmiakRHqtkTuU/8ALVCeHX1HP+c1r+J4PMihOOBJz+RrlNa0Nr7ybuwmNpqtqd1vcL2P91vVT/nuDaptx5o7noYbkq0XRqOyvdPs/wDJ9fvO71ezafZLEMumfl9R/kVzs7Y3Kcgjgg8EUvhXxgNQnOm6vELDW4hhoW4Wb/ajPce3866C8s4L0hWjJmP3SvB/P0p0qttDCSnhZclRf13XdHG3DfKc9ayLo5z6V3F34RmePMN3Gz9wykD865678ManG48yJQhIXeHBA5/OunmRpHEU3szE0C8+xa/Y3PRUmXcR/dJwf0JpdbsHgu7+BI3MKyt5bbSAVJyMfhiu68O+E4LCQXM7edMPukjAX6D196f4mmNlLDMi/upPkb2Pb+v5Vx4hqevY1w2LcatoK9zC+GN8U0+5tJ5Xj8p8orKMEN1HI9R+orb1V4IvMuZYwsMali0YMecf1/CsWz15YNTjWcAROdrH0z3re8Q3a2lrF0bzH2ke2Cf6CphU5Y27GGJoynXu18R5pJPI10ilt00jbnJ7k1u2fE02Dxvbn8aiuLLTbu9E8EjW06ndjqhP07V02i+FZniD3FyiAk/dUknnrTwqtJtnoYvFU1FJ6GUeRV/SNIe+lWSVStqpyzHjd7Cugj8P21owkBNy4/hlA2n/AD75qd7nzE4+VRxt6Y9q6KlRrY8qeKUtIDbh1UYUAIowBXkfjmdb3WpSnzCNQg/r/Ouu8U+I47Ui0tmDXL5HHRPrXnkpImDkn5uTn9f6/pXmV5/ZNcLTd+dnT/Cp3Se+hzmP5WHpnmvVNHuNs727MAGG9AfXv/MH868/+Hlg1tpr3TDBnbK/7o6f1qfxrqY00WEh3AmU8qcEcdR+la03ywVzGprUfKepUVz/AIX1oajbIkrhnIyr/wB8f41v1sIWiiigAooooAKQgEEEZB7UtFAD7W5ltCFTMkP9wnlf90/0/lWza3MdzHvjbPOCDwQfQisOmjckglhYpIO47j0I7iqjKxEoJ7HSUVSsb9bj93INk4GdueD7g96u1qncwatowooopiCiiigAooooAKpa5/yBNQ/695P/AEE1drJ8XOI/CmtOxwq2UxJ9MRtVQV5JCexm/C7/AJJ/of8A17j+ZrqK574eIY/AuggjBNlEfzUH+tdDV19akvVih8KCiiisigrz/wAbf6N8TvAN50RnvLZz67ohtH5g16BXn3xi/wBFs/DerDgafrVtK7ekZJVv5ioqfDc7MBrXUe6a+9Nfqeg0UUVZxhXm/hD/AIpP4h6x4ak+TT9UJ1PTc9Ax/wBbGPoRkD0Ge9ekVxnxR0C61bRIb/R/l13SJftlkw/iYfej+jAdO5AqJrquh2YOceZ0Zu0Z6ej6P79/K52dFYvg7xDa+KPDtnqtn8qzL+8jJyYpBwyH6H+hraqk7q6OWcJU5OElZoKZNIsUbSOcKoyT7U+srWpdzR24PH33Ht2H5/yobshRV3Yob2ld5ZBh3Oceg7CnUlLWB1BRRRQAUUUUAFFFFABWbqt20Y8mE4dhlmH8I/xP+e1aJrnrlzJNM/q5H4Dj+lDFJ2RyHiS6CH7NF94/e9vauq8N3wvdPj3n98g2uPf1/GuEcPcahNI/dz+HNbWmNLayLJCeR1HZh6VuqXueZr7C9PzOr1O0Fxbuh4yMg+h7VzQBGVYbWHBB7GuosryO7jyDgjgg9RVLVdOM37yHAlA/769qmnPkdmZUqnI7M47X9Is9YgVLyM70OY5UOHjPqp7VT0zxDrnhdjHqcL61p3T7VF/x8xqOm5f4vr+JNbU2VdlkBVh1U1RmOSa2lTUnzLc9ONRSh7Oa5o9v8n0/q51Xh7xdpGuoDp97FI/eInbIv1U8/j0q/qU4kWONTnc4/Tn+leSaxo9hfSeZPbqJgciVPlcH1yKgsZNb0+5RLLXpfKHCrfJ5yj2LdQPpWcudLa/oc08voyfNTnbyl/mv8ke0NJjgHjFZeuW5vdMuIgMvt3J/vDkVy0OseMYFHm6NpupD+9aXXlZ/77pt9401KztnNz4X1KCQgqhBWRd3bJFcjmuooYKrzJ02n6SX5Xv+BjTRLdxIQeSOtWsTSQxJNPLKIxhd7Zx9K4rUNQm1CbTtKiivtPjuH2ySTx+WzKOy88//AKqk1jSo/Cv2TUNKmmUmZY5InbIlBz/hWHMfSLCrRSdpPb/h+h172wKmur8Ja3JGI7LUH3IRiKU9Qf7pP8jXE+KdSOj+H76+RDJLFGfKQDO6Q8KMf7xFea6R4t1rTdIudNujctdR3ELfbL2Ms0cEmAz4zyFYNzn+Ielb0m46ni4twqrkkv8AgH09q2r2lhCXuZ44l9WPX6DvXmXiPxfLes8elboIyMPK3DN9B2+teXprOuavqFmJZ0Z5RcMbqWFm81I5AFZV3DG4HP61Q0XUb9odHMzm9u1+170YOrKyqSqNzgk+46EUVaspppaHn0cPCDTlq/8Ahv8AM7EBhMh3Es24knr0J5/xrc0jSptW1BIYVxGGJkfHCLkZ/Hrisf4baTqHipGmN5G0aIpmPkmMQMwO5ACeSMEY7d+tey2lnb6VZi2tBwOWY9WPqa54UW3eWx0VMQoq0dxAsdvCkMICxxgKAOwFea/EC+F5qMcCHckCnOP7xxn+ldT4j1pLON4oTuuSOFH8Pua86uxuYSE5Lck+p9f1qq0/sozw1Jt87Or+G2pEStYyMcr88Zzzj/6x/nXsmn3P2mDLYEina49/WvBvBEDt4khKDhFZm+mP8a9k0uby76MdpAVP4DI/r+daUZXjqRWXLU0N+ikpa2ICiiigAooooAKKKKAGsucYJBHII6g+1aenXplPk3GBMOjdA4/x9RWdTXXcOpBHII6g+opp2JlFSR0lFUtNu/tEZSQjz0+9juOxq7Wydznas7BRRRTEFFFFABXPfEOXyfAuvNkDNlKnP+0pH9a6GuP+L03kfDnWnBIzGicf7Uir/WtaCvVivNEz0iza8IxeR4U0WHBHl2UK89eI1Fa1Q2MP2eyt4cY8uNUxnPQYqaok7ybGtEFFFFSMK5D4t6d/anw4163Ay625nXHXMZD8f98119MniSeGSKVQ0bqVZT0IPBFKSumjWjUdKpGoujT+4zvC2pDWPDWlaiCCbq1jmOOxZQSPwOa1K8/+CsskPhW50S4JNxol9PYMT1YBtyn6Ybj6V6BSg7xTLxVNUq04LZPT06fgFFFFUc559qMemfDW613xPdX0sWj35jJ02GHezXTNjMYByWb+6B6knA4mHxLsYYNOfVdE1/SZL/VINJhhvrVUcyzAlG4cgp8pyQSQe1X/AIm+ED4z8NpYQ3psb62uYr6zudm8RzRtlSy5G4dRj3z2rlfFfw+8ReN9I0iz8Y6no1ylprVtqEsFraPHE9vGrq8fzMzFn39TgCkklsaVKsqr5pu7/wAjX1r4raBpNtrk1xDqMg0i/j06dYoQzNLIMrsG7kflWHffEqxhewafSNbGp6tLItrpz26RzssYGW+dwoGCDy3JJxmue8QfBb7P4Z8SaRpNxp9taapq8F7a27ROY4kjHMbAHJzz0NF98Mr298L6dpM9l4QaG2aY/ZvsM4iTeQQ0bCXejdcjODx0xUya2HTT3Rs6t8UbHSX09L7w/wCJo3vnEUCmwGWlJI8v73LfKeBn1Ga7mwuPtljb3PkzQedGsnlTrtkTIB2sOzDOCPWvPY/hvcweH/A2mLq7XTeHb9LySe4U7pwNx2rycAbsAEnAAFelVm7dDVX6hRRRSGFFFFABRRSGgCjrF8LGzaRQDKeEU9z61z+lSm4sQztucMwY+pzVnWmNzLKf4IyUUfTqfz/lXKeHdSNtfTRyt+4kfPP8LetCTlsTZyvboWr/AE82t4zgfu5TuB9D3FSxLgV0zQx3MBSQAqawbu2ezbD5aPs+P0NdFOpfRm9KtdcrI0kaGQSRNtcd/Uehra0/VEuRtb5ZR1U/0rnpGqszkMGUkMDwR1FXOmpeppUoqevU62/sINQT5vkkHRh1Fc1d6FfLKyQR+eAN2VOMD6GrNlrTR4W6BYf31HP4iuk0a9imtjJHIrFmJPqOwz+GKzgpRdmckp1KB5ffwy277Jonjb0ZcVkTHJOa90uIra8j8u5hjlQ9mUGud1HwTpF2xaIS2zH/AJ5tx+RzW3MaQxsX8SOT8HX7yq9o5JaMbkJ9O4rW1UNeyxxt92MdPeprPwW2lXq3VreeaEBzGyYLAjpnNXRAjN5i96460ddAhVgqnPE47XfDMOsWqxSs8Ukbb4pY/vI1ZFv4OkS9guNX1SfUfIO6KN12qD6nk5r0pkUA8VlyxtLcBFXLMcAeprD2aO5ZnVhHli9P6+4888c65Np11YaZZRRvc3rMN0rlEUKM4JAJz7Yril8RahDrdzFLDDLZfa7W3XEvMJljU/LhfmG5ickjjp7e73/w60jVXdtW8y7DsGKOqlMj0BBrQs/AXhm05Gk20jbkfMqhvmQAKeeMjAwe2Kv6vJ7o5XjUloz56sfFN9eWF5fQ6NKbSOLzkYsyqf3qxkFiuAcup4z6V1uiTzWGtJHrmmQNFDqU+myeRdGQCaODzwQhjG5CuB1Byenr7J/wj3hyA3TJoekq90As7C0jzMAQQH4+bkA89wKxNf1jw9pchk+yWcl755uVWKFDIZiu0yE44Yr8u4844rRUKUPekc0sVVqvlicmfivcJo7XEui24L2Nrf20MF5keVPOsQRyUG1huB4BB5HGKyPEfxPvoNXbS7XSUaaJY/tUsczSrGXOMqdgBA45OMnIHTmrqbW94l0ttp9hZWly6vNb29uirIynKmTA+Yg85Pes8WFpNerNc2tvLLFEzJI8asVwRjBIyOtc068b2R0U8LK15GPN4tufsJ1R7SNoppDFCvnkyFvMCZcbeB34z2Heql14nultYgdPWOdYZ5XSWUoAIiOmVzyDkZArqbXR7OaeQR6dbvNcgrJiFSZeejcc/jXVaP8ADvR7ZrS61OwtZJYY2WO1MSGFNxBJ24xuyo5qKcYzexrVnKmtzmPCviW/0ZPEF3cafayRxPZxwg3BR1adYiit8mAv7zLNngjAB61ral8Sb2O6s7KHT4V1IajNaSFLsiNTEqncrbMkHeOo4II5rq9WtdHja5vr2wsnlli8mWR4FZ5E4+QnGWHA4PHFeZahBbS3cT21nb26QsVhjhiVViB/ugDjPfHWtpTjBWSOaFOVVuTZ7F8PvH8/ifXLzTL2wisJ4YmljjLyGSRFcJ5gzGEKnIOVc4yBz1HoNcR4D03TtMuZZLLT7O2mul/eyQwqjSEc/MQMnv1rtq1vcmOwtFFFAwooooAKKKKACiiigBA7wyLNEMunb+8O4/z3AroY3WSNXQgqwyD6iueNaGiSnZJAf+WZyv8Aun/6+auD1sZ1I6XNOiiitTAKKKKACuH+L+JfC9taEZ+16hbwfm+f6V3FcP8AEQmfW/Bll/f1VbnH/XJSf61vhv4qfbX7tSKnws7iiiisCwooooAKKKKAPO9OP9g/GfUbUnba+ILJLqMdvPh+VgPfbljXolef/GK3mtdK03xNZIWu9Au1uiFPLwkhZV/EYz7A13VncRXlpDc2ziSCZFkjcdGUjIP5Gojo3E7cT+8p063lyv1j/wACxHqln/aGnXNp9oubXz4zH51s+yWPI6q3Y+9fO2kf2gngT4p6tf8AjPxGJ9C1DUtOsDLqZVf3Kq0OemXLYHB5zjHNfSdVH0ywkgmheytWhmkMssZiUrI56swxyeByas4j51PiO8fTvh7b6j4k1MaLfaI19PdR6r9ne91HapNs91keWAScLuHoelT6N451u91H4ZXHhFNT1K21G31Rm0/VNT2NN5cjKPMl2kNswduQTgAE55r6C/srT/sX2L7DafY858jyV8vOc524x1qRbK0SSCRbaBXgUrEwjGYweoU9h9KAPlLUNY1/UPghY+I5fEetw6tbXjwMYrw7WD3ZT5uMkhcgH6VseNb/AMSeEPHcUWjarqmpaZpGhC+vLW6nMj3Eb3Equ+ePnQMpB9IwK9xksbJ/tEIs7b7M0pIi8pdmQeu3GOozWF4vstcM0GoeG/sEk8SNHPa3MQ/0mMnO3zOoxzgcDJ5rGUjrpUudqN7ep4Lf+Ktbksvh+J9eu4lvNIkmuWfWRp4lkDkBmmZWGfYjmtjxv4iv9K8VXVxNrdxqmlKbWCC20rXRBd2jFVBzb4xcFiwOSCCD2GcemaN4j8N6rNFput6Vb6VqkI2LZX8CgD/rmxGCM9MYz6V2f2Cz+0JcfZLfz4xtSTyxuUegOMgUlNPYqrh6lF8s1b+vxPCLrxFqFj8TSuoavcatbXOui1thpOtbGtAHx5Etl0YDaQzY6c56V9A1XWytVuzdLawC6YYMwjAcj/e61YobuQlYKKKKQwpKWo55UgheWVgqINzE9hQBzp+e3Dd2+Y/jzXExQmO5lQjkOR+tdnZyrNaRsmdpHGaxNTtTFqBcD5ZfmH1HB/pWlF2kOg7TL2kX5twsc5/ddAx/h+vtXQlY5kwQCDXJKPlxVmyv3tMKctF6d1+n+FXOl1iXVofaiTajo0iZe05X+4T0+lYD5VirAhhwQRgiu3t7tJow8bBlPcVHe2Frfr+8XD9nXgiphVa0ZFOu46SOIJquZXhk8yJ2R/VTit7UNCubcFof38fsMMPwrn58gcgj610RkpbHXGcZrQuW/iq/tWxKFmUevB/MVs2fjaykIW43wN/tDI/MVxM+Qd2OAapalCUYSD7jd/em4oxnhaUulj2CPU4rmAPA6yI3RkORWaYJrmWSa3l8uMngEZB9TXmOjXNxDfQi2ldCzqrBSRkZ716+rCO1jCgDiuetpockqHspbmW9peYIMy49lqvDDPZXcdy7NKEPK8dCMce/Nawck0SDchB7iudOzuJq5Su/F2lW24PeJuXgqASR+GKwNS+IEQGLK3llJON0nyiuQ8TWhtNbnWRcpL86+4PUVmsDGOPnjPY9RWNTF1E7LQ66WCptKT1NXV/EOrahkSXHlRH/AJZxfKCPr1rHCowOR+J7fWrmn29xet5VtBLOT0CKSR9a6rTPh7qV2yveOlmnfJ3MR9B/jWHLUqu+51OVKgraI46Ntp2nhwOvXIrb0HwvqGqSPPFCIbdgF82QYBGckgd+1d/Y+C9M0to5QDdzpyPOwVz7Dt+taz3RkTj5V6Y9Pat1hXHWZzTxqlpTMXTNFstEtwluPMnxhpW6n/CqGs6lDYxGS4fk9FHU1Hr3ia2tS8Nqyz3A64OVX6muEubiTUGWe5cvI3Jz2B7Up1FDSJNKhKq+aWwmsahLf3Su5xGPuoDwKr6Pam61W2jxkblZvoOtRyj5wP8Ab/xrsPBul+VGbyYfO/CfT1rCCc5anVVap07I7fSP3c9qB13gfnxXWivN9cvltLSE7yjtKqqQcEHr/Su40K+/tDTYpmx5n3Xx6j/Oa70+h58TRoooplBRRRQAUUUUAFFFFABUli/l6jCezgof5j+X61HSBgksTnoJF/mBTW4pK6OjooHSitzlCiiigArhtb/0z4t+HIOv2GyuLsj03/u/6V3NcN4eH2/4p+J73gpZW8FijfUb2H4EVvQ05pdk/wAdP1In0R3NFFFYFhRRRQAUUUUAQX1rDfWVxaXSCS3njaKRD0ZWGCPyNcL8Ibuays9S8J6jIWvtBnMKM3WS3b5on/Lj2GK9BrzX4jI3hfxRpHja2VvsyEWGqqo+9buflc/7rY/8dFZz0tI7sJ+9jLDv7Wq/xLb71detj0qimxuksayRsrowDKynIIPQg06tDhCkchVLMcAck0tVNWbbp0/qy7B9W4/rQxpXdjEgBEKZ+8Rk/XvUlIOlLXOdRm65oema7a/Z9XsobqPnG9fmX3VuoP0NcmPCWv6AM+EdfZ7Zfu6fqgMsYHorj5lHsPzrvqKTimdFLE1Ka5U7rs9V9zODHjTV9L+XxN4Vv4VHBubAi5iPuccqPrmtLTfiD4W1AgRazbRP3W4JhIPp8+K6qs/UtF0vU8/2jp1ndEjGZoVc/mRStLuae0w8/ig16P8AR3/MsWt5a3a7rS5hnXGcxSBh+lWK465+GnhG4Ys2jxxt1BilkjwfUbWAqH/hWWgrxDJqcK/3Y72QDPr1ovLsLkwz2m1/26v/AJI7auc8T3eYpIgf3UYy+P4j6VlP8N9ERGZrvV9qjJ/0565bxD4J02x0ppluNSMhx967YjJo956WJdPD7e0f/gP/AATd8JX/AJ6T27kZRiye4PX9f51vXVuLu3KZAkHKn0NeS2HhazbDedeg+1wwrqrPwRpFxCsi3OqDsR9sfg1c4yhrYqph6EHf2j/8B/4JrAEZDDDA4IPY1geLNeOhpabLR7qS5k8pERsHPbsc1oXHw40qWItb3OpeaOcNdsc+1cR4r8NPpF3pdxpttqF3Lb3KySRNI0hwpB49M461o60nHRHdg1hqtRRcr+TVune5ft/Gt9a6haQzaPdWf2mZYg0j8EkgdMc9a9EstajkIWf90/qfun8e3415Lql5qWt6po+7RLy1jt7tJGdwSMbhnsMV255ohH2l7snH4WnaLUVFu97O/wCrO5+0MUAjYEv8qkc9e9aflQNEI3jRkAwARmvNre4mtZFe3coQcgdvyrQTxDeLkuYiB/sn/GtI03E8WrhZ3906uTQtLkzm0iGf7o2/yqs3hjSiMCAgegc4/WuaHjOWNsS2+V9VarUHjixdgsnnRsePmTP8qqzMnTrx6M1h4Z06D5oEMbg5B4wD9KcW3wI3TI6elNOsQSr/AK5F/wB7iiMHyBkYJ5x6ZrCqKDk37widaWYkCnIOaZcfdrE0GRaBpmqQJNqNsJpDnBLEYGTwMGrMXhfQYTldOhJ/2iW/mawbrxTb6HGsV0sjB2OzYAfc5rIu/iKWJFpZOT2MjgZ/KtHOjH4rXJjCvL4b2PSIfs1nEI7aKKFB/CigCq13qUMKF5ZFVR3ZsCvJr3xbq1yeJI4Eb/nmv9TWHdSTXLZuppJGPG52JrOWMivhRtDATlrN2PSNZ8dWFsGW2LXUnpH90fVv8M1wmpa7quomUtcNFGxyYYvlGPr1P41lQjaWJ5H8X+NSNmMjvGfukdVrkqYidT0O2lhadPXdkVoSJyD3Q89jyKswjaEU9Qo/z+lQKwa4dkALbAox3JP/ANauu8PeE7i5c3Woq0EBxhDwzAfy71lGDm7I2nUjTV5GToGiyardebIrLaKSS3Tdz0H4V3uFjUIgAVRgAdqsFI4IlhgUJGowABWBr2prYwEIQbhgdi/1+ldcYqmjzpzlWkc14+v/ADbiK3ib/UZZiP7x/wABXffDPUfPtUDHiZc/8CH/ANbP5V5BdFpWd3JYuM5Pf/Oa7z4aSNFpSTf885S34A5P6ZqKU+abNq1NQgvI9fpaQUtdRgFFFFABRRRQAUUUUAFRXRxbSkdQhI/KpajnGYZB6qaBnTDkDFFR2x3W8Teqg/pUldBxhRRRQA2R1jjZ5GCooJYnoAO9cR8I42n0C+1iQESavfzXfPULu2gf+On86u/FHUn07wXfLb5N3eYsoFHVnkO3A98bj+FbugacmkaJYadHjbbQpFkdyByfxOTW692i/wC8/wAv+HRG8vQv0UUVgWFFFFABRRRQAVV1Swt9U065sb6MS21xG0UiHupGDVqigabTujzv4X6hc6VdXvgnWpC19pQDWcrcfabQ/cYe68A+nA7GvRK4j4l+Hbu/gs9d8Pjb4i0hjLbY/wCW6fxxN6hhnHv6ZNbng3xHaeKtAt9TsjtDjbLEfvQyD7yN7g/mMGs4PlfKztxUVWj9Zh1+Lyl/k91810NuszW2+SCIfxPuI9gP8cVp1i6q+/UAvaOP9WPP/oIqpbHJTV5FeiiisToCiiigAooooAKKKKAK2pHGn3P/AFzYfpXKeKojPo0uP4cN+RrrNQXdY3AyBmNuT24rECrcWzIQGVh09RQnZkydmmcNYrha2bKV7d90fIPBU9DVP7M1rcPC3VTwfUdjVqPpXbpJHc7TXkY3hPxRNP8AEvxlp17qCC0tjYixgkKqVLwkuF7klsetYrfFBdU0nQ5Hs7Jry8TUnniSY77f7MkjJx1G7yxnPrXSS6HpD6qmpyaTp0uoo6yC5ktkaTcuNp3EZyMDBzkYFaNlpHhya5eYaLpcd45dnY2se5y4Kud2OdwJB9QTmuecHDU4Z0pQ1R5ZP4z1nT7J7vUtOspI5dBj1y3W2lYkIzogV9wHOXBOOgB61DceNdZtRq1s9lYXN9ZNaqDbSEo3nKzEhScvtC9AcnrXtF1oWnT2clvHawWxazNgs0EEYeKA/wDLNSVICjA+XBXjpWJ4e+HXhvR7G+tPsSX/APaDx+b9thiZSUyEwiIqKF3MeFHU01WYKtNbs5rwfrTa9oMV67Ql2d0bykdACrEYIbkH1HP1rSlruYfB2kW9rHb2SvawxjCRxbQo/DGB+FRSeDrZul3MPqAa3UjaOLp21PN7vvTtFsvOufPcHy4ume5rv/8AhB7MnMt1cMO4GBn9K04PD2nwIEWNig6At/hihyFUxkGrROG1G4W1tnlbr0UeprsLMubOHzBh9oz9at3GjacQu61jJHKluSp9RmolbfChxgkA1zVuhz+0U9hU60y4+6aeops33axA8x8bgtfQqRxtJU++a51cYz0x1/2T/hXslnpthqMk8d9bRzgBSu7t1zj0plz8PtFmYvCbiAnskmR+oNZTwsp+9E6aWLhBckkeTqQqnPKfxe1OZAU2k5B6HuK9MT4a6ej7hfXYHoNv5dKvW3gbRLfG9Jpsdnk4/TFQsHUe5q8fSXc8gQMHwBmT0A+99K6HR/CWq6ku5YRb2rD704K/kOteq2el6dYHNpZQRt/eCjP59asSzgA8j8K2hg19pnPUzBvSCscl4e8L6bpRM5Uz3e7JaQD5T7Cti5k3Z7Cqmp6hbWErSXEyRqy5O49x7f56VxeteLnuHMOmgxoQcysOTx2Hb8ac3GloRTU62psa/rMOnqEyHnb7sY/mfavP7i5lu5RcTnMhOD9CKWZmmMM0rF5CTlick8VGcBSB/fAH5f8A1q4qlRz9D0aNFU15lWcfdA9x+tel+D7M2ehwRuMMy7mH1rj/AA7pJ1O+RnH+jRMWc+vOQK9FLrDEzcBVGfwrWhH7Rz4ud3yo7LT7hLqxgnjOVdAas1yHw/vvMtGtmbIA3p9O/wDSuvrrRggooooAKKKKACiiigApsnKN9KdSGgDdsjmzgPrGv8qmqtphzptofWJP5CrNbo5XuFFFZPinW7fw7oN3qV1ysK/ImcGRzwqj6nH86qMXJqK3ZLdtWcxqp/4SL4m2GnrlrLQo/ttxjoZ2/wBWp9wPmH413tcr8OtGuNL0NrnU+dX1KQ3l4T1DtyF+ijAx65rqq2ryV1COy0/z/EmC0u+oUUUVgWFFFFABRRRQAUUUUAFeY+KbS58B+IpvFmjQvNot2f8Aic2UfVT/AM/CD1Hf8fUkenU11V0ZHUMjDBUjII9KmUeY3w9f2MtVeL0a7r+tn0ZBp19a6nYQXunzpcWs6h45UOQwrJuWD3lww/v4/IAf0ribqC9+F2pSXljHNd+CbqQvcWyAs+muTy6D/nn6jt/PqNMvYNRso720lWa3uMyo6nIIJJrNyvo9zeeH9n+8g7wez/R9mv8AgrQt0UUVJAUUUUAFFFFABRRRQBleJJNulyIDzKQn4dT+gNc54dv1mt9mfnhOxh7dj+Vb/iEbhEvba7fiNv8Aia800i6e11N5E5BOGX1FOMXJ6CUHNtI7nVrL7Uglhx5i9vUelYyHj0PcHtW9ZXKyRq8Z3I1Mv9OE5M1uQJD1B6NWlOpy6MqlV5PdlsYbnrVSXnNWZg0bFZFKuOxqo5rpTudqaa0LVrqlzb4UkSp6P1/Or8OuRCeN3idQuT2POKwab1qfZxvexlOhCR1//CS2g+8XH1U01vE9kvWUj/gDf4Vx0jcVAzqpJYZI6CnymLwUO7O2bxNbcbWc5/2T/Wqt14piihkl2yFU68AZ/WuQ3lYy7nnGTVG/lLaUn+22T+ppcpH1SFzpF8aLd3UcAgeNJDtLlskZ9q62MAoCvTFeT6FYzXd9CY4nMSupdwpwoz3NetqnlxIPasK++hNSnCm7RExUcw+U1NUU3Q1gQc3q2stojC5VN/IQpnG4E0+2+Iemuo8xLqJu4KBsfkabrWjSa0j20DKsu0upbpkdv1rzzU9LvdMuDHe27xPnGSOG9we9ROrUp6rY2pUaVXST1PTf+E+0vH+sm/79GoZPH+mY+U3BPtF/jXmUZIYbxwePxoZTEwwMr2/wrP65U8jf+z6XdnoEnj+0bcI4Lp2HYgL/AFrIvvHF7L8tpbpACOHc7j/hXLyRhiskZweoNBxInoQef9k+v0qJYqo+pccFSj0uMu5ri4ujLeSNLI38bnpQF2uzDtG368Y/WngCVNrcMKZGDsbOWLOFUDqQP/r/AMqwu3qzpSSVkSn7kajs5/l/9er+j6RcapKnlgrCGLPIRwPb64rb8PeDri6SO41LdBDgkR/xNn19K7Axw2sKw2yKkajACjpW9Oi3rI5a2JS0huUrW1hsrdYLdcKv6+5rH8X6itlpEsYP76YFFA9DwT+RrT1K9hsYGlmYAdh3J9BXnGuX0l/PLNL2O1VH8IxwK0qT5VZHPQpOpK72O5+Gk5MVg5ODnYf1FeqV5N8P4zFp9m54xIp/8fruvG3iWHwnoD6pcW090olihWGAqGZpHCLjcQOpHU1tT1SJejZv0Vw9n8QrW4uPsc1hcWGqRahBp9zZ3rqrxGZSyOpQurghTjB5weRWg/jzw5FJqEdxfSW0lgiy3CXNpNCyozhA4DoNyliBuXI5FXYLo6iiuG1L4maJZ3OnKn2iaC4up7OdxbyrJbSRRGQhoSnmEngYA/iB5Falp448OXlxYQWuppNNfW6XVuiRuS8TFgG+7xyrDnGCOaLMLo6WiuVT4geG2tr2Zr6aM2csUM0MtnPHOryf6tREyB2LYOMKc4PpUV18R/CtrZR3U+pssMizMMWsxYCJtshZQm5dpODkDFFgujr6Q9Kx/D/iXSPEL3aaRd/aGtGVZlMboV3DKn5gMqRyGGQexrZpAaujsDp0IH8AKf8AfJI/pV2srRHw1xF6ESD2BGP5qT+NaUsiQxPJM6xxoCzMxwFA6kmt46o5pqzY52VFZnYKqjJJOABXndhnx94pj1JlJ8M6TIfsoYcXdwOsnuq9v/rkUl3e3PxFuZNP0ppbfwtE227vQNrXhH/LOP8A2fU//qPf2NpBYWcNpZxLDbwqEjjXooHauq3sFr8T/D/g/kY/G/InooormNAooooAKKKKACiiigAooooAKKKKAKmqsF0643AHchTB5BJ4/rXkl3oOqeDLuTUfB6G70qQ77rR2boe7wnsf9n+fAHqWtvkQQj+Ji5+i/wD1yKoVjUV2d2ErSop9U909n/XfcxvDHibTPEloZtNnzInEsEg2ywn0Ze38q2q5PxL4Ks9VuxqWnzy6Vracre2vBb2dejj68+/astPFmt+GmEPjXTGktV4GrWCl4iPWRByv+cCs+a3xHU8PGtrh3r/K9/l3/PyPQKKz9H1nTdathPpV7BdRdzG4JX6jqD7GtCqOSUXF8slZhRRRQSFFFFAGTrQzJCPVH/mteXrC0OpzxsORIcfTtXqmrj54G/3k/MA/0ridfsjHdx3Kjhvlf+hrSlK0iqUuWpr1Cxnktzuj6Hqp6GtyLVraOLfJMseOqsfm/KuMN5LcuYNOAJH35T0X6VYttNjhcSysZZ+u9ucH6VpOHP8ACbVKKnqjoLrU4tQGy0sJrg9mI2gfj/8AqrGutG1xstEkMa/3WbJ/Pmtux1ZDtS4xG3QMOFP+FbUc+AM8isbyg7M5uaVN2R5pLZakj7Z7oxt6bKYbK7/5/m/75/8Ar16e0dvczwJLGrruJKsMjgH+uKnOj6aTn7JD/wB81vCXMrsv62lo0eSPbXy/dvAfqtNSw1uZsQQfaM/3UP8APpXsMdlaQcw28SH1VAKV5FXqQKr0Iljn0R5Uuha4Uxe2ZijPUxnecfQf41u6ZZ6DbRql/Dcuy/8APynyj8B/WuqvdVtrRC08qRr6scZrldW8aWu1kt42uD0G4bV/WlaTMvaVa2iX3G/Le6d9geKzlt1QIQEQhe3pU27cAc5ryp7ttS1e2MsaKGkUeXGNowTiu7TQzGitaXk8LEdM5FYVrpq5XsXT36m3UcvSsnydZgOEuIJ1/wBsYNJJdasi/PYxP7pIB/WsQsWbaZbfUYpHIVMlST2B/wDr4ronW1u4vKuI45oz/C4BFeba5f3ZtJVawlQspGQc9q47SPFWraWoELSvF0Eco3AH0HcVSrqGkgWHlU1juj2K98E6FegkW/kse8TFf06fpWFefDQFCLTUcjsJkz+o/wAKxrD4mJt23tjcRt6x/MPyOK17f4j6W/BadT6MmKbVCfYFLE0+/wCZlf8ACudZiJCzWkinod7A/wAqaPh1rROQ9ojevmH/AArpofHWny/cMj+y4P8AWrQ8WwMMi2vCPZP/AK9L6tRexX1uutGc1D8N7zO64vLdR3WLJOPYkYzXSaRoOkaTEj20PmSgf6yT5m/+t+FDeKYWB/0W8/791z19450q1lmDeeWznYqZ5xz3/wA80OnTpq6JVWrVdmdbczFgewrltd161sEcKwlnAzsU/wAz2rh9e8aXeo70gdrW3/ur94/U1mmaMRuxlTAhJYk9OO9c0638p1U8LfWZa1e/ub6cvcOTjlVHRRx0rLv7mC0illu5Uij+TLOcc+n1qtLqk+oNINDgWWPYM3k2RCOv3e8n4ce9a/g7wzHd66l1evJezW+HaebHynPRFHC9O3OOpNYqLk/eOmUlCPu7I6nRX1rUrK1t9KhbSLEBVN7dR5nfpzHEfu/7z/8AfJruNY8A2Go+FptFF7qERmuI7qS8aXzp3lRlYMS+R/COMYA4AAqlLcrahJWGVR0Yj1AYV3isGAIOQRkGu+LtsebHW9ziLb4cWKXAvLrUdQvdUfUbfUp72cpvmeFSsaEKoVUAY8ADrXM33wZgtdE1aHQtRla9u7ZbVGu1jUBftCzFnZI9zv8AKRubcT3r1+iquyuVHGab4Bs7PWbPVpb+9utRgvZr+SaXYPOkkg8nBCqAFVMYAA6c5pnh34d6docIjt7y9dRpC6Pksqt5YeR94IHD5kPPsK7aii4WR5OPhHFo+k3A8P3ckup+bZTQPM0Vssb2xfa2UhYEkSNncjbj1x1q3onwvC6H5Ot6hI9/Naajaztb42YvJN7kEqMleMHAB54HSvTay9R8QaRpoP27UrSFh/C0g3f98jmqipTdoq4morVlPw54YttC1HULy3nmke9itonWTGFEMexcYHccmugrjW8dRXjFPDulahqz9pEjMcX4u3T8qb/Z3ivW/wDkKahDo1o3W3sfmmI9DIeh9xW31aS1qNR9d/u3I9qn8Gv9dzc1Pxdpvh28C3DtPdSIVS0txvmduNo2jp361WTQ9b8aSJP4szpuigho9Ihf55e4Mzj+Q/Q1LoPhzS/DzpPYWwE4cNJcSHfIwz82WPtngYFd8Olawqwpq1Lfu/0XT8zKpCTd5kVrbw2lvHb2sSQwRgKkaKAqj0AqWiisdxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFMmdYonkc4VAWJ9hQBi38plv5cfdjAQfXqT+oH4VFUcW4oGf77ZZvqeT+pqSsG7nUlZWCkIBBBGRS0UijktX+H2gahcm6ht5NOvuoudPkMDg+vHGffFUhoPjPTABpXia3v4h92LVLbn8ZE+Y13VFTyo6Y4yqlyyfMvNJ/nt8jhxqnj22AE/hzS70jqbW98oH6b6X/AISPxn/0In/lYh/wrt6KOV9x/WYPelH/AMm/SRxH/CR+M/8AoRP/ACsQ/wCFH/CR+M/+hE/8rEP+FdvRRyvuH1in/wA+o/fL/wCSPN9b8UeK4oYWufBYgUSjDHVYmycEY4HHXrWJrGt+JtSRtPXwp5UrrlsajEx2/lgV6B40TzLNE/2Wb8tv+Nct4JvROJnuGzeE4JPVlHpS5X3JeIp7+xjp5z/+SOYt73xBYxi3HhbaVGT/AKfHz79KkfV/EOOfDGP+4hH/AIV6Pf2CXsQZDtkHQjtXOXcUtu+yZdp7HsfpXTTblpzP8P8AI6KWMpz0dON/+3v/AJI5RtX1/PPhr/yfj/wqa18ReJrXiHw98n9xr6Mr/Lj8K2mOTSZFaOm3o5P8P8jV1actHSj/AOTf/JFeLxn4jjlWQ+FVOARgagg6/hU7+PvEP/QqY/7iMf8A8TTSagkYCkqNtpP8P8jJww71dFffL/5IJvHniIjjwyB9b9D/AErIvfGPiibI/sgQr6R3SA/n1q5I9U5Xp+yf8z/D/Iajh46qjH/yb/5IwrjU9XkYtLpBZj1LXak1XN/qec/2T/5Mr/hXRWNjdalcCGyieZz3HRfcntXofhzwba6eFnv9l1ddQCPkT6Dv9TQ4tfaf4f5Cq46jSVnTjf8A7e/+SPOdCs/EsMsOpHwu88Kgsoa+jj/HnnH4V2Da94r4/wCKMwP+wpF/hXR+LvEmkeHLWA6zcMhunMMEMUbSyzNjkKiAsfy44rC0rxvo1/eQWiXLpJJavdq88TQrsWXymzvwQ2/jBHY1z1YS3v8Al/kcX16FR3lRj/5N/wDJEB17xX/0Jn/lUi/wqKXXvFOMHwdj/uKRf4V1k13bxSxRSTxJLL/q0ZwGf6DvWbqWr2Notwbi7gQwRmWVS4LIoGSSOvSseV9yvrNP/nzH75//ACRyk+o+J71jAnhP94QcD+0Yjj9K8zj0cy65qVvq9u0FzE4VoxIDtbnjI4PSvfPCN/a6jC+o206SWckaOkucAqRkHnpwR1qhrPw68L6vqV3f3zTC5lYPKVuNoBPTjtRPDucU09TqwWaUqLnFx5LreN2913keK6DbrBqGpQRdEZNueo61uPGCN4Xnow9a3NQ8EW/h9759IuY72KFTJNGsoM0QXPVfbNcrp+uWl/cpHb+Zl7ZLn5kx8jE4P6VxzpTg9UdNfF0sTUc4Sve3roki48KNtK9T0x3ppkNuuVNxjuI88VYdQATzsPJx2PrSoSDnuOGA/nSpyUZXkrr7jGcXJWRlS6zcsCivKQePncn9KmW6hMe1xITjrs7+tWr61SddxUFh37kU5QFRSpJwOpr0a2Jwc6cVCk01vr+tn+hyUqFeM3eat6foZz3ETREMjl8Y5SoNVtdN1CQebbSOqHKptOM+pXofxrZkCtJGe+Rn6da0NH0m91WdPs8TeWSS0jDCgfWueNShf3ab/wDAv+AaSjUS96at6f8ABOfhluCzRwQzzA4AHlnIA+n412Wga1b2NkIINL1aWTO6Rktgcsfx6V1WmaPb6PBsjPmTty8h6k/0FZmvolsjXsDiKdOTj+P2+tdMXRhr7PX1OGpOpUfLzaehkar4jkkMcI0u+jdjuCyKFJA/Guy0jxPrT6bbrb+F7ydUQJvM6JnHHf6V5daajJqmurcS8Ehht7KB2r3TwvxpzL/dkx/46p/rV069KW1Nfe/8xSpSg7OX5GR/bXi2QfJ4Tii/66ajG2fyFH2nxvKcR2GiQdsyzO34/LVrRfHPhvW9V/s3TNUjmvfn2xFHTfsOH2lgA2O+M1t/b7MwTTfa7fyYWKySeYu1COoY54P1rX28VtTX4/qxcjf2n+H+RzX2XxvMP3mpaLbZ/wCeEDvj/vqkPh3xHPn7Z4umAP8ADb2aR4/HOa6f7daYiP2qDEuBH+8Hz56Y9c4NRWWqW12szIZIhFNJAROhjJZDhiu7GV9GHBHNH1mS2SXyX+QeyXVv72c6fAdncZ/tPVNZ1AHqs92dv5ACtLTvCGgadg2uk2oYdGkTzGH4tk1bv9e0qwsb68ur+3W2sVL3LBw3lAf3gMkfSrKahZv9n23UGbgZhHmDMg/2R3qZYmtJWcnYapwXQsqAqgKAAOAB2pah+0wbgvnR7i20DcM59PrT43SRd0bKy9MqcisCxZFDoynoRitzT5TNZQu33igz9e/61iVpaKw+zyJn7kh/XB/rVw3M6q0NGiiitTAKKKKACiiigAooooAKKKKACiiigAqhrLhbTyz1lYJj26n9Aav1jau++9jTtGm4/U//AFgfzqZOyKgryKopaKKxOkKKKKACiiigAooqOeTyoXfGSoyB6n0oAkopBS0AYviKPzPKB6FXH/oP+FeaQRPZ37qhKsjZUivTPEs4hjs8/wAU4Un0BBH8yK5DX7Py5hcqOOjVdOVpWfUqlJKdn1NXSdUE2EkISb07N9P8K1pkhu4ikygg9jXnc93HEpZmAA5yTjFSWHj6wt5Vgvpw65wJE+Yj64qqlPl1Q6tC2sTob7w/LGS1q29f7rHn86xLqKa2OJonTtkjj8+ldrZ30dxAk1tKk0LDIZTkGp8xTzwpLGrKW5BHBwCf54ohVexEcRKC11POZJlHU1SmuVJwvJPYV68+n6c5y1nbE+8S/wCFPit7ODmGGKP/AHEC/wAq6OYbxy6RPJrTRdX1Eg29nIiH+OX5B+vX8K39L8BEuJNWudw/55Q8A/Vq7uSeJe9UL7VoLSIyXEkcMY/ikYKKlyMJ4upPRaE9pa29jAIrWJIYl6KoxTnmBOE5Neeat8QEuLlLLQITeXcrBEZgQmTx9T+leg2ULxW0QnZXmCgO4GAWxyQKiM1LYwnCUdZdTi/G/hvWLvxH4e8R+HzZS3+kmZDa3jskcscqhWwyglWGPT/A814j8C6r4s1pr7xBZaPLcyaFcWMcUbM6RXLSlo2UsuflTGW45zgdK9YnlOQiAszHAA6k1bs7UQAsx3St1b09h7UTlYdODk/I+cbv4a6x9rtJbo292ws7GBt115L2ktvGqttYxOxUspb5SpJJzToPh3qt/wCKtUWGHTltb4XbP5rLcFmlUhXBMQeMAkE5dvQdq9u1q1SbUZt4OcKRgkdsf0qv4chFvrhVBgNCwP5rXPzO5vyq9jF8G+Evs/wybwrq1jZWUrWrWdwtq29ZCU2mYnavzN97v9TXE6P8KvE323Rp9ZvrKZZpoW1lA7MJI7bYLdU45zsO7OPvGvd7q383Dodsq9D6+x9qrQzbiVcFXU4KntW8ZKRjUg4PyPGIPhv4lPjcaxdLpYUSajvmgkCGZJ4pFjBjWIYwzAks7EnJ+u/4C+Hlxpup20mvRWU9vHoVrpxCsWImjZixGQOMEc16d1rl9d8WJoeqLbahayrBIAY51+YH1GKcnFL3tiY80naO5Jc/D/SJc/Z/Ng9kfI/XNY9z8NSGDWt+Vxxh488fga37HxZpF2B5N9ECegZtp/I1rxX8bjKShh6g5rP2NKetjX6xWhpdnnP/AArvVYxtS4tpB2JLA/yqIfDvWN5w9qFPX5z/AIV6cbxf79Na/AHDE1H1SmX9eq9zhtM8Bx2NxHLqsqTgjaI0ztB68+vArp5GSGIRwIEUDAwMYpNSvVCK8rqi7s5Y49c1xHiDxtbQbo7AefIP4/4R/jUTUKWi0HCVSu7vU2tZ1KCwhaSd8dcDqT9K8813Upr+bcxKxAfKmffr9ao67qyIHudTusGRQFB5JJz8qqOSfYCsmePUdX+/5mmWIA+UEfaJPqekY+mW+lck5ufkjvpUVT31Y+xvxb+KFtrGBr68ccW8TAYJxy7HhB7nn0Br2zwVouoTSjVNfv3e4ilJhsrR2S2hJQAk9DK2DjL8eirXD+FPCkWk28VxFCsLbw6oOoHqT1JPcmvUvBspmsbps5H2htv0wtdFJcqsctSXNO55z4d+E2qaPqkN5/a0cokjv4JkaSRhbLcOSsttkYSTBAYcA4/Gq1l8H7620KayL6e0xNrh0uJY95g37X+4Qh+YYBVx1yemPa5HEaFm6DrXlFy/jW98Uui6lrVnp8muTWAWGyi2R2f2YOswZoif9Z8ockjt1rdNshxSMY/DbXbvVpNOuzYvF/Z9hFJqpgEZRop5JG8hVGA+Noz8vXJ9K6W1+GrPrljc6sNOvbGDVtT1B7eWPzAy3JzGNrDG5Tgn9K5m58U/EK18MRu9jrL6jceHo3h8nSvMKX4mcOXGw7W8vYdrDHoM1oarq/j6LxL4li0qK/vFWG5awzbGKCEqo8tTvhAlYnJUpK2T95QOA9RaEK/CTV7u51+TVdQ0+V9S0u5sfNCsd0jzLJHIY9oVdu3GBnnnJzxe1D4ZajeyEj+xrVbm3s4JDEjFrHyJmk3W3yj7+ec7cNzz0qC+XWrjUvD1/oo17U7q0j1Ixy6vYG3KSm0Ty1YeWmEMnAJHJ3AEgCsy31f4gf8ACMXTy3epi5+02pw+lT+aoMchmjBW2zjcqYdY3Vc43YIINRaGz4i8ATaf4O8S3WnWkM/iabVpNWsbi0hBm3faPMiQswGQMkEE4AJr0LwVoSeGvCmmaQjb2tYQsj9fMkPzO/4sWP40/wAIz3tz4Y0ufVILmC+kt0aaK5KmVWxyHKqoz64UfQdK2KlstJbhVrR223sqH+OMMP8AgJ5/9CFVafaNs1C3b+8Sh+hGf5gUR3Caumb9FA6UVucoUUUUAFFFFABRRRQAUUUUAFFFFAAa5yR/NuZ5Ou5yB9BwP5Vv3Mogt5ZT0RSx/AVz0S7IkX0AFZzfQ1pLdj6KKKzNgooooAKKKKACobiJrhfKTlsF8D/ZGR/49tqarOkJuvZX/uRgD/gR5/8AQRTSu7Ck7K5VUgjI6UtRwgomw9YyU/I4/pUlIZz/AIvj821Re4DEfXis6xmi1fSUk4YOpVx6MOCPzre1xN0UJ7b9p+hB/qBXmujX50Dxfc6ZcnFpfN5sJPRXPBH41LdiWm3ocJ4w0S8sNbliu5pZrdyXhZjwV9PTI6Vlx2igcLXvHiXQodd04xnCzL80b/3T/hXkt7ps2nXT291HskUj6EeorkxHMnd7HdhZxqKz3Kul6hqGkvv0+5eLnJXqrfUdK6q2+It7E0ButPikZHyzRuVyMYPHPPNcs6gBvx/rTZlHPsDWMK0o7M3qYeE90ekH4maZsybW/Df3di/z3Vl3vxPYgiz0pyezTS4/QD+tcMwG4/So3HC8d63eMqNHOsBSRuX/AI38QXmQk8VonpAnP5nJrnrua4vJDJeTy3En96Ri386s2lncX1ytvZwvNMx4VBk9K9T8F+Ao9PZL3WFWW7BykPVY/c+p/SnBVa730Co6OGWi1IPhj4QNiF1bUo9tyw/cRsOYwf4j7mu9upgi47+g71LNII0JJqDTo/PujK33Y+n+8f8AAfzr0YxVKNkeTKUq07suWNt5S75cGZuv+yPQVbpBS1k3c60klZGJroEU8U+OHXy2PuOR/M1B4dtzLeS3hGIwpjT/AGiSMn9APzrduII7iIxzoHRuqmnRxrGipGoVFGAAMACpsK2tx1Vry280b4yFlHQ9j7GrVFUnYbSaszLglOSrgqwOCD1BqLWtHtNd097W8TIIyrD7yHsQat6nASnnxj95HycfxL3H9R/9emwyAgEHmt01NanHKLpy0PDvE3he80K5Mdyu6FjmK4UfKT7+h9qzbaWWHBjkki7EI5GDX0TNHBdwNBdRpJGwwVYZBridc+HcE7NJpUwhLdYn5U/Q9R+tcNTCOLvTPQo4yMlaoea/2jqSZVb+6B7fvTSTahqDxhvt90VPUGRuK1dS8J61YK3nWbyKvIki+cEe+ORWIu5ZCrKRnhlbgg1yy9pHSVzsiqU9Y2YhJkXfM8kh6NubOKhuoFVePu/w/wCFSkGF/wDZPH19qu6Zpd3qd35VpC0qL3xwufU1CvJlu0UUVsrY6h9reJDcJGsfmEZKjkkD069q63wxoTTH7bfoRGTuSNh19CR6Vt6P4Wi04ebfMs05O7aB8q+n17VqXEoAJ6KK6YUrayOKtiLrlgVNRn8m2fbw54X610fgiLy9GP8AtSk/oB/SvPrW8Or6zI6H/QrVeD/eY9T+Qr0LwU+/SHPfzmJHpkA/1reLuc6XK7M175WaznCY3lCFz64qWNw6Kw6EZpJRkKv95lX8yBU1xH5F5NGPuk71+h/+vmrt1KvrYbRRRQAUUUUAFFFFABUcreWok7RsHP0BBP8AKpKbIodGU9GGDQB0g6UVDZyedaQyf30DfpU1dByBRRRQAUUUUAFFFFABRRRQAUUUUAZ+tPiz2DrI6r9RnJ/QGswVd1psz20fb5n/ABGB/wCzGqdYz3OimvdCiiipLCiiigAooooAK0NFQCKd+7SfyA/+vWfWpoq4sFP99mb8ycfpirhuRU+EzrxPK1Cdez4kH4jH8xTKua0m2a3lHfMZ/mP5H86p0pKzHB3ijH8Us0elGROWSRXA9cHNcB8Q9LXUNJS/t+ZIPnBHde/+Nej63GJNOkB9V/mM1xPh26WWS80m7wXgbAVv4oz0/wAKzmrqw03GXMuhF4C8SNqNv9mu2H2yIDk/8tF9fr610Ws6LZ65bbZ1xIOVdeGU/wCe1eVeI9OuPDus7rZmjUfvIJB6en4dK7zwh4mi1i3COyxXyDEkWcbv9pfUfyrGnO/uT3NKtPltVp7HGa34R1SwudsUL3UbHKtCuTj3HaqA8N61MSE0y66Y5Qj+de3WM+biVmxwqgfmf/rVdM8ffFaLBQlrcl5hUjpZHidt4E164bLWqQg95JAP5V0GnfDMZVtSvicdUgX/ANmP+Fejvcp25rI1fxBYaZEz3t3DCB/Duyx+ijk1pHC0oasylja09F+BY0jR9P0WDy9Pt0iz95urN9SeauSTADjk15jceMdR8RajHpvhqF4RIcNcSDLBe5x0A+ua9Ft7YWtqkbu0jKoDOx5Y+prenOMtI7I56kJR1nuyKdmdu59AO59K2LOAW9uqcFurH1J61R06HzZjM3+rQ4X3Pr+FalRUld2NqMLK7FooorM2CiiigAooooASslU8mZ4Oy8r/ALp6f4fhWvVPUISyrLGCZI+w/iHcVcJWZnVhzIiBZevSnrcAHAbFNikWVAQcg1zPjqDULfTvtuiuyTwtvkVBnenfjvW0nyq5yxjzOx16z5HODUFzbWV0f9JtYZf99A3868rsPH94hVbm1jmGM7o22k/hzW1bePrCT/WLcxHvlM4/I1lHEU5dTaWGrQ6HZrpWkpyun2gP/XFf8KrXwjt18y2jSIL94IoAI/D0rA/4TXSSMm82j3jb/CqGp+N9Ljt3Mcslw+CAiIQCfcmm507bolU6rezNq6lwCzngetcF4m1t7lmtrNsREHc4/ixjj6VSvvEF3qkUYYeTCTjYp+8MHqfwq54W0n7Q8d1cD9zEBgH+Jq4JVOd8sT0YUVSXPUL1vb/2R4eggbi5unVW9cseR+ArufBEnOoQ9ldGH4rj/wBlrgWuf7X8URRpzb22WHuema7D4e3Amu9SKnguwH4ORW0GtkYSTTu9zt4l33VunrID/wB8/N/SresptuYJP7ysh/Qj+tR6Wm/UN3aOMk/UnA/QNVvWk3WyOOqSA/nx/Wt0vdM5P30ZtFFFQaBRRRQAUUUUAFIaWigDT0Vs2Kr/AHGZPyPH6Yq/WXojYNynowb8xj+lalbR2OaatJhRRRVEhRRRQAUUUUAFFFFABRRQaAMTU23akw7LGo/Els/0qCnXDCS8uGXpvx+QA/pTawe51R0SCiiikMKKKKACiiigBkrbI2b0BNb9lH5VpDGeqoB+lYEi79kf99lX8yBXS1pTMqr2RT1dd1hKwGTGN/5HJ/TNZAromAIIIyDXNxKYwYj1jYpz7cA/iMH8aJoKT6DbmMS28sZ/jUr+Yry3xKGs7qy8QWikqgCzqO6GvV688t2heabSLsArKhKqe46Efgf51jJXRpezTLV7ZWninRVUODuXfFKOxryfVtMu9F1ExThop0+ZHU4yOxBrr9LuZ/B+sHTr5ibCZt0Ex6L9f6122q6ZYeJNP8m5AEgGUkXqp9RWM4e1V1o0bU6jouz1izzbT/HWrWyYlS3uDgAs4IJ/L60tx4+1iTiJLWH3CFj+pqHVfBusae8hS2e5gVtolhG7P4dRWZDoeqXEmyHT7pmJ/wCeRFZe0rx93U3VLDS97QL3xHrN6pE+oTBT1WM7B+lVNF0a91zUBb2MZkcnLyN91B6sa7bQvhteXJEmrSi1j/55phnP49B+tekaZptlo9ottYQpFGOuOrH1J7mtqeGnUd6jMauKp0ly0lqZ3hPw3a+G7Dy4f3lw4HmzEcsfQegrTfdczCGM47s390ev19KddTbU46nsKuWFv5EPz481+WI/l+FdrtCNonnwTqy5pE8aBECIAFUYAFPpqOsgJRgwBKnB6EdRTqxOoKKKKACiiigAooooAKKKKAKF1bOrma3GSeXT19x70sEqyp6g9fartZ16pguFlH3JDhvZux/H/PWtYT6Mwq0/tI4vxb4AFwz3ehlY5idxhzhSfb0+nSvOr+1udNuit5byQyHhkZcfiPUfSvfY7gr1pLy2stSh8q9t4p4/R1Bx9PSsquFjPWOjNKONlDSWqPn5dvmEDBVuR9ajmiRocR53MQB9a9hu/h/oM5LRG4t8nOI5OAfxBqS18K6PphMkULSzdpJGyQfUdgfeuZYOd9WdTx9O2iOB8P8Ahm4uCstyjwWi4ChhhmA9u1afijUo9OsjZ2WFk2EAD+EetaniDXUsbRdxBncYVB3Pr9K4/R7GbXNUaS4JMWCZG9eeAPwFDSh7kNxRbq/vKnwo0vDluNK0a61K4GGdS6567QOPzNdB8IomFhJI/VlLf99MT/SsTxhceasGlWuA0zAMB2X/AD/Ku28EQLa2FwyjEabYx9FGf61pBWdl0Mm3L3n1O50RB5U0ndnxn2HH881a1GIzWUyKMsUO369v1pNOiMNlCjfeCgt9Tyf1qzXYlpY5W/euc2jB0DL0IyKdTVTymki/55uVA9s8fpinVgdIUUUUAFFFFABRRRQBZ0ltt+6/348/kf8A7KtmsCzbZqNuf7xZPzGf6Vv1rDYwqbhRRRVmYUUUUAFFFFABRRRQAVBfT/Z7WSTqwHyj1PYfnU9ZOsybpoYQeF/eMP0H9fypSdkVFXdihGuxAuckdT6n1p9FFYHSFFFFABRRRQAUUUUAPs18zUIF7KS5/AY/mRW/WRo43XMzdkUKD7nJP8lrXrWGxhUd2FYmpReXfs38MqhvqRwf021t1m62n7uKb/nm+D9G4/ninNXQqbtIzjXmHxBgms9upWnE9lOW+qk9D7YIr0+uf8S2SXG+OVcw3KGNvrj/AA/lXPJXR0Xs7mC0Nl4x8OoeNzLlG7xt6f0rjtI1288M6g2masrmGM4VupQeo9Vo8MXsvhfX5tNviUhkf5WPQHsfoRiu38SaDbeJbIFSsd7GP3cn9D7VjrNc0d0XpB8ktYs3NC1i3uLFXhnjlBZj8rA9TmtCTUIgM7a+eNS0y80u4CXUUtu7Dcp5AYeoPeqqfbbpxDFJdTMTgIrM2fwrRYy3uuOongb+9GWh7prHivTtOQm6vIYyP4A25j+A5qxpNy99YpeyRvEko3RpIMNt7E+metcB4I+Hsgnjv9ej2KuGS2PJY+r+3t+delT5mkWGM4J7/wB0dzXTTlKS5pKxx1IQi+WDuyGK5t47lJbyQRoWKxbuhYdTnoMep9/SqEupyXerQpaXN3aTl/La3Kq6yJkjzFyCBjqemRTtfjiCwSJdrBCUCxickQkqTht3IBOevUjGCOas+FbILB9tcENIW8tBIzqinGcZ/vFd2fpUN3dzeMeVWRtWVstpbrEhZgMksxyWJOST7kmp6KKksKKKKACiiigAooooAKKKKACo5o1mjaOQZUjmpKKAMmHKSNBP99e/qPWue8ctqulwQ6jo8hMceVmiI3KR2OPzGa6+7txOgIO2ReVb0/8ArVVgnxvinQZHyup5H/6q2vzxtezOZx9nK9ro8zt/iJe+QTJYxOy9dkhX9CDVLUPHWo3R8qJIrZWH3x8zfrx+ldrqPgbRry5a4tmltHf7yxkFT+BqnD4C0i2dWnlnuQpyEYhV/HFczjiNrnTGeFXvcup5/pWnX2tag5G51Urvmc8Dr+dd0wttB0sRoeFHXux/xrS1OS3sLdCgSCCPK4HAAxn+lcS6z+JdUiWDctpGdxc9APX6ntWbh7LRatlKo6+r0iibwxavf3c2q3WSOkefX/8AVXqWiW3laXbxkYaZgW/4Ew/p/Kuf0qwSSWKygTFvGBvx0Cjt+NdrbKGvrVf9sn8lP/1q0pxtoTKXM3I6Giiius5DD1BNmoSEdHVX/HkH9AKhq7rSkSWz9vmQ/U4P9DVKsZbnTB3igoooqSgooooAKKKKAE3iJ45T0R1Yn0GeT+Wa6OubdQ6FWGVIwR7Vs6ZMZ7KNmOZFGx/94cH/ABrSD6GVVdS3RRRWhiFFFFABRRRQAUUUUAFc48nn3Es3Z2wv+6OB/j+NbWpSNFZTNGcOV2qfQngH9axEUKoVRgAYArOb6G1JdR1FFFZmoUUUUAFFFFABRRUczFYmKDLY+Uep7UAa2iJi0aTvK5b8Og/QCtCo7eIQQRxL0RQo/AVJW6Vkcsnd3CobuET20sR/iUjPpU1B6UxHNRMXjViMEjkehqK+txc2zx5wx5U+hHSrVygivZ4xwM7wPY//AF802sHoda1R5r4q8PjXYMqBHqFuCuD/ABf7J/oa5jQ/E97obfYdUjkZYjtyfvp7H1FevarYGfE9vgTqOR03j0+tc3f6bp+qApqdoGlA27+VdfxrGUHfmjuVGaS5Jq6L9p4h0TU7JFeezmj2j5JSvH1DUW+r6LFcpa6c1p58hwI7ZQSfrt/rWGvw58PyLHI0t4AVBK+YMH9M1u6ZpmmaJGY9KtEiZhgsAWdvx6muqDn9pI45+zXwts0ribyU7lj0A71ma1cyWOmyNalpLrevnGMnMYHrgE4/+ufar7LJbolw6Brh5FjjRzhUycZOM8//AKu9Z+uxyiSBpwbVnlVWmD+ZGByevDLnGDjA560pyvoi6dPlV3uRaXA+tGO4leRI8/vwG4nGOPmQ7WIIHOAcDBFdbVTTIEhtV2lHZ/mZ1IO4/XHOOmTzVyszdBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVK/gLYliGZFGCv94f41dpKadtRSSkrMxVIkXMb/hWJqk+swu4tdOS4T+FhMBn6g11VzYxykupMch/iXv8AUd6ovYXo4VoWHqWI/TBrRz5lvY5/ZOL2ueeajoWtazuk1eWK2tl5EaHJA74Hr9TXQafaR2sUdhpsRY9v8Sa3m0e5nVkmmjjVhglcsf1xWpp9hBYxlYQSx+87feasXBJ3W5snKSs9EJpliljb+Wh3Oxy7nqxrS05d2oxnssbH9QP61DVvSObuX1VB+p/+tVR3HPSJr0UUVucxR1lN1i7DrGQ/5df0zWVXQyKHRlYZUjBHtXORqyAxv95CUPvjv/WsprqbUnpYfRRRUGoUUUUAFFFFABVrSJPLupYieJBvA9xwf0x+VVaazmF45h1jbcfp3/TNNOzFJXVjpKKAQQCOhorc5QooooAKKKKACiiigDM1t+IIgfvNuP0A/wASKoVPqj79Q29o4x+ZJ/wFQVjJ3Z001aIUUUVJQUUUUAFFFFABSwLvu7dAM5cMfoOf6CkqzpEe+8kc9I0Cj6nr/IfnTirsUnZGzRRRW5yhRRRQBkaym26gf+8rKffGCP61Uq9rnS1/66n/ANBaqNYy3Oin8IVBcWkFzjzo1YjoehH41PRUllJdOgAA/ebRwBvNWIYIoQRFGq564HJqWindiUUtiG7t0urd4ZCQGxgrwVIOQR7ggGqiQXcs8BvDB5cDbw0ZOZGwQCQenU8ZNaNFIY1FCDCgAegp1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVvRR/pVyf8AYT+b1Uq5ov8Ax8XP+6n82qobk1PhZrUUUVscwVh6khjvyf4ZV3D6jg/+y1uVma4v7uCT+7Jg/Qgj+eKma0Lpu0ihRRRWJ0BRRRQAUUUUAFIRkYPSlooA1dHcvYxq33o/kP4dP0xV2srRZMTXER6fLIPx4P8AIfnWrW0XdHNNWYUUUVRIUUUUAFFFFAHPTtvvblv9vA/AAf40lRwtvUv/AHyX/M5/rUlc7OtKysFFFFABRRRQAUUUUAFaWiJizMh6yMW/DoP0ArKmYpE7AZIBIHrXQ28QhgjjXoihR+FXBamdV6WJKKKK1MAooooAytb5e1H+0zfpj+tUqua0f9Kth/sOf1WqdYz3Omn8IUUUVJQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVb0X/AI+7n/cT+b1Uq3pBAu5B3ZP5H/69VHcmfws16KKK2OYKpawudPlP9zDn/gJB/pV2o7iITQSRt0dSp/EUnqhp2dzApaZC2+JG9QDT6wOoKKKKACiiigAooooAksG2ajET0dWT8ev/ALKa3q5st5ckMn9yRTn0GcH9Ca6StYbGNVa3CiiirMgooooAKjuZPJt5ZD/Apb8hUlU9WP8AxL5h/fGz/vo4/rSY1qzGiXZGq+gAp9LikIrA6goopKAFopM0ZoAWiikzQAIvmXNvH/ekH6fN/SujrE0pN+oFu0cf6seP/QTW3WsFoYVXqFFFFWZhRRRQBj6yc3sA9I2/Ur/hVWrGrc6gB6RD9Sf8Kr1jLc6YfCgoooqSgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqbTmxqUY7GNx+q/4VDT7I41K399w/8AHTTjuKWzN+iiitzlCiiigDnCvlyzRf3JCB9Oo/QilqfU08vUM9pUB/EcH9MVBWD0Z1Rd1cKKKKQwooooAKKKKAGTJ5kTpnG5SM10NvIJoY5B0dQw/EVgVq6M2bCNf7hKfkTj9MVcNzOqtLl6iiitTAKKKKACqmpjdAqf3nH6c/0q3UVwu4L7HNJ7DW5kslMKmtB4qhaKs3E2UintpMVZMdN8upsVcgxRiptlHl0WC5DikxU/l0112ozHsM0WC5c0VB5U0nd3xn2HH881o1XsIvJtIkPULz9ep/WrFbJWRzyd3cKKKKYgooooAxdU/wCQj/2yX+bVWq5qg/09T6x/yP8A9eqxFYy3OiGyG0UuKTFSWFFJS0AFFFJQAtFJmloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACikozQAtFFFABT7P/kJW31b/wBBNMxU1kv/ABMIPYMf0prcmWzNyiiitzmCiiigDO1qPMMUo6xuM/Q8fzxWbW/cwie3kibgOpXPpWAu7HzDDDhh6Edaymtbm9J6WFoooqDQKKKKACikpcUAFX9FbBuI/wDaD/mMf0qkBVvTRtuj/tJj8j/9c1UdyJ6o1aKKK2OcKKKKACkYZpaKAIytNKVNikxSsO5XMdNMVWsUmKLD5ir5VHlD0q1ijbS5Q5ir5NNkg3AL6kCru2k28j2o5Q5h1FFFUSFFFFABRRRQBn6gm65jP+w38xVcx1pTpuZT6A/0qIx1DWppGVkZ5jppStAxe1MMVTyl8xR203bV0xU0xUuUfMU8UYqyYvammP2pWHzEGKTFTmOk8s0WC5DijFS7DSFDRYdyKipdhpNppWC4yin7aNtAXGUU/afSjbQFxlFP2ml2GiwXI8UYqTYfSl2GnYLkWKMVN5dKIzRYLkOKXbU4i9qcIvanYXMVgtOCVaENPWH2o5RcxUEdWLOPF2jeit/Sp1iqaKPD59BVJESloT0UUVoZBRRRQAVl39vtnLqPlfk/WtSmTJ5iEGlJXRUXZmGUNJtrSMHtTDB7VnymvOUNtLtq6Yfak8n2pco+YqBfanBKtiH2qRYvanyiciokVWreLbIp9KmWKpVXFUokOQ+iiirMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBGGabtp9FAEe2kKVLiiiw7kJSmmOrGKMD0pWC5VMdIY6t4HpRgelFh8xSMVJ5VXdo9KNo9BS5Q5iiYqaYvatDaPQUbV9BRyj5zOMNIYq0ti+go2L6CjlDnM3yqTya0ti+go2L6CjlDnM3yaURVo7F9BS7F9BRyhzmd5PtR5NaOxfQUbV9BRyhzmeIacIavbV9BRtHpRyhzlIQ04RVbwPSlwPSjlFzFYRU4R1PgelGKdhXIhGKUJUlFOwXGhacBiiigQUUUUAFFFFABRRRQAhFJtp1FADNlJsFSUUWC5HspwWnUUAAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The symptom of dyspnea likely arises from a range of sensory inputs, many of which lead to qualitatively distinct descriptive phrases used by patients. The sensation of respiratory effort arises from signals transmitted from the motor cortex to the sensory cortex (green arrow) when outgoing motor commands are sent to the ventilatory muscles (blue arrow). Motor output from the brain stem (blue arrow) may also be accompanied by signals transmitted to the sensory cortex, contributing to the sensation of effort (dotted green arrow).",
"    <br>",
"     The sensation of air hunger probably derives from a combination of stimuli that increase the drive to breathe such as insufficient oxygen or excess carbon dioxide (mediated by signals from chemoreceptors in the carotid body and aortic arch), acute hypercapnia or acidemia (mediated by signals from the peripheral and central chemoreceptors), airway and interstitial inflammation (mediated by pulmonary afferents), and vascular receptors. The intensity of air hunger is increased when there is a perceived mismatch between the outgoing efferent messages to the ventilatory muscles and incoming afferent signals from the lungs and chest wall.",
"     <br>",
"      Chest tightness, commonly associated with bronchospasm, is mediated by stimulation of vagal-irritant receptors. Afferent signals (red arrows) from airway, lung, and chest wall receptors most likely pass through the brain stem before being transmitted to sensory cortex, although it is also possible that some afferent information bypasses the brain stem and goes directly to sensory cortex (dotted arrow).",
"      <div class=\"footnotes\">",
"       Red arrows: afferent signals; Blue arrows: efferent signals; Green arrows: signals within the central nervous system; Dotted lines: hypothetical pathways; Circles: chemoreceptors; Squares: mechanoreceptors.",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30967=[""].join("\n");
var outline_f30_15_30967=null;
var title_f30_15_30968="Treatment of actinic keratosis";
var content_f30_15_30968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of actinic keratosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/15/30968/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30968/contributors\">",
"     Joseph Jorizzo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/15/30968/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30968/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30968/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/15/30968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30968/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/15/30968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actinic keratoses (AKs or solar keratoses) are cutaneous neoplasms that develop on sun-damaged skin. Multiple modalities have been used for the management of these lesions, including physical or chemical destruction, topical medication, and photodynamic therapy.",
"   </p>",
"   <p>",
"    The treatment of AKs will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of AKs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/49/18200?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of actinic keratosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKs are increasingly considered lesions that are on a continuum with cutaneous squamous cell carcinoma (SCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/1\">",
"     1",
"    </a>",
"    ]. Although most AKs do not progress to SCC, AKs are a concern because the majority of cutaneous SCCs arise from preexisting AKs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], and AKs which will progress to SCC cannot be distinguished from AKs that will spontaneously resolve or persist. Because of these factors, most clinicians routinely treat AKs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/4\">",
"     4",
"    </a>",
"    ]. Improvement in associated symptoms and cosmetic appearance can be additional benefits of treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/49/18200?source=see_link&amp;anchor=H17075268#H17075268\">",
"     \"Epidemiology, natural history, and diagnosis of actinic keratosis\", section on 'Clinical course'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major treatment options for AK include destructive therapies (eg, cryotherapy, surgery, dermabrasion), topical medications (eg, 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [5-FU],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/35/38451?source=see_link\">",
"     ingenol mebutate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ), chemical peels (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    ), and photodynamic therapy (PDT). Given the multiple effective treatment options for AKs, the choice of therapy is influenced by factors such as the number and distribution of lesions, lesion characteristics, patient preference for the mode of treatment (eg, office-based versus home administered, duration of therapy), patient tolerance for side effects (eg, pain, inflammation, hypopigmentation, scarring), treatment cost, and treatment availability.",
"   </p>",
"   <p>",
"    In general, lesion-directed treatments, such as cryotherapy and surgical intervention are the primary approach for isolated lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/4\">",
"     4",
"    </a>",
"    ]. Therapies that can be used to treat areas with multiple AKs (field-directed therapies), such as topical 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/35/38451?source=see_link\">",
"     ingenol mebutate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    , and PDT, are particularly useful for treating patients with multiple lesions.",
"   </p>",
"   <p>",
"    The ability of topical drugs and cryotherapy to penetrate hypertrophic AKs (",
"    <a class=\"graphic graphic_picture graphicRef63461 graphicRef72634 \" href=\"mobipreview.htm?13/34/13865\">",
"     picture 1A-B",
"    </a>",
"    ) must be considered during treatment selection. Many clinical trials of topical pharmacological agents have excluded hypertrophic lesions due to concerns about drug penetration. We consider surgical intervention for hypertrophic AKs that have failed to resolve after other therapies and for the initial treatment of hypertrophic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/49/18200?source=see_link&amp;anchor=H17075261#H17075261\">",
"     \"Epidemiology, natural history, and diagnosis of actinic keratosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3202133\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have reported beneficial effects of the interventions mentioned above for AK. A systematic review and meta-analysis of randomized trials that were published prior to April 2011 found sufficient evidence to conclude that the following field-directed therapies are superior to placebo for complete clearance of lesions in the treated field in patients with AKs: 3%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    in 2.5% hyaluronic acid (RR 2.46, 95% CI 1.66-3.66), 0.5% 5-FU (RR 8.66, 95% CI 3.67-21.44), 5%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    (RR 7.70, 95% CI 4.63-12.79), and 0.025% to 0.05%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/35/38451?source=see_link\">",
"     ingenol mebutate",
"    </a>",
"    (RR 4.50, 95% CI 2.61-7.74) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the systematic review and meta-analysis found that photodynamic therapy (PDT) performed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    (ALA-PDT) with red light (5.94, 95% CI 3.35-1.54) or blue light (6.22, 95% CI 2.88-13.43) or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/7/35955?source=see_link\">",
"     methyl aminolevulinate",
"    </a>",
"    (MAL-PDT) with red light (4.46, 95% CI 3.17-6.28) was superior to placebo for the treatment of individual AK lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/5\">",
"     5",
"    </a>",
"    ]. Additional trials are needed to clarify the relative efficacies of these and other therapeutic options for AK, as well as to identify the best approach to treatment.",
"   </p>",
"   <p>",
"    Cosmetic outcome is a common consideration during the selection of therapy. The meta-analysis also found that treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    or PDT generally resulted in better cosmetic outcomes than 5-FU and cryotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Liquid nitrogen cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liquid nitrogen cryotherapy is the most widely utilized treatment for AK. This treatment may be quickly performed in an office-based setting, and is well tolerated by patients.",
"   </p>",
"   <p>",
"    The efficacy of liquid nitrogen was demonstrated in a study of 70 patients with a total of 1018 treated AKs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/6\">",
"     6",
"    </a>",
"    ]. A cure rate of 99 percent was reported after one year of follow-up. Most of the lesions treated were thin, not on the arms or hands, and aggressive therapy was used (thaw times of 20 to 45 seconds).",
"   </p>",
"   <p>",
"    A randomized, vehicle-controlled clinical trial performed in community and academic outpatient clinics compared the efficacy of cryotherapy alone to cryotherapy following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    applications for the treatment of AKs in a total of 144 patients with five or more visible or palpable AKs on the face. After six months, more patients treated with combination therapy remained clear of AKs (30 versus 8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition to noting increased efficacy with combination treatment, these results support the importance of clinical follow-up for patients treated for AK. Combination treatment with cryotherapy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    also appears to be more effective than cryotherapy as monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since liquid nitrogen cryotherapy does not produce a specimen for histologic confirmation, the procedure should only be performed when the clinical diagnosis of AK is relatively certain. If there is doubt about the diagnosis, either an opinion from a dermatologist or histological confirmation is warranted. Although hypertrophic AKs can be effectively treated with cryotherapy, thick lesions may respond less well than thin lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/8\">",
"     8",
"    </a>",
"    ]. AKs on the dorsum of the hand may also be more resistant to liquid nitrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical destruction with shave removal or curettage is useful for hypertrophic lesions. In addition, if lesions appear indurated (a finding that suggests the possibility of SCC), shave removal with histopathologic examination of the specimen is indicated. A low threshold for considering the possibility of SCC is particularly important in immunocompromised patients, since these patients are more likely to have biologically aggressive lesions. There are few data on the efficacy of surgical therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=see_link&amp;anchor=H574869#H574869\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37832?source=see_link&amp;anchor=H7860393#H7860393\">",
"     \"Epidemiology and risk factors for skin cancer in solid organ transplant recipients\", section on 'Squamous cell and basal cell carcinoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=see_link&amp;anchor=H10#H10\">",
"     \"Skin biopsy techniques\", section on 'Shave biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Topical 5-fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU) inhibits thymidylate synthetase, a critical enzyme in the synthesis of DNA. The lack of DNA synthesis, particularly in fast-growing dysplastic cells, prevents cell proliferation and causes cell death. Topical 5-FU has been used with good success in patients with multiple AKs. It causes inflammation and destruction of the lesions (",
"    <a class=\"graphic graphic_picture graphicRef76480 \" href=\"mobipreview.htm?13/46/14051\">",
"     picture 2",
"    </a>",
"    ). Inflammation typically subsides approximately two weeks after 5-FU is discontinued. It typically takes four to six weeks (two to four weeks of which are active treatment) for the skin to progress through erythema, blistering, necrosis with erosion, and reepithelialization.",
"   </p>",
"   <p>",
"    A systematic review found an approximately 50 percent overall efficacy rate of 5-FU for 100 percent clearance of AKs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/9\">",
"     9",
"    </a>",
"    ]. However, in patients who do not have hypertrophic AKs (which generally require destructive modalities of treatment), topical 5-FU is effective in more than 90 percent of patients who can tolerate it, and has the advantage of treating clinically undetectable AKs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians utilize topical corticosteroids in combination with 5-FU to reduce the inflammatory response associated with treatment. The sequential method of combination therapy involves application of 5-FU (1 or 2 percent on the face, 5 percent elsewhere) manually twice daily until superficial erosion occurs (usually two to three weeks). This is followed by a low potency topical corticosteroid cream twice daily to reduce inflammation until complete healing occurs. The inflammation induced by therapy can be severe, sometimes resulting in patients stopping before adequate treatment has occurred. The combined method, which is primarily used on the face, produces less inflammation: 5-FU (1 or 2 percent) is applied to the face once daily, followed in 15 minutes by a low-potency corticosteroid cream. The length of treatment is usually four weeks.",
"   </p>",
"   <p>",
"    A 0.5 percent preparation of 5-FU is also available. Once daily application is associated with minimal systemic absorption and is better tolerated than higher strength preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/11\">",
"     11",
"    </a>",
"    ]. Treatment is continued for up to four weeks as tolerated. Treatment courses of one, two, and four weeks have demonstrated superiority over placebo for the clearance of AKs, with the four-week course demonstrating the greatest benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    cream, a topical immune response modifier that stimulates local cytokine induction, is an effective therapy for AKs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/5,9,13\">",
"     5,9,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"       Imiquimod",
"      </a>",
"      <strong>",
"       5% cream",
"      </strong>",
"      &ndash; A meta-analysis of five randomized trials (n = 1293) found that treatment with imiquimod 5% cream (two to three times per week for 12 to 16 weeks) resulted in complete resolution of AKs in 50 percent of patients compared to 5 percent with the control vehicle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Adverse event information was reported on 1200 patients. The proportion of patients with treatment-related adverse events was higher with imiquimod than with the control vehicle (42 versus 12 percent). Patients most frequently experienced local adverse events that included erythema, scabbing, and flaking. All-cause withdrawals occurred more frequently with imiquimod than with vehicle (12 versus 7 percent). Withdrawals due to adverse events were not significantly different between imiquimod and vehicle (4 versus 3 percent).",
"      <br/>",
"      <br/>",
"      Although treatment with imiquimod 5% cream is associated with adverse events, several studies have found better clearance rates in subjects with the most severe adverse events",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an increase in the number of lesions during initial treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/14-16\">",
"       14-16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The manufacturer's prescribing information for imiquimod 5% cream states that patients should be treated twice weekly for 16 weeks and that treatment should be applied to a single contiguous treatment area of approximately 25 cm",
"      <sup>",
"       2",
"      </sup>",
"      (forehead, scalp, or one cheek) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/17\">",
"       17",
"      </a>",
"      ]. Shorter course therapy with a treatment-free interval and retreatment if needed may also be effective for non-hypertrophic AKs, and would be less expensive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/15,18,19\">",
"       15,18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"       Imiquimod",
"      </a>",
"      <strong>",
"       3.75% cream",
"      </strong>",
"      &ndash; A cream containing a 3.75% concentration of imiquimod is also available and has been shown in randomized trials to be superior to placebo for the treatment of AK [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. When applied to the entire face or scalp daily for two two-week treatment cycles, imiquimod 3.75% cream led to a higher complete clearance rate than a 2.5% formulation of imiquimod or placebo (36, 31, and 6 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Treatment-related adverse effects (most commonly discomfort at the site of application) occurred in 19 percent of patients treated with 3.75% imiquimod cream, an incidence lower than reported in randomized trials of twice weekly application of imiquimod 5% cream for 16 weeks (34 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/22\">",
"       22",
"      </a>",
"      ]. Expected local skin reactions (erythema, scabbing, weeping, flaking, and erosions) were assessed separately. Similar to the 16-week trials of imiquimod 5% cream [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/22\">",
"       22",
"      </a>",
"      ], severe local skin reactions occurred in approximately one-third of patients.",
"      <br/>",
"      <br/>",
"      Although the complete clearance rate reported with imiquimod 3.75% cream is lower than the 50 percent clearance rate reported with longer courses of imiquimod 5% cream [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/13\">",
"       13",
"      </a>",
"      ], differences in study methodology (eg, size of area of application) preclude a conclusion on relative efficacy. The shorter duration of therapy may be preferable for some patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Organ transplant recipients",
"      </strong>",
"      &ndash; Based upon evidence from small randomized trials, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      in immunosuppressed organ transplant recipients appears to be effective and safe. In a trial that included 43 renal, heart, and liver transplant patients, application of imiquimod 5% cream three times per week to a 100 cm",
"      <sup>",
"       2",
"      </sup>",
"      area led to complete clearance of AKs in 62 percent of subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/23\">",
"       23",
"      </a>",
"      ]. No signs of graft rejection or deterioration of graft function were observed. Another trial of 21 renal transplant patients reported similar safety data; there was no evidence that imiquimod therapy worsened renal function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=see_link&amp;anchor=H2294677#H2294677\">",
"       \"Management of skin cancer in solid organ transplant recipients\", section on 'Actinic keratoses'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3581609\">",
"    <span class=\"h3\">",
"     Ingenol mebutate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/35/38451?source=see_link\">",
"     Ingenol mebutate",
"    </a>",
"    gel (PEP005), a substance derived from the sap of the",
"    <em>",
"     Euphorbia peplus",
"    </em>",
"    plant, is an effective treatment for AK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The mechanism of action involves two stages: initial disruption of cell plasma membranes and mitochondria leading to cell necrosis (chemoablation) followed by the induction of neutrophil-mediated antibody dependent cellular cytotoxicity that eliminates remaining tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. In January 2012, ingenol mebutate 0.015% and 0.05% gel (Picato&reg;) was approved by the United States Food and Drug Administration for the treatment of AK. The 0.015% formulation is indicated for a three-day treatment course on the face or scalp; the 0.05% formulation is indicated for a two-day treatment course on the trunk or extremities.",
"   </p>",
"   <p>",
"    An advantage of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/35/38451?source=see_link\">",
"     ingenol mebutate",
"    </a>",
"    over other topical treatments is the short duration of therapy. A combined analysis of the findings of two randomized trials with 547 patients revealed that ingenol mebutate 0.015% gel applied once daily for three days to a 25 cm",
"    <sup>",
"     2",
"    </sup>",
"    area on the face or scalp with multiple AKs was superior to placebo for lesion resolution. At study day 57, complete clearance of AK was detected in 42 versus 4 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/30\">",
"     30",
"    </a>",
"    ]. Similar results were obtained in two randomized trials with a total of 458 patients in which ingenol mebutate 0.05% gel was applied once daily for two days to a 25 cm",
"    <sup>",
"     2",
"    </sup>",
"    area on the trunk or extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/30\">",
"     30",
"    </a>",
"    ]. By day 57, 34 versus 5 percent of patients had complete lesion clearance.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/35/38451?source=see_link\">",
"     ingenol mebutate",
"    </a>",
"    appears to have a lasting effect. Although approximately half of the patients who achieved complete clearance in the above trials had recurrence of one or more AKs in the treatment area within one year, the number of lesions remained dramatically reduced in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/30\">",
"     30",
"    </a>",
"    ]. After one year, the mean percentage reduction in lesion numbers was 85 percent for the face and scalp and 87 percent for the trunk and extremities.",
"   </p>",
"   <p>",
"    Local skin reactions are an expected event during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/35/38451?source=see_link\">",
"     ingenol mebutate",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/28\">",
"     28",
"    </a>",
"    ]. Erythema, scale, crusting, edema, vesiculation, pustulation, or ulceration may occur. Patients may complain of symptoms of pain, pruritus, or irritation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7122473\">",
"    <span class=\"h3\">",
"     Topical diclofenac",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     Diclofenac",
"    </a>",
"    is a nonsteroidal antiinflammatory drug that inhibits both cyclooxygenase and upregulation of the arachidonic acid cascade. Because the production of prostaglandins from arachidonic acid may play a role in ultraviolet B-induced skin cancer (eg, basal cell carcinoma and squamous cell carcinoma), inhibition of this cascade by diclofenac may explain its efficacy in the treatment of AKs.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    gel, 3% diclofenac in 2.5% hyaluronan gel, is effective for the treatment of AKs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/5,31,32\">",
"     5,31,32",
"    </a>",
"    ]. A meta-analysis of three randomized trials (n = 364) found that treatment with diclofenac gel resulted in complete resolution of AKs in approximately 40 percent of patients as compared with 12 percent with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/33\">",
"     33",
"    </a>",
"    ]. The efficacy of diclofenac may be lessened for AKs on sites other than the face (eg, scalp, arms, forearms, hands). A meta-analysis with subgroups found that diclofenac treatment for 90 days was not significantly better than vehicle (2.5% hyaluronic acid) for achieving complete clearance in these locations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     Diclofenac",
"    </a>",
"    is applied twice daily for 60 to 90 days. The most common adverse effects of diclofenac gel are dry skin, pruritus, erythema, and rash at the application site. Twice daily treatment with diclofenac gel appears to be better tolerated than twice daily application of 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/34\">",
"     34",
"    </a>",
"    ], although it may be somewhat less effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical retinoids have been studied for the treatment of AKs. In a nine month randomized trial of 90 patients with multiple AKs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     adapalene",
"    </a>",
"    gel (0.1 or 0.3%) applied daily as field therapy for four weeks and twice daily thereafter significantly but modestly decreased the number of AKs compared with placebo, and also appeared to improve the appearance of photodamaged skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast, a randomized trial of 1131 patients found that long-term use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=see_link\">",
"     topical tretinoin",
"    </a>",
"    0.1% cream was ineffective in reducing the number of AKs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/36\">",
"     36",
"    </a>",
"    ]. Additional studies are necessary to determine the role of topical retinoids in the management of these lesions.",
"   </p>",
"   <p>",
"    AKs and SCCs occur at an increased frequency in transplant recipients. Systemic retinoids have been used in the secondary prevention of AKs in renal transplant recipients. A 12-month study found that low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    therapy (20 mg daily) is safe, well-tolerated, and partially effective in chemoprophylaxis of nonmelanoma skin cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519985\">",
"    <span class=\"h2\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy (PDT) is an effective therapy for AK that consists of topical application of a photosensitizer followed by exposure of the treatment area to a light source. The procedure results in cellular destruction. 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    (ALA) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/7/35955?source=see_link\">",
"     methyl aminolevulinate",
"    </a>",
"    (MAL) are the two photosensitizing agents utilized in PDT for AK.",
"   </p>",
"   <p>",
"    Multiple PDT regimens have been used for treatment. In addition to the choice of topical photosensitizer, the incubation times, light sources, and pretreatment regimens used for PDT have varied across studies. An effect of the length of the incubation period on treatment efficacy was illustrated in a randomized trial (n = 149) in which patients were treated with a self-adhesive ALA patch. The trial found that a four hour incubation period was more effective for complete clearance of AKs than shorter incubation times (0.5, 1, or 2 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple trials have compared PDT to other therapies for AK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/39-45\">",
"     39-45",
"    </a>",
"    ]. Although data are insufficient for definitive conclusions on comparative efficacy, the cosmetic outcome from PDT appears to be superior to 5-FU and cryotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of sequential treatment with MAL-PDT and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    was investigated in a randomized trial completed by 105 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/39\">",
"     39",
"    </a>",
"    ]. Better response rates were seen for combination treatment than for either monotherapy; however, the difference in response was statistically significant only for the comparison between combination therapy and MAL-PDT monotherapy.",
"   </p>",
"   <p>",
"    Photodynamic therapy has the advantage of allowing application to multiple lesions without the need for repeated topical applications. The most common complaint during photodynamic therapy is burning or stinging during light exposure; in addition, there is a small risk of producing pigmentary changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Dermabrasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermabrasion, or surgical skin planing, is a procedure in which a specialized hand-held instrument is used to \"sand\" the skin to improve skin contour. The surface of the epidermis of the skin (the stratum corneum) is removed, leaving the skin very red and raw-looking. The procedure can be very painful and usually requires a general anesthetic or twilight anesthesia.",
"   </p>",
"   <p>",
"    Dermabrasion is useful in treating large areas such as a sun-damaged bald scalp or forehead, when lesions are too large to treat effectively with topical preparations. A retrospective study of 23 patients found that 96 percent remained free of new AKs at one year after dermabrasion; the benefits of dermabrasion gradually diminished with 83 percent clear at two years and 54 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/46\">",
"     46",
"    </a>",
"    ]. These results require confirmation in prospective studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chemical peels",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chemical peel is a procedure in which a topically applied wounding agent creates smooth, rejuvenated skin by way of an organized repair process and exfoliation. Usually, this procedure is performed on the face.",
"   </p>",
"   <p>",
"    A medium depth chemical peel with 35 to 50 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    (TCA) alone or at 35 percent in combination with Jessner's solution, 70 percent glycolic acid, or solid CO",
"    <sub>",
"     2",
"    </sub>",
"    , may effectively treat multiple non-hypertrophic AKs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/47\">",
"     47",
"    </a>",
"    ]. In a nonrandomized split-face study, Jessner's solution plus 35 percent TCA demonstrated similar efficacy and decreased rates of morbidity when compared to 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medium depth peels cause injury at or through the level of the papillary dermis and should be applied by a physician in a controlled setting. Prior to treatment, patients should be educated about possible complications of stinging or burning sensation, visible peeling (which usually lasts 5 to 7 days), pigmentary changes, infections, and rarely scarring.",
"   </p>",
"   <p>",
"    Patients with a history of herpes simplex virus (HSV) infection, previous radiation exposure, immunosuppression, postinflammatory hyperpigmentation, keloids, recent facial surgery, or taking photosensitizing medications may experience higher rates of complications from chemical peels.",
"   </p>",
"   <p>",
"    Patients likely to be noncompliant with post-treatment sunscreen use or who are unable to avoid sun exposure because of occupation are unsuitable candidates for a chemical peel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H252292\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional therapies that have been utilized for AKs include ablative laser resurfacing with carbon dioxide (CO",
"    <sub>",
"     2",
"    </sub>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/49\">",
"     49",
"    </a>",
"    ] and erbium:yttrium aluminum garnet (Er:YAG) lasers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/50\">",
"     50",
"    </a>",
"    ]. A few uncontrolled studies have reported reductions in AKs following treatment with nonablative fractional lasers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]; however, a six-month follow-up with histological evaluation performed in one of the studies revealed persistence of AKs after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3202061\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoiding sun exposure is one aspect of preventing the development of AKs. In addition, sunscreens reduce the development of AKs, as demonstrated by a small, controlled trial which found that daily application of sunscreen decreased the number of AKs over two years by 51 percent compared with vehicle application [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30968/abstract/54\">",
"     54",
"    </a>",
"    ]. Daily sunscreen use may also decrease the risk of AK and SCC in immunosuppressed organ transplant recipients, a higher risk population for nonmelanoma skin cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=see_link&amp;anchor=H28#H28\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=see_link&amp;anchor=H2294684#H2294684\">",
"     \"Management of skin cancer in solid organ transplant recipients\", section on 'Follow-up and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/8/19586?source=see_link\">",
"       \"Patient information: Actinic keratosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A wide variety of treatment options are available for the treatment of actinic keratoses (AKs). Destructive therapies, topical medications, photodynamic therapy, and chemical peels are used for the removal of these lesions. The choice of treatment is influenced by the clinical presentation and patient preferences. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with isolated AKs be treated with liquid nitrogen cryotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Surgical curettage and shave removal are alternative destructive therapies that are useful for persistent hypertrophic lesions. These destructive modalities treat visible AKs but, unlike field therapies, do not eliminate early AKs in adjacent areas. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Liquid nitrogen cryotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Field-directed treatments are useful for patients with multiple AKs in a given area. We suggest treating these patients with topical 5-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (5-FU),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/35/38451?source=see_link\">",
"       ingenol mebutate",
"      </a>",
"      , or photodynamic therapy&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      is an alternative field therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pharmacotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H519985\">",
"       'Photodynamic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive strategies (eg, sunblock, avoidance of sun exposure) and ongoing monitoring for lesion recurrence and cutaneous malignancies are required in all patients with a history of AKs. (See",
"      <a class=\"local\" href=\"#H3202061\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30136?source=see_link\">",
"       \"Sunburn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29443235\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Avanta Collier, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/1\">",
"      Padilla RS, Sebastian S, Jiang Z, et al. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol 2010; 146:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/2\">",
"      Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/3\">",
"      Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/4\">",
"      Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol 2013; 68:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/5\">",
"      Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev 2012; 12:CD004415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/6\">",
"      Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol 1982; 7:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/7\">",
"      Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol 2004; 140:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/8\">",
"      Jeffes EW 3rd, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol 2000; 1:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/9\">",
"      Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005; 9:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/10\">",
"      New treatments for actinic keratoses. Med Lett Drugs Ther 2002; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/11\">",
"      Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther 2001; 23:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/12\">",
"      Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002; 70:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/13\">",
"      Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006; 126:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/14\">",
"      Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004; 140:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/15\">",
"      Chen K, Yap LM, Marks R, Shumack S. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol 2003; 44:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/16\">",
"      Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141:467.",
"     </a>",
"    </li>",
"    <li>",
"     www.aldara.com/pdfs/aldara_ppi.pdf (Accessed on May 09, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/18\">",
"      Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/19\">",
"      Imiquimod (Aldara) for actinic keratoses. Med Lett Drugs Ther 2004; 46:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/20\">",
"      Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010; 62:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/21\">",
"      Hanke CW, Beer KR, Stockfleth E, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010; 62:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/22\">",
"      Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/23\">",
"      Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157 Suppl 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/24\">",
"      Brown VL, Atkins CL, Ghali L, et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005; 141:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/25\">",
"      Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol 2009; 60:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/26\">",
"      Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol 2009; 50:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/27\">",
"      Ogbourne SM, Hampson P, Lord JM, et al. Proceedings of the First International Conference on PEP005. Anticancer Drugs 2007; 18:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/28\">",
"      Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol 2013; 68:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/29\">",
"      Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol 2012; 66:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/30\">",
"      Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/31\">",
"      Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/32\">",
"      Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/33\">",
"      Pirard D, Vereecken P, M&eacute;lot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res 2005; 297:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/34\">",
"      Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006; 5:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/35\">",
"      Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol 2003; 49:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/36\">",
"      Weinstock MA, Bingham SF, VATTC Trial Group. High-dose topical tretinoin for reducing multiplicity of actinic keratoses (abstract). J Invest Dermatol 2010; 130 Suppl 1:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/37\">",
"      Carneiro RV, Sotto MN, Azevedo LS, et al. Acitretin and skin cancer in kidney transplanted patients. Clinical and histological evaluation and immunohistochemical analysis of lymphocytes, natural killer cells and Langerhans' cells in sun exposed and sun protected skin. Clin Transplant 2005; 19:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/38\">",
"      Hauschild A, Popp G, Stockfleth E, et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Exp Dermatol 2009; 18:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/39\">",
"      Serra-Guill&eacute;n C, Nagore E, Hueso L, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol 2012; 66:e131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/40\">",
"      Hadley J, Tristani-Firouzi P, Hull C, et al. Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses. Dermatol Surg 2012; 38:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/41\">",
"      Sotiriou E, Apalla Z, Maliamani F, et al. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol 2009; 23:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/42\">",
"      Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006; 155:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/43\">",
"      Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol 2002; 47:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/44\">",
"      Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003; 14:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/45\">",
"      Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008; 158:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/46\">",
"      Coleman WP 3rd, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg 1996; 22:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/47\">",
"      Monheit GD. Medium-depth chemical peels. Dermatol Clin 2001; 19:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/48\">",
"      Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/49\">",
"      Hantash BM, Stewart DB, Cooper ZA, et al. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol 2006; 142:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/50\">",
"      Ostertag JU, Quaedvlieg PJ, van der Geer S, et al. A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med 2006; 38:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/51\">",
"      Weiss ET, Brauer JA, Anolik R, et al. 1927-nm fractional resurfacing of facial actinic keratoses: a promising new therapeutic option. J Am Acad Dermatol 2013; 68:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/52\">",
"      Katz TM, Goldberg LH, Marquez D, et al. Nonablative fractional photothermolysis for facial actinic keratoses: 6-month follow-up with histologic evaluation. J Am Acad Dermatol 2011; 65:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/53\">",
"      Prens SP, Vries KD, Neumann HA, Prens EP. Non-ablative fractional resurfacing in combination with topical tretinoin cream as a field treatment modality for multiple actinic keratosis: a pilot study and a review of other field treatment modalities. J Dermatolog Treat 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30968/abstract/54\">",
"      Naylor MF, Boyd A, Smith DW, et al. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 1995; 131:170.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5336 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30968=[""].join("\n");
var outline_f30_15_30968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3202133\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Liquid nitrogen cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Topical 5-fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3581609\">",
"      - Ingenol mebutate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7122473\">",
"      - Topical diclofenac",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H519985\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Dermabrasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chemical peels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H252292\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3202061\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29443235\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5336|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/20/16709\" title=\"picture 1A\">",
"      Hypertrophic actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/61/37843\" title=\"picture 1B\">",
"      Multiple actinic keratoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/46/14051\" title=\"picture 2\">",
"      Actinic keratoses treated with 5-FU",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37832?source=related_link\">",
"      Epidemiology and risk factors for skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/49/18200?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=related_link\">",
"      Management of skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/8/19586?source=related_link\">",
"      Patient information: Actinic keratosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_15_30969="AIDS-related lymphomas: Primary effusion lymphoma";
var content_f30_15_30969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   AIDS-related lymphomas: Primary effusion lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/15/30969/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30969/contributors\">",
"     Lawrence D Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/15/30969/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30969/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/15/30969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30969/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/15/30969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with HIV predisposes to the development of neoplasms, including lymphoma. AIDS-related lymphoma is generally divided into three types: systemic non-Hodgkin lymphoma (NHL), primary central nervous system lymphoma, and the primary effusion (\"body cavity\") lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Systemic NHL accounts for the great majority of lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to primary effusion lymphoma (PEL) will be reviewed here. The epidemiology of and risk factors of AIDS-related lymphoma and the other AIDS-related lymphomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7242?source=see_link\">",
"     \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary effusion lymphoma (PEL) is one of the least common of the AIDS-related lymphomas, accounting for less than 1 to 4 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The overwhelming majority of cases of PEL occur in HIV-infected patients. However, this lesion can occur in the absence of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/6-9\">",
"     6-9",
"    </a>",
"    ] and rarely has been seen following solid organ transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/10-12\">",
"     10-12",
"    </a>",
"    ] and in chronic hepatitis C virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be a strong male predominance with men accounting for all 15 cases in one of the original descriptions, and for 10 of 11 cases in a separate single-institution study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. This may largely reflect the markedly increased prevalence of HIV infection among men. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27206?source=see_link&amp;anchor=H1560489307#H1560489307\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although earlier studies of this rare condition had reported low CD4 counts in patients with PEL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/15\">",
"     15",
"    </a>",
"    ], larger and more recent series do not support this observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/3,4,16\">",
"     3,4,16",
"    </a>",
"    ]. Among those infected with HIV, patients with PEL are similar to those with other NHLs in age, race, and HIV transmission category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described below, human herpesvirus-8 (HHV-8) plays a role in the pathogenesis of PEL. Those individuals with other disorders related to HHV-8 infection have an increased risk for developing primary effusion lymphoma, and vice-versa. These disorders include Kaposi's sarcoma and multicentric Castleman's disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19192?source=see_link\">",
"     \"Disease associations of human herpesvirus 8 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6970?source=see_link&amp;anchor=H5#H5\">",
"     \"Castleman's disease\", section on 'Role of interleukin-6'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant cells of PEL are monoclonal B cells (as defined by rearrangement of the immunoglobulin gene) that express cell surface CD38 and contain genomic material from human herpesvirus-8 (HHV-8, also called Kaposi's sarcoma-associated herpesvirus or KSHV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/6,17-19\">",
"     6,17-19",
"    </a>",
"    ] and, in many cases, Epstein-Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/6,20,21\">",
"     6,20,21",
"    </a>",
"    ]. The importance of EBV in lymphomatous transformation in this setting is uncertain, as opposed to its primary role in PCNSL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cell of origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise B cell subset from which these cells are derived and the biological mechanisms responsible for its unusual growth pattern (ie, limited to body cavities) are uncertain. It has been suggested that the cells represent a preterminal stage of B-cell differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/23\">",
"     23",
"    </a>",
"    ]. However, others suggest that the development of PEL is not restricted to one stage of B-cell differentiation and may represent transformation of B-cells at different stages of ontogeny [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PELs express a common gene profile that is distinct from that of other AIDS-related NHLs or lymphomas in the immunocompetent population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This profile suggests that, unlike AIDS-related NHLs, the tumor cells are not of germinal center or memory cell origin. Rather, they more likely correspond to a stage of B-cell development intermediate between that of immunoblasts and plasma cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with PEL have HHV-8 infection and many patients also demonstrate evidence of EBV infection. While HHV-8 infection is required for the development of PEL, the mechanisms by which HHV-8 infection might promote tumor growth are uncertain. Loss of the HHV-8 genome results in the death of PEL cells, demonstrating that genes of this virus play a vital role in PEL cell survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following latent gene products of HHV-8 appear to play significant roles in the development of PEL by promoting proliferation and impairing apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Latency-associated nuclear antigen (LANA-1)",
"     </li>",
"     <li>",
"      Viral cyclin (v-cyclin)",
"     </li>",
"     <li>",
"      Viral FLICE inhibitory protein (v-FLIP)",
"     </li>",
"     <li>",
"      Viral interleukin-6",
"     </li>",
"     <li>",
"      Viral interleukin-8 receptor homolog (vIL8R), also known as viral G-protein coupled receptor homolog (vGPCR)",
"     </li>",
"     <li>",
"      The transmembrane protein K1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proposed pathogenic roles for LANA-1 in PEL development include tethering HHV-8 DNA to chromosomes during mitosis to permit segregation of HHV-8 episomes to the progeny cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/33\">",
"     33",
"    </a>",
"    ], activation of EBV promotor regions in co-infected cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], and inhibition of tumor suppressor genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    V-cyclin binds and phosphorylates the cell cycle inhibitor p27 (KIP1), thereby inhibiting the negative cell cycle control function of p27 and promoting the rapid proliferation of PEL cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Further, v-cyclin forms a complex with cyclin-dependent kinase (CDK-6) to form an active kinase inhibitor that also promotes cell proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HH8 K1 gene is expressed in PEL cells and is up-regulated when these cells enter the lytic phase of the virus life cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/28\">",
"     28",
"    </a>",
"    ]. The product of this gene promotes the survival of infected cells and further dissemination of HHV-8. This occurs through the activation of nF-kappa B, by disrupting cytokine regulation, and by its ability to bind and disrupt other proteins.",
"   </p>",
"   <p>",
"    HHV-8 infection results in the constitutive activation of nuclear factor-kappa B (NF-kB) in endothelial cells perhaps through the latent protein v-FLIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/34,42-44\">",
"     34,42-44",
"    </a>",
"    ]. Much like in other virally-mediated lymphomas, the survival of PEL cells depends on the unregulated production of NF-kB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/45\">",
"     45",
"    </a>",
"    ]. Inhibition of NF-kB has been shown to induce apoptosis in PEL cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interleukin (IL)-6 and IL-10 may act as autocrine growth factors to promote lymphomagenesis and the growth of PEL cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The HHV-8 genome encodes viral IL-6, a cytokine that promotes plasmacytosis and angiogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional studies suggest that constitutive phosphorylation of Signal Transducer and Activator of Transcription-3 (STAT3) in the cells of PELs occurs secondary to IL-10 and viral IL-6. Phosphorylation of STAT-3 directly contributes to the malignant progression of PEL cells by activating the prosurvival (anti-apoptotic) protein survivin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of PEL depend upon the extent and distribution of disease. PEL originates on serosal surfaces, including the pleura (60 to 90 percent), pericardium (up to 30 percent), peritoneum (30 to 60 percent), joint spaces, and, rarely, the meninges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/3,6,16,53\">",
"     3,6,16,53",
"    </a>",
"    ]. Most affected patients present with a symptomatic serous effusion containing high-grade, malignant lymphocytes, but with no detectable mass lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. As such, patients usually present with symptoms related to fluid accumulation such as dyspnea (from pleural or pericardial effusions), abdominal distension (from ascites), or joint swelling.",
"   </p>",
"   <p>",
"    Radiographic testing in primary effusion lymphoma reveals evidence of the local effusions. Chest radiographs and CT reveal the pleural",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericardial effusion, slight serosal (pleural, pericardial) thickening, and the absence of parenchymal abnormalities, solid masses, or mediastinal enlargement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/6,17,54\">",
"     6,17,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although PEL is characterized by its predilection for body cavities, these tumor cells may rarely appear as HHV-8 positive solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. These solid tumor variants predominantly occur in the gastrointestinal tract.",
"   </p>",
"   <p>",
"    With increased screening measures for HIV, many patients are treated with highly active anti-retroviral therapy (HAART) before the development of complications such as PEL. It is unknown how the clinical manifestations of PEL which develops in patients undergoing treatment with HAART differs, if at all, from those of patients who are HAART-naive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the patient suspected of having PEL involves imaging techniques to detect the effusion followed by fluid examination. While the morphology and immunophenotype can vary, the key diagnostic criterion for PEL is the presence of HHV-8 in the nuclei of the malignant cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fluid examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Samples of the effusion are almost always positive for malignant cells due to the unique liquid-phase of growth of these tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/6,54\">",
"     6,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant cells exhibit a range of appearances, from large immunoblastic or plasmablastic cells to those with more anaplastic characteristics; some cells can resemble Reed-Sternberg cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/58\">",
"     58",
"    </a>",
"    ]. A perinuclear hof consistent with plasmacytoid differentiation may be seen. The cytoplasm is deeply basophilic with vacuoles in occasional cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunophenotype of the malignant cells in PEL often reflect that of a mature B cell shifting towards terminal plasma cell differentiation. Over 90 percent of cases demonstrate expression of CD45. Other B-cell (ie, CD19, CD20, CD79a) and T-cell-associated antigens are typically negative, but can be seen in a fraction of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/15,21,59\">",
"     15,21,59",
"    </a>",
"    ]. Activation and plasma cell-related markers such as CD30, CD38, CD71, CD138, and epithelial membrane antigen are usually present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/29,58\">",
"     29,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;No characteristic genetic abnormalities have been identified in PEL but complex and recurrent cytogenetic abnormalities in the tumor cells have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, immunoglobulin genes and T-cell receptor genes are often rearranged and can be used to demonstrate a monoclonal B cell population by Southern blot analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/24,60\">",
"     24,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Viral testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key diagnostic criterion for PEL is the presence of HHV-8 in the nuclei of the malignant cells. The most common method for detecting HHV-8 positivity is immunohistochemical staining for the latent viral gene product known as latency-associated nuclear antigen (LANA-1). Despite the usual co-infection with EBV, staining for latent membrane protein (LMP1) is negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for patients who present with an effusion that is subsequently found to contain lymphoma cells includes systemic lymphomas with secondary involvement of the body fluid (ie, secondary effusion), extranodal variants of various subtypes of lymphoma (eg, extranodal large cell lymphoma), and lymphomas that develop as a result of chronic pyothorax (ie, pyothorax associated lymphoma). Primary effusion lymphoma is characteristically distinguished from all of these other types of lymphoma by its HHV-8 positivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, there is a broad differential diagnosis for pleural effusions in HIV infected patients which include both infectious and non-infectious causes. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23993?source=see_link\">",
"     \"Pleural effusions in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Extranodal Burkitt lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Burkitt lymphoma can sometimes present with an effusion as the sole marker of disease, most frequently in the context of HIV infection. The defining biological feature of Burkitt lymphoma is c-myc deregulation, which is not found in PEL. Ninety percent of the time the malignant cells of Burkitt lymphoma display a translocation between the long arm of chromosome 8 (the site of the c-myc oncogene) and one of three other chromosomes resulting in t(8;14), t(2;8), or t(8;22). The principal feature that distinguishes Burkitt lymphoma from primary effusion lymphoma is its HHV8 negativity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35720?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pyothorax associated lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyothorax-associated lymphoma, reported mostly from Japan, is a rare complication of long-standing pyothorax, most often in association with tuberculosis in the context of Epstein-Barr virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/61\">",
"     61",
"    </a>",
"    ]. In contrast to primary effusion lymphoma, these lymphomas have no association with immunosuppression and are HHV-8 negative. They also typically present with a tumor mass within the body cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ann Arbor staging system is not useful in PEL since all patients have stage IV disease by definition (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"mobipreview.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/63\">",
"     63",
"    </a>",
"    ]. In addition, the International Prognostic Index used in most other types of NHL has not been validated in patients with PEL. However, a pretreatment evaluation can help determine the extent of disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Computed tomography (CT) of the chest, abdomen, and pelvis is recommended for all patients with consideration given to nuclear imaging with positron emission tomography (PET) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/64\">",
"     64",
"    </a>",
"    ]. The use of other imaging modalities, bone marrow biopsy, lumbar puncture,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endoscopy is driven by the clinical manifestations.",
"   </p>",
"   <p>",
"    Evaluation of the newly diagnosed patient should also include a complete blood count with differential, chemistries with liver and renal function and electrolytes, serum lactate dehydrogenase (LDH) level, and HIV serologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although they have little propensity to disseminate, PELs cause local destruction and have a uniformly poor prognosis without treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/6\">",
"     6",
"    </a>",
"    ]. The median survival after diagnosis without treatment is approximately 2 to 3 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/21,65\">",
"     21,65",
"    </a>",
"    ]. Even with aggressive chemotherapy, historically the median survival extended on average to only six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/6,17,21,53,65\">",
"     6,17,21,53,65",
"    </a>",
"    ]. While many cases demonstrate a response to chemotherapy treatment, remissions are often of short duration.",
"   </p>",
"   <p>",
"    There is a paucity of data to guide the treatment of patients with PEL. Since the disease is so uncommon, there are very few retrospective series and no prospective trials in this patient group. In addition, PEL's unique clinical manifestations make trials of other NHL subtypes largely inapplicable.",
"   </p>",
"   <p>",
"    Treatment approaches that have been used for PEL include highly active anti-retroviral therapy (HAART), cytotoxic chemotherapy, radiation therapy, antiviral therapy, and combinations of these.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     HIV infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of PEL in HIV infected patients is unknown. All patients should be encouraged to enroll on a clinical trial. Outside of a trial, most clinicians advocate the administration of both HAART and combination chemotherapy as initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Initial approach",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26795974\">",
"    <span class=\"h4\">",
"     HAART",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key component of the treatment of all HIV infected (HIV+) patients with an AIDS-related NHL is the administration of an effective HAART regimen. This is supported by retrospective studies in other AIDS-related NHL subtypes that have reported a survival benefit with HAART plus chemotherapy compared with chemotherapy alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38346?source=see_link&amp;anchor=H1225504#H1225504\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\", section on 'Effect of HAART'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective studies evaluating the use of chemotherapy in patients with HIV+ PEL have included patients who did or did not receive HAART. Although data are limited, patients treated with HAART alone appear to have similar outcomes as those administered HAART plus chemotherapy and far superior survival compared with those given chemotherapy alone.",
"   </p>",
"   <p>",
"    The following is a survey of these retrospective analyses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective single-institution study reported outcomes of 10 HIV+ patients with PEL, five of whom had received prior HAART therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/3\">",
"       3",
"      </a>",
"      ]. Five patients were treated with CHOP-like chemotherapy plus HAART, which resulted in two complete remissions (CRs) and a mean overall survival of 16 months. One received HAART alone resulting in a CR and was alive at 14 months of follow-up. Three were treated with chemotherapy but no HAART which resulted in a three month overall survival. One patient received neither chemotherapy nor HAART and was dead in two weeks.",
"     </li>",
"     <li>",
"      A multi-center retrospective study evaluated the outcomes of 17 HIV+ patients with PEL treated with combination chemotherapy plus HAART [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/16\">",
"       16",
"      </a>",
"      ]. Only two patients were HAART-naive at the time of diagnosis. There were eight CRs. Median survival was six months and the one-year survival rate was 40 percent. This series also reported on two patients who received CHOP chemotherapy without HAART, neither of whom achieved a CR and both died within six weeks. By multivariate analysis, predictors of worse survival were shown to be Eastern Cooperative Oncology Group (ECOG) performance status greater than 2 and lack of HAART treatment prior to PEL diagnosis.",
"     </li>",
"     <li>",
"      Another retrospective series of seven HIV+ patients reported on the use of standard doses of CHOP chemotherapy plus high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      rescue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/53\">",
"       53",
"      </a>",
"      ]. Five patients received chemotherapy plus HAART. Three had a CR and were alive at an average follow-up of 40 months. A fourth died from plasmablastic NHL with PEL in CR at the time of his death. Two patients were treated with chemotherapy without HAART; one had a CR and started HAART one month after chemotherapy and was alive 78 months after diagnosis while the other patient was dead 22 days after the diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Case reports have demonstrated that some patients with PEL can obtain CRs with HAART alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/3,29,66-68\">",
"     3,29,66-68",
"    </a>",
"    ]. However, we reserve this approach for patients with poor performance status or other comorbidities that would preclude the use of combination chemotherapy. For HIV infected patients with newly diagnosed PEL, we suggest the use of chemotherapy in addition to the institution of HAART or modification of an existing HAART regimen rather than administering HAART alone. As with all antiviral therapy in HIV+ patients, the goal is to achieve an undetectable viral load. Chemotherapy options are discussed in the following section.",
"   </p>",
"   <p>",
"    When choosing among HAART regimens, it is important to take into consideration overlapping toxicities or interference of anti-retrovirals with chemotherapeutic agents that may be used in the future. As an example, anti-retroviral drugs with excessive myelotoxicity, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , should be avoided in patients who are receiving or may soon receive myelotoxic chemotherapy. The choice of initial HAART regimens in patients with HIV is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26795981\">",
"    <span class=\"h4\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of combination chemotherapy with or without HAART in patients with PEL has been evaluated in uncontrolled retrospective analyses, some of which are described in the section above. For HIV-infected patients with newly diagnosed PEL, we suggest the use of chemotherapy in addition to the institution of HAART or modification of an existing HAART regimen rather than administering HAART alone. We reserve the use of HAART without chemotherapy for patients with poor performance status or other comorbidities that would preclude the use of combination chemotherapy. Patients should be enrolled on clinical trials, if available.",
"   </p>",
"   <p>",
"    The following options are offered based upon our clinical experience, case reports, or in vitro data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CHOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef66136 \" href=\"mobipreview.htm?0/54/876\">",
"       table 2",
"      </a>",
"      )) or dose-adjusted EPOCH (cyclophosphamide, doxorubicin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , vincristine, prednisone) with antiretroviral therapy results in response rates of 40 to 50 percent and appears to extend median survival from two to three months in those not receiving therapy to a median survival of five to six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/5,29\">",
"       5,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the tumor is found to have a very high growth fraction, we would consider a more aggressive regimen, such as",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC",
"      </span>",
"      (the Magrath regimen) or Hyper-CVAD (hyperfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ), similar to those used for other tumors with high growth fractions (eg, Burkitt",
"      <span class=\"nowrap\">",
"       lymphoma/leukemia).",
"      </span>",
"      Since these regimens have greater toxicity, they are reserved for patients with a very good performance status and few comorbidities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36217?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of Burkitt leukemia/lymphoma in adults\", section on 'CODOX-M plus IVAC'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36217?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of Burkitt leukemia/lymphoma in adults\", section on 'HyperCVAD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rare cases of PEL are comprised of CD20 positive cells. In such cases,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      may offer a therapeutic possibility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"      has demonstrated in vitro activity against PEL with efficacy varying depending upon the timing of administration and combination with other agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/29,46-48,69\">",
"       29,46-48,69",
"      </a>",
"      ]. It is thought to sensitize PEL cells to chemotherapy-induced apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/42,70\">",
"       42,70",
"      </a>",
"      ]. The only published reports on its efficacy are mixed: one series of three patients demonstrating no responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/71\">",
"       71",
"      </a>",
"      ] and a case report in a case of HIV-negative PEL showing a significant response to a combination of bortezomib with pegylated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More intensive regimens, such as high-dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) or allogeneic HCT have had mixed results with two case reports showing success and another showing no response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/73-75\">",
"     73-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is standard practice to use granulocyte stimulating growth factors to limit the period of neutropenia in patients with AIDS-related lymphoma receiving chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/5,29\">",
"     5,29",
"    </a>",
"    ]. We also routinely administer Pneumocystis jiroveci pneumonia (PCP) prophylaxis, ideally with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX).",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    can be myelosuppressive and may synergize with chemotherapy to result in a more profound and longer nadir. As such, blood counts must be monitored during therapy. PCP prophylaxis is continued for several months after completion of chemotherapy and until the CD4 counts are stable above",
"    <span class=\"nowrap\">",
"     200/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    Fungal prophylaxis and screening for cytomegalovirus reactivation while on therapy may be considered in patients with a CD4 count &lt;50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When systemic chemotherapy is not possible or a patient has failed other treatment regimens, local radiation therapy to the body cavity of origin may be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/76\">",
"     76",
"    </a>",
"    ]. This may palliate the patient for up to 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     HIV negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is even less evidence to guide the treatment of HIV-negative patients with PEL. This is an extremely rare patient population and the majority are being administered chronic immunosuppressant agents to prevent rejection of a solid organ transplantation. Therapy is based upon extrapolation of the data from HIV infected patients discussed in the sections above. HAART therapy is not indicated in the absence of HIV infection so initial therapy is with chemotherapy. Radiation therapy can also be given to patients who are unable to tolerate or have failed other treatments.",
"   </p>",
"   <p>",
"    Based upon clinical experience that HIV infected patients with PEL treated with HAART have better outcomes than those who do not receive HAART therapy, we would expect that patients without HIV infection on immunosuppressive therapy would do better if their immunosuppressive therapy were decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with HIV negative PEL, we would consider the use of CHOP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) or dose-adjusted EPOCH (cyclophosphamide, doxorubicin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , vincristine, prednisone) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    added in cases that express CD20. If the patient is receiving immunosuppressive therapy, we decrease this immunosuppression, if possible. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'HIV infected patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients initiating HAART or changing a HAART regimen, we reevaluate their HIV status four weeks after starting the regimen with a measurement of viral load. We expect to see a drop in the viral load by at least one log(10) at this time. By 12 weeks the viral load should become undetectable. If it is still detectable at 12 weeks, a change in regimen should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Response of the PEL to therapy is evaluated six to eight weeks after attainment of an undetectable viral load or completion of chemotherapy with a history, physical examination, laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile), and a",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, which provides information on the size and activity of residual masses and allows for the distinction between active disease and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/64\">",
"     64",
"    </a>",
"    ]. Disease response can be determined by the International Workshop Criteria (IWC) as detailed in the table (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"mobipreview.htm?29/27/30140\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While many patients will demonstrate a response to treatment, these remissions are often short-lived. Following documentation of a complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician.",
"   </p>",
"   <p>",
"    We generally follow our patients every three months. At these visits, we perform a history and physical examination, complete blood count, chemistries, LDH, and imaging studies if indicated based on signs and symptoms. A biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy.",
"   </p>",
"   <p>",
"    Causes of death include not only progression of lymphoma, but also opportunistic infections and other HIV-related complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30969/abstract/5\">",
"     5",
"    </a>",
"    ]. It is critical for these patients to be closely followed by their HIV specialist in order to control their HIV infection and prevent opportunistic infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary Effusion Lymphoma (PEL) is one of the least common of the AIDS-related lymphomas. Although most cases occur in HIV-infected patients, this lesion can occur in the absence of HIV infection most often in patients with other causes of immunocompromise (eg, solid organ transplantation recipients). Latent gene products of human herpesvirus-8 (HHV-8) appear to play a role in the pathogenesis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PEL originates on serosal surfaces and most affected patients present with a symptomatic serous effusion containing high-grade, malignant lymphocytes, but with no detectable mass lesion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PEL is usually made based upon a cytologic examination of the effusion which almost always contains malignant cells. The key diagnostic criterion is the presence of HHV-8 in the nuclei of the malignant cells. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PEL have a poor prognosis. Mean overall survival is less than three months without treatment and approximately six months with chemotherapy and highly active anti-retroviral therapy (HAART).",
"     </li>",
"     <li>",
"      There are limited data to guide the treatment of patients with PEL and recommendations are based on expert opinion, case reports, and small retrospective case series. Treatment is modified based on whether the patient is HIV infected. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consideration should be given to enrollment on a clinical trial, if available.",
"     </li>",
"     <li>",
"      For HIV infected patients with newly diagnosed PEL, we suggest the institution of HAART or modification of an existing HAART regimen plus the administration of combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Care must be taken to choose a HAART regimen with minimal overlap of chemotherapy-related toxicities. (See",
"      <a class=\"local\" href=\"#H26795974\">",
"       'HAART'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26795981\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The selection of combination chemotherapy to administer in conjunction with HAART is largely dependent upon patient and tumor characteristics (see",
"      <a class=\"local\" href=\"#H26795981\">",
"       'Chemotherapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most patients, we prefer CHOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) or a CHOP-like chemotherapy regimen.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      is added if the tumor expresses CD20.",
"     </li>",
"     <li>",
"      For patients with a very good performance status and few medical comorbidities, a more aggressive regimen, such as",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC",
"      </span>",
"      or Hyper-CVAD, may be considered, especially if the malignant cells exhibit a high growth fraction.",
"     </li>",
"     <li>",
"      For those with a poor performance status or significant medical comorbidities, a liposomal anthracycline alone or a liposomal anthracycline plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (or an equivalent steroid) may be considered. These agents are administered in combination with continued HAART. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are unable to tolerate or who have failed combination chemotherapy may be treated with HAART with or without local radiation therapy to the body cavity of origin. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with HIV negative PEL should be treated with CHOP or a CHOP-like regimen and a decrease in immunosuppressive therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'HIV negative patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/1\">",
"      Sandler AS, Kaplan LD. Diagnosis and management of systemic non-Hodgkin's lymphoma in HIV disease. Hematol Oncol Clin North Am 1996; 10:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/2\">",
"      Cot&eacute; TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/3\">",
"      Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003; 21:3948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/4\">",
"      Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Pleural and peritoneal lymphoma among people with AIDS in the United States. J Acquir Immune Defic Syndr 2002; 29:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/5\">",
"      Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007; 12:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/6\">",
"      Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/7\">",
"      Said JW, Tasaka T, Takeuchi S, et al. Primary effusion lymphoma in women: report of two cases of Kaposi's sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. Blood 1996; 88:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/8\">",
"      Gandhi SA, Mufti G, Devereux S, Ireland R. Primary effusion lymphoma in an HIV-negative man. Br J Haematol 2011; 155:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/9\">",
"      Ganzel C, Rowe JM, Ruchlemer R. Primary effusion lymphoma in a HIV-negative patient associated with hypogammaglobulinemia. Am J Hematol 2011; 86:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/10\">",
"      Jones D, Ballestas ME, Kaye KM, et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med 1998; 339:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/11\">",
"      Dotti G, Fiocchi R, Motta T, et al. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia 1999; 13:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/12\">",
"      Melo NC, Sales MM, Santana AN, et al. Pleural primary effusion lymphoma in a renal transplant recipient. Am J Transplant 2008; 8:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/13\">",
"      Makis W, Stern J. Hepatitis C-related primary effusion lymphoma of the pleura and peritoneum, imaged with F-18 FDG PET/CT. Clin Nucl Med 2010; 35:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/14\">",
"      Nakayama-Ichiyama S, Yokote T, Kobayashi K, et al. Primary effusion lymphoma of T-cell origin with t(7;8)(q32;q13) in an HIV-negative patient with HCV-related liver cirrhosis and hepatocellular carcinoma positive for HHV6 and HHV8. Ann Hematol 2011; 90:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/15\">",
"      Lynch JW Jr. AIDS-related non-Hodgkin's lymphoma. Useful techniques for diagnosis. Chest 1996; 110:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/16\">",
"      Boulanger E, G&eacute;rard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23:4372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/17\">",
"      Karcher DS, Alkan S. Human herpesvirus-8-associated body cavity-based lymphoma in human immunodeficiency virus-infected patients: a unique B-cell neoplasm. Hum Pathol 1997; 28:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/18\">",
"      Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/19\">",
"      Cesarman E, Nador RG, Bai F, et al. Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J Virol 1996; 70:8218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/20\">",
"      Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 1997; 90:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/21\">",
"      Komanduri KV, Luce JA, McGrath MS, et al. The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/22\">",
"      Arvanitakis L, Mesri EA, Nador RG, et al. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 1996; 88:2648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/23\">",
"      Gaidano G, Gloghini A, Gattei V, et al. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood 1997; 90:4894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/24\">",
"      Matolcsy A, N&aacute;dor RG, Cesarman E, Knowles DM. Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation. Am J Pathol 1998; 153:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/25\">",
"      Klein U, Gloghini A, Gaidano G, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 2003; 101:4115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/26\">",
"      Wilson KS, McKenna RW, Kroft SH, et al. Primary effusion lymphomas exhibit complex and recurrent cytogenetic abnormalities. Br J Haematol 2002; 116:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/27\">",
"      Jenner RG, Maillard K, Cattini N, et al. Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A 2003; 100:10399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/28\">",
"      Wies E, Mori Y, Hahn A, et al. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 2008; 111:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/29\">",
"      Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol 2008; 140:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/30\">",
"      Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol 2007; 60:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/31\">",
"      Wang S, Wang S, Maeng H, et al. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 2007; 109:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/32\">",
"      Ballon G, Chen K, Perez R, et al. Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. J Clin Invest 2011; 121:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/33\">",
"      Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 1999; 284:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/34\">",
"      Inoue Y, Tsukasaki K, Nagai K, et al. Durable remission by sobuzoxane in an HIV-seronegative patient with human herpesvirus 8-negative primary effusion lymphoma. Int J Hematol 2004; 79:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/35\">",
"      Groves AK, Cotter MA, Subramanian C, Robertson ES. The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters. J Virol 2001; 75:9446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/36\">",
"      Katano H, Sato Y, Sata T. Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. Cancer 2001; 92:3076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/37\">",
"      Friborg J Jr, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/38\">",
"      Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000; 6:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/39\">",
"      Di Bartolo DL, Cannon M, Liu YF, et al. KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood 2008; 111:4731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/40\">",
"      Sarek G, J&auml;rviluoma A, Ojala PM. KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood 2006; 107:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/41\">",
"      J&auml;rviluoma A, Koopal S, R&auml;s&auml;nen S, et al. KSHV viral cyclin binds to p27KIP1 in primary effusion lymphomas. Blood 2004; 104:3349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/42\">",
"      An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004; 18:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/43\">",
"      Caselli E, Fiorentini S, Amici C, et al. Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NF-kappaB pathway. Blood 2007; 109:2718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/44\">",
"      Matta H, Chaudhary PM. Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci U S A 2004; 101:9399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/45\">",
"      Ghosh SK, Wood C, Boise LH, et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood 2003; 101:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/46\">",
"      Thome M, Schneider P, Hofmann K, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/47\">",
"      Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/48\">",
"      Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000; 96:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/49\">",
"      Jones KD, Aoki Y, Chang Y, et al. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 1999; 94:2871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/50\">",
"      Sin SH, Roy D, Wang L, et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007; 109:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/51\">",
"      Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996; 274:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/52\">",
"      Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003; 101:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/53\">",
"      Boulanger E, Daniel MT, Agbalika F, Oksenhendler E. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 2003; 73:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/54\">",
"      Morassut S, Vaccher E, Balestreri L, et al. HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients. Radiology 1997; 205:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/55\">",
"      Mate JL, Navarro JT, Ariza A, et al. Oral solid form of primary effusion lymphoma mimicking plasmablastic lymphoma. Hum Pathol 2004; 35:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/56\">",
"      Chadburn A, Hyjek E, Mathew S, et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004; 28:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/57\">",
"      Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol 2007; 60:1365.",
"     </a>",
"    </li>",
"    <li>",
"     Banks PM, Warnke, RA. Primary effusion lymphoma. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.179.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/59\">",
"      Ascoli V, Mastroianni CM, Galati V, et al. Primary effusion lymphoma containing human herpesvirus 8 DNA in two AIDS patients with Kaposi's sarcoma. Haematologica 1998; 83:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/60\">",
"      Hollingsworth HC, Stetler-Stevenson M, Gagneten D, et al. Immunodeficiency-associated malignant lymphoma. Three cases showing genotypic evidence of both T- and B-cell lineages. Am J Surg Pathol 1994; 18:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/61\">",
"      Nakatsuka S, Yao M, Hoshida Y, et al. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 2002; 20:4255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/62\">",
"      Iuchi K, Aozasa K, Yamamoto S, et al. Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Summary of clinical and pathological findings in thirty-seven cases. Jpn J Clin Oncol 1989; 19:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/63\">",
"      Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1977; 61:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/64\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/65\">",
"      Valencia Ortega ME, Mart&iacute;nez Santos P, G&oacute;mez Aguado F, et al. [Primary cavity-based lymphoma and HIV infection]. Rev Clin Esp 1999; 199:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/66\">",
"      Oksenhendler E, Clauvel JP, Jouveshomme S, et al. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol 1998; 57:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/67\">",
"      Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001; 15:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/68\">",
"      Ripamonti D, Marini B, Rambaldi A, Suter F. Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. AIDS 2008; 22:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/69\">",
"      Sarosiek KA, Cavallin LE, Bhatt S, et al. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci U S A 2010; 107:13069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/70\">",
"      Yu D, Carroll M, Thomas-Tikhonenko A. p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood 2007; 109:4936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/71\">",
"      Boulanger E, Meignin V, Oksenhendler E. Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol 2008; 141:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/72\">",
"      Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma 2008; 8:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/73\">",
"      Waddington TW, Aboulafia DM. Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. AIDS Patient Care STDS 2004; 18:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/74\">",
"      Won JH, Han SH, Bae SB, et al. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol 2006; 83:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/75\">",
"      Bryant A, Milliken S. Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma. Biol Blood Marrow Transplant 2008; 14:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/76\">",
"      Cassoni A, Ali U, Cave J, et al. Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma. J Clin Oncol 2008; 26:5297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/77\">",
"      Riva G, Luppi M, Barozzi P, et al. How I treat HHV8/KSHV-related diseases in posttransplant patients. Blood 2012; 120:4150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30969/abstract/78\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4752 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30969=[""].join("\n");
var outline_f30_15_30969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cell of origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Viral infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fluid examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Genotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Viral testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Extranodal Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pyothorax associated lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HIV infected patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Initial approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26795974\">",
"      HAART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26795981\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HIV negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4752\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4752|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/54/876\" title=\"table 2\">",
"      CHOP chemotherapy NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/27/30140\" title=\"table 3\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7242?source=related_link\">",
"      AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=related_link\">",
"      AIDS-related lymphomas: Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19192?source=related_link\">",
"      Disease associations of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23993?source=related_link\">",
"      Pleural effusions in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_15_30970="Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease";
var content_f30_15_30970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/15/30970/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30970/contributors\">",
"     Richard W Nesto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/15/30970/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30970/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30970/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30970/contributors\">",
"     Arie Pieter Kappetein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/15/30970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/15/30970/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/15/30970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary heart disease (CHD) is a major cause of morbidity and mortality among patients with diabetes mellitus. Compared to nondiabetic patients, patients with diabetes are more likely to have CHD, which is most often multivessel, and to have episodes of silent ischemia. As a result of these and other factors, diabetic patients with CHD have a lower long-term survival rate than nondiabetic patients with CHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with diabetes comprise as many as 25 to 30 percent of those who undergo revascularization. Outcomes data, from large registries and subgroup analyses of randomized trials of patients undergoing revascularization are available to guide management decision making. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Outcomes after PCI'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Outcomes after CABG'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The medical and revascularization management of CHD, including the indications for revascularization, are generally similar in patients with and without diabetes. However, the short-term and long-term results of revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) are often worse in diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Outcomes compared to patients without diabetes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will focus on the approach to revascularization in patients with diabetes and multivessel coronary artery disease. The approach to revascularization in diabetic patients with left main or lesser degrees of coronary disease is similar to the broad population of patients and is discussed in other topics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4426?source=see_link\">",
"     \"Management of left main coronary artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to medical versus interventional therapy for stable angina in nondiabetic patients and to silent ischemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4665?source=see_link\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY VERSUS REVASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for revascularization in patients with diabetes and stable angina or acute coronary syndromes are generally similar to those in patients without diabetes. Our recommendations for revascularization in the broad population of patients with coronary heart disease (CHD) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Outcomes have been less well studied in CHD patients with diabetes compared to those without diabetes; consequently, the optimal strategy is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/2\">",
"     2",
"    </a>",
"    ]. The best available evidence regarding the optimal strategy for these patients comes from the BARI 2D trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/3\">",
"     3",
"    </a>",
"    ]. In BARI 2D, 2368 patients with type 2 diabetes mellitus and stable ischemic heart disease (defined as either a &ge;50 percent stenosis of a major epicardial coronary artery associated with a positive stress test or &ge;70 percent stenosis and classic angina) were enrolled. Prior to randomization to either revascularization (either CABG or PCI) with intensive medical therapy (IMT) within four weeks or IMT, patients were chosen to be placed in either the CABG or PCI stratum based on individual physician&rsquo;s preference.",
"   </p>",
"   <p>",
"    At five years the primary endpoints of the rates of survival or freedom from major cardiovascular event (death, myocardial infarction [MI], or stroke) did not differ significantly between the revascularization group and the IMT alone group (88.3 versus 87.8 percent and 77.2 versus 77.7 percent, respectively). However, in sub-group analysis, the rate of freedom from major cardiovascular events was significantly higher in the CABG plus IMT stratum compared to the corresponding IMT stratum (77.6 versus 69.5 percent), predominantly attributable to a reduction in nonfatal MI. The rates for this end point were not significantly different between the PCI stratum and the corresponding IMT group (77.0 versus 78.9 percent, respectively).",
"   </p>",
"   <p>",
"    This sub-group observation was further evaluated in an analysis of the prespecified secondary endpoints of cardiac death and myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/4\">",
"     4",
"    </a>",
"    ]. Five-year cardiac mortality did not differ significantly between revascularization (PCI and CABG) with IMT and IMT (5.9 versus 5.7 percent, respectively). In the PCI stratum (n = 1605) there were no significant differences in the rates of cardiac death or MI between PCI with IMT compared to IMT alone. However, in the CABG stratum (n = 768), MI occurred significantly less frequently with revascularization plus IMT compared to IMT alone (10 versus 17.6 percent), as did the composite endpoint of cardiac death and MI (15.8 versus 21.9 percent). The investigators postulated that the lower event rate in the CABG plus IMT stratum was due to a preference for CABG, rather than PCI, in patients with more extensive disease.",
"   </p>",
"   <p>",
"    In an attempt to understand further which patients might benefit from CABG, a risk score was developed from baseline angiographic (myocardial jeopardy index, total number of coronary lesions, prior coronary revascularization, and left ventricular ejection fraction) and clinical variables (Framingham Risk Score) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients were then stratified into high- and low-risk subgroups using either angiographic or clinical variables or both. The endpoint of interest was the combination of death, MI, and stroke. The following findings were noted at five years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients selected for CABG, compared to those selected for PCI, had higher angiographic and clinical risk scores.",
"     </li>",
"     <li>",
"      There was no significant difference in the composite endpoint between the IMT and combined coronary revascularization group.",
"     </li>",
"     <li>",
"      The composite end point occurred significantly less often in the CABG stratum than in the IMT group (24.8 versus 36.8 percent) among those in the highest angiographic risk tertile and this effect was even more pronounced in patients with both high angiographic and high clinical risk (27.1 versus 47.3 percent; hazard ratio 2.10, p = 0.0051).",
"     </li>",
"     <li>",
"      There were no significant differences in all other treatment group comparisons, including lower risk CABG groups and all PCI groups; in this comparison, risk was determined using a combined angiographic and clinical score. The event rates in the low risk PCI stratum, high risk PCI stratum, and low risk CABG stratum, all compared to IMT, were 18.7 versus 18.5, 34.2 versus 34.8, and 17.0 versus 19.9 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although this study suggests that in patients with diabetes only those at high angiographic and clinical risk benefit from revascularization with CABG, the analysis is limited by small sample size in subgroups and lack of validation of the angiographic risk score used.",
"   </p>",
"   <p>",
"    A second randomization within BARI 2D, comparing a strategy of insulin sensitization to insulin provision, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H13#H13\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'BARI 2D'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OUTCOMES COMPARED TO PATIENTS WITHOUT DIABETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes after revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) are often worse in diabetic compared to nondiabetic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     With PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who undergo elective PCI, the procedural success rates are similar in patients with and without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. However, patients with diabetes have higher rates of restenosis and lower rates of event-free survival than nondiabetic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic patients have increased rates of both restenosis and progression of coronary disease compared to patients without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/10-16\">",
"     10-16",
"    </a>",
"    ]. The following studies illustrate the magnitude of the increase in restenosis risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of 3090 patients who underwent PCI with bare-metal stents, 418 of whom (14 percent) had diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/14\">",
"       14",
"      </a>",
"      ]. At six-month angiographic follow-up, the rate of restenosis was significantly higher in the diabetic patients (31 versus 21 percent in nondiabetic patients).",
"     </li>",
"     <li>",
"      In an analysis of 10,778 patients in the j-Cypher registry who underwent PCI with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -eluting stents, there were 966 patients with insulin-dependent diabetes, 3404 with noninsulin-dependent diabetes, and 6378 without diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/17\">",
"       17",
"      </a>",
"      ]. At three years, the rate of target lesion revascularization was significantly higher in the insulin-dependent and noninsulin-dependent groups compared to those without diabetes (19, 14, and 10 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Predictors of restenosis in diabetic patients included smaller vessel caliber, greater length of the stented segment, and lower body mass index.",
"   </p>",
"   <p>",
"    It is unclear why diabetic patients are more prone to restenosis after PCI. Exaggerated intimal hyperplasia has been demonstrated, possibly due to the stimulatory effect on vascular smooth muscle of growth factors, such as insulin-like growth factor-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/18\">",
"     18",
"    </a>",
"    ]. An accelerated fibrotic response also may be important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Event-free survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have shown that event-free survival (events such as death or MI) is worse after revascularization with PCI in diabetic compared to nondiabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/6-13,20-22\">",
"     6-13,20-22",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a consecutive series of patients with successful stent placement, comprising 715 patients with diabetes and 2839 patients without diabetes, the patients with diabetes had, at one year, significant reductions in event-free survival (72 versus 79 percent), (",
"      <a class=\"graphic graphic_figure graphicRef76068 \" href=\"mobipreview.htm?31/29/32221\">",
"       figure 1",
"      </a>",
"      ), and increase in overall mortality (8.3 versus 3.8 percent) and cardiac mortality (5.7 versus 2.9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Longer-term outcomes are also worse in patients with diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. In one study, patients with diabetes undergoing balloon angioplasty (previously referred to as percutaneous transluminal coronary angioplasty or PTCA) had, at five years, a lower rate of survival, a higher incidence of MI (19 versus 11 percent), were more likely to require repeat balloon angioplasty or CABG, and had a higher combined rate of revascularization or MI (64 versus 47 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/7\">",
"       7",
"      </a>",
"      ]. Most of the events occurred in the first year after balloon angioplasty, the time at which restenosis is most common.",
"     </li>",
"     <li>",
"      In the j-Cypher registry discussed above, the adjusted risk of a serious cardiovascular event (composite of all-cause death, MI, and stroke) at three years was significantly greater in the insulin-dependent group (hazard ratio 1.12, 95% CI 1.03-1.23), but not the noninsulin-dependent group, compared to those without diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/17\">",
"       17",
"      </a>",
"      ]. Outcomes at longer-term follow-up will be helpful for increasing our confidence in these results.",
"     </li>",
"     <li>",
"      The SYNTAX trial compared PCI with drug eluting stents (DES) versus CABG in patients with complex coronary artery disease (left main",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      three vessel disease). The trial included 452 patients with diabetes. At five-year follow-up, the rate of repeat revascularization of patients undergoing PCI (n = 231) was higher in patients with diabetes (29 versus 19 percent). Mortality was also increased in the diabetic population (20 versus 12 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     With CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who undergo elective CABG, the procedural success rates are similar in patients with and without diabetes. However, during follow-up, death and adverse nonfatal outcomes after CABG are higher in patients with diabetes, and predictors of worse outcomes have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although diabetes does not appear to affect in-hospital mortality after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/23-26\">",
"     23-26",
"    </a>",
"    ], short- and long-term survival after CABG are significantly reduced in diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]. In different large observational studies, diabetic patients had higher mortality rates at 30 days (5 versus 2.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/30\">",
"     30",
"    </a>",
"    ] and at five and ten years (22 versus 12 percent and 50 versus 29 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the worse long-term prognosis after CABG in patients with diabetes, the outcomes are still better than with medical therapy or PCI in selected subgroups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'PCI versus CABG'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Nonfatal adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes is associated with more perioperative noncardiac morbidity, such as renal failure and wound infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/23,25,35\">",
"     23,25,35",
"    </a>",
"    ]. It has been suggested that bilateral internal thoracic (mammary) artery grafting may be contraindicated in diabetic patients in whom the incidence of sternal wound infection is as high as 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/35\">",
"     35",
"    </a>",
"    ]. The risk may be reduced by maintenance of strict glycemic control during the perioperative period and skeletonization of the internal mammary artery during harvesting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Perioperative glycemic control'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H18#H18\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Sternal wound infection and mediastinitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with mortality, nonfatal coronary outcomes after CABG also may be somewhat more common in diabetic patients. In the previously discussed report of over 12,000 patients, diabetes was associated with a lower rate of freedom from PCI at 10 years (83 versus 86 percent) but no difference in either MI or additional CABG at five or 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/31\">",
"     31",
"    </a>",
"    ]. Another report evaluated 1615 patients who underwent CABG at a single center, had one or more repeat angiograms, and were followed for &ge;25 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/32\">",
"     32",
"    </a>",
"    ]. Diabetes was associated with a relative risk of 1.39 for progression of atherosclerosis or recurrent symptoms. The increased rate of progressive disease is seen in both nonbypassed and the bypassed native coronary vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OUTCOMES AFTER PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with diabetes who undergo PCI, outcomes such as the rates of target lesion revascularization, myocardial infarction, or survival may be influenced by the stent type as well as diabetes-related factors. This section will discuss these issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Stent type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stents (DES) are now used in preference to bare metal stents (BMS) in many cases because they are associated with marked reductions in the incidence of restenosis and target lesion (TLR) or target vessel revascularization (TVR). The general discussions of comparisons between bare metal stents (BMS) and drug-eluting stents (DES) and between different DES are found in other topics. In most cases, the first generation DES,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stents (SES) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting stents (PES), are no longer used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative efficacy and safety of differing stent types (",
"    <a class=\"graphic graphic_table graphicRef65603 \" href=\"mobipreview.htm?11/39/11901\">",
"     table 1",
"    </a>",
"    ) in patients with diabetes have been evaluated in many of the early stent trials. Based on the evidence presented below, similar to patients without diabetes, DES are associated with a lower rate of target vessel revascularization and similar rates of adverse outcomes compared to BMS.",
"   </p>",
"   <p>",
"    Among the DES, only the Resolute zotarolimus-eluting stent has specific indication for diabetes in the United States, although the everolimus-eluting stents appear to also have an excellent efficacy and safety profile. This decision by the United States Food and Drug Administration was based on a prespecified analysis from the Resolute US clinical trial in which the outcome for death, MI, and target lesion revascularization was similar to patients without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The individual trials are limited in their ability to compare two stent designs due to relatively small number of enrolled patients; the following summarizes the results of those studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BMS versus first generation stents: Significantly lower rates of TLR with first generation stents compared to BMS in subgroup analyses of major trials such as SIRIUS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/40\">",
"       40",
"      </a>",
"      ], from small multicenter trials, such as SCORPIUS and DIABETES, that enrolled only patients with diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/41,42\">",
"       41,42",
"      </a>",
"      ], and in a pooled analysis from the first five TAXUS trials, in which 827 of 3513 patients had treated diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/43\">",
"       43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The rate of adverse cardiovascular events after placement of DES in diabetic patients was evaluated in a meta-analysis of randomized trials that compared either first generation SES or PES to BMS placed for on-label indications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/44\">",
"       44",
"      </a>",
"      ]. There was no significant difference in the rates of either total or cardiac mortality in those trials (including over 3100 patients with diabetes) that specified dual antiplatelet therapy for at least six months. Similar findings have been noted in other studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SES versus PES: The relative efficacy of SES and PES in diabetic patients has been evaluated in two small randomized trials (ISAR-DIABETES and DES-DIABETES) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/47\">",
"       47",
"      </a>",
"      ], in subset analyses of randomized trials that included some patients with diabetes, and in large registries. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=see_link&amp;anchor=H71604313#H71604313\">",
"       \"Comparison of drug-eluting intracoronary stents\", section on 'Sirolimus and paclitaxel stents'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A 2008 meta-analysis, which evaluated studies published before DES-DIABETES, concluded that the rates of TLR were not significantly different between these two stents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/48\">",
"       48",
"      </a>",
"      ]. The 400 patient DES-DIABETES trial found that primary endpoint of in-segment stenosis at six months was significantly lower in the SES group (4.0 versus 20.8 percent, respectively) and at nine months there was no significant difference in the incidence or MI or death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/49\">",
"       49",
"      </a>",
"      ]. At four years there was no significant difference in the rates of major adverse cardiovascular events (11.0 versus 16 percent respectively) or TVR (7.5 versus 12 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/50\">",
"       50",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The relative incidence of major adverse cardiac events after stenting with either SES or PES was evaluated in two meta-analyses cited above, both of which found no significant difference in outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/44,48\">",
"       44,48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Second versus first generation stents: In a prespecified subgroup analysis of the SPIRIT IV trial, which randomly assigned patients to second generation everolimus-eluting stents (EES) or PES, there was no significant difference in the primary outcome of target vessel failure between the EES and PES groups in patients with diabetes (6.4 versus 6.9 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=see_link&amp;anchor=H2#H2\">",
"       \"Comparison of drug-eluting intracoronary stents\", section on 'Everolimus-eluting stents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best available evidence concerning the relative efficacy and safety of the various drug-eluting or bare metal stents in patient with diabetes comes from a 2012 mixed treatment comparison analysis of 42 randomized trials with 22,844 patient years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39609?source=see_link&amp;anchor=H110188312#H110188312\">",
"     \"Systematic review and meta-analysis\", section on 'Network meta-analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared to bare metal stents, SES, PES, everolimus-eluting stents (EES), and zotarolimus-eluting stents (ZES) were associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A significant reduction in target vessel revascularization, with EES having the highest probability of being the best (with limited usable data for the ZES-resolute stent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No increased risk of any safety outcome (death, MI, or",
"      <span class=\"nowrap\">",
"       probable/definite",
"      </span>",
"      stent thrombosis). For these three outcomes, the EES had the highest probability of being the best stent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diabetes-related factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several diabetes-related clinical factors have been evaluated for their impact on outcome after PCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of diabetic nephropathy appears to be an important predictor of risk after PCI. This was suggested in an observational study of 537 diabetic patients in which those with proteinuria had a significantly higher two-year mortality rate following PCI (20 versus 9 percent in those without proteinuria, adjusted hazard ratio 1.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The independent prognostic importance of proteinuria was not confirmed in a subsequent retrospective analysis of 6542 patients, 842 of whom had diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/54\">",
"     54",
"    </a>",
"    ]. At a median follow-up of 28 months after PCI, a baseline serum creatinine above 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in men and 1.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in women (133 and 115",
"    <span class=\"nowrap\">",
"     &micro;mol/L,",
"    </span>",
"    respectively), which was present in more than one-half of the diabetic patients, was a stronger predictor of outcome than proteinuria. With multivariable analysis, an elevated serum creatinine accounted for the effect attributed to proteinuria. These findings are consistent with the observation that chronic kidney disease is associated with an increase in coronary heart disease risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of restenosis after PCI in diabetic patients may be lower if optimal glycemic control is achieved. This was suggested in a study of 239 patients, 179 with diabetes, who underwent elective PCI (67 percent with stenting) after measurement of glycosylated hemoglobin (HbA1c) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/55\">",
"     55",
"    </a>",
"    ]. Diabetic patients with a preprocedural HbA1c &le;7 percent had a rate of target vessel revascularization at 12 months that was comparable to that in nondiabetic patients (15 versus 18 percent), while diabetic patients with an HbA1c &gt;7 percent had a significantly higher rate of target vessel revascularization (34 percent).",
"   </p>",
"   <p>",
"    Data were not available concerning the effect of glycemic control after the procedure, which appears to improve the outcome after CABG. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Perioperative glycemic control'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experimental observations that the thiazolidinediones inhibit vascular smooth muscle cell proliferation and migration and reduce intimal proliferation after vascular injury provided the rationale for assessing their effect on limiting in-stent restenosis in both nondiabetic and diabetic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29081?source=see_link&amp;anchor=H9#H9\">",
"     \"Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention\", section on 'Thiazolidinediones'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential efficacy of this approach has been evaluated in two, small randomized trials in which patients with type 2 diabetes who underwent PCI with stenting were randomly assigned to either a thiazolidinedione (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    ) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In both studies, the rate of angiographic restenosis was lower in the thiazolidinedione group. Further studies are required to confirm the efficacy and safety of this approach, particularly with the use of drug-eluting stents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Glycoprotein IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors reduce the risk of ischemic complications in most patients undergoing coronary artery stenting, including those with an acute coronary syndrome and higher-risk patients with stable angina. On the other hand, in lower-risk patients undergoing elective stenting, a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor may not provide any additional benefit if the patient is pretreated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (600 mg) as shown in the ISAR-REACT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/58\">",
"     58",
"    </a>",
"    ]. The data supporting these conclusions are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H11#H11\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'GP IIb/IIIa inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In subset analyses of major trials, the indications for use and efficacy of the GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in diabetic patients undergoing stenting appear to be similar to those in patients without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/58-62\">",
"     58-62",
"    </a>",
"    ]. It has been argued that the indication is more compelling in diabetic patients, since pooled analyses or meta-analyses of trials of patients undergoing elective or urgent PCI or those with an acute coronary syndrome suggested a significant mortality benefit at 30 days and one year in the subset of patients with diabetes that was not seen or was not significant in nondiabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only one trial, ISAR-SWEET, which was published after these analyses, specifically evaluated patients with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/66\">",
"     66",
"    </a>",
"    ]. In this trial, 701 diabetic patients (29 percent insulin-dependent) who were undergoing elective PCI were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (70",
"    <span class=\"nowrap\">",
"     U/kg)",
"    </span>",
"    or placebo plus heparin (140",
"    <span class=\"nowrap\">",
"     U/kg).",
"    </span>",
"    All patients were pretreated with 600 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    at least two hours before the procedure. Patients were treated with balloon angioplasty, bare metal stents, or drug-eluting stents (10, 80, and 10 percent, respectively).",
"   </p>",
"   <p>",
"    The primary endpoint of death or MI at one year did not differ between the two groups (8.3 versus 8.6 percent with placebo); there was also no difference in mortality at one year (4.8 versus 5.1 percent). However, follow-up angiography at a median of seven months demonstrated a reduction in the rate of angiographic restenosis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    (29 versus 38 percent with placebo) and, at one year, a significantly lower rate of target lesion revascularization (23.2 versus 30.4 percent). These modest benefits need to considered in the context of other trials of abciximab with stenting that did not show a consistent antirestenotic effect in diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/59,62\">",
"     59,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUTCOMES AFTER CABG",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the rates of death and adverse nonfatal outcomes after CABG are higher in patients with diabetes compared to those without diabetes. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Outcomes compared to patients without diabetes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A variety of factors contribute to the worse prognosis. Diabetic patients who undergo CABG have a worse risk profile, tending to be older with more three-vessel disease and lower left ventricular ejection fractions than nondiabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/24,27,30,67\">",
"     24,27,30,67",
"    </a>",
"    ]. The increase in long-term mortality after CABG is in part independent of these factors due, for example, to progressive atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comorbidities of diabetes influence post-CABG survival. This was illustrated in a cohort of 36,641 patients undergoing isolated CABG between 1992 and 2001: 70 percent did not have diabetes, 22 percent had diabetes without renal failure (requiring preoperative dialysis) or vascular disease (peripheral or cerebrovascular), and 8 percent had diabetes with renal failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/68\">",
"     68",
"    </a>",
"    ]. The annual mortality rate for patients without diabetes (3.1 percent) was similar to that for patients with diabetes but no renal failure or vascular disease (4.4 percent). Patients with diabetes who had renal failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular disease had a significantly higher annual mortality rate (9.4 percent).",
"   </p>",
"   <p>",
"    Another observational study of 905 patients found, on multivariate analysis, that an elevated serum creatinine (not renal failure as in the prior study) was an independent predictor of five-year mortality (adjusted hazard ratio 1.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/69\">",
"     69",
"    </a>",
"    ]. Proteinuria was also an independent predictor of mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Internal thoracic artery grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients undergoing CABG, including those with diabetes, should receive an internal thoracic (mammary) artery (ITA), to improve survival. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link&amp;anchor=H15134962#H15134962\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Internal mammary versus saphenous vein grafts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, we prefer bilateral to single ITA grafting for many patients with diabetes based on two observational studies. This recommendation is made despite the fact that the rate of sternal wound infection may be modestly increased with bilateral compared to single ITA grafting and that diabetes may be a risk factor for the development of postoperative mediastinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=see_link&amp;anchor=H5#H5\">",
"     \"Postoperative mediastinitis after cardiac surgery\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our threshold for recommending bilateral ITA grafting is higher in older individuals. We are concerned that the survival benefit may be small for those older than 70&nbsp;to 75 years of age and that the risks might outweigh the benefits in these individuals.",
"   </p>",
"   <p>",
"    The issue of whether bilateral ITA improves outcomes compared to single ITA in patients with diabetes was evaluated in study of 1107 consecutive patients who received either a single or bilateral ITA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/72\">",
"     72",
"    </a>",
"    ]. After propensity matching, two cohorts of 414 individuals were created. There was no significant difference between the single and bilateral ITA groups in operative mortality (2.4 versus 3.1 percent, respectively), sternal wound infection (1.7 versus 3.1 percent), or total complications (17.1 percent). However, late median survival was significantly lower with single ITA grafting (9.8 versus 13.1 years). Similar improvement in long-term survival after placement of bilateral ITA among patients with diabetes was reported in another 2012 observational study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The randomized ART trial found similar survival between bilateral and single ITA grafting in the broad population of individuals undergoing CABG. Longer-term outcomes are pending. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link&amp;anchor=H13#H13\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Bilateral ITA grafts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bilateral ITA grafting has not been widely adopted by thoracic surgeons and multiple explanations have been put forth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/74\">",
"     74",
"    </a>",
"    ]. Similar to all operative procedures, it should be performed only by well trained surgical teams.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Perioperative glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among diabetic patients with an acute MI, outcomes are worse in patients with significant hyperglycemia and possibly better with intensive insulin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=see_link\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intensive glycemic control may also improve both cardiac and noncardiac outcomes in diabetic patients after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/36,75,76\">",
"     36,75,76",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    In a prospective trial, 141 patients with diabetes who were undergoing CABG were randomly assigned to tight glycemic control (125 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [6.9 to 11.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    with a glucose-insulin-potassium (GIK) infusion or standard therapy with intermittent subcutaneous insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/76\">",
"     76",
"    </a>",
"    ]. Patients treated with GIK had lower mean serum glucose concentrations in the perioperative period (138 versus 260",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [7.7 versus 14.4",
"    <span class=\"nowrap\">",
"     mg/dL]).",
"    </span>",
"    At two years, GIK patients had significantly lower rates of wound infections (1 versus 10 percent), recurrent ischemia (5 versus 19 percent), and mortality (2 versus 10 percent).",
"   </p>",
"   <p>",
"    A lower rate of wound infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/36\">",
"     36",
"    </a>",
"    ] and postoperative mediastinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/36,76\">",
"     36,76",
"    </a>",
"    ] have been found in observational studies with a continuous intravenous insulin infusion compared to conventional insulin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=see_link&amp;anchor=H11#H11\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Glycemic control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H18#H18\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Sternal wound infection and mediastinitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of strict perioperative glycemic control in heart surgery patients without diabetes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=see_link&amp;anchor=H11#H11\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PCI VERSUS CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with diabetes and multivessel or left main coronary artery disease, the evidence suggests better outcomes with CABG rather than PCI with stenting. This section will present the supporting evidence.",
"   </p>",
"   <p>",
"    Early trials comparing balloon angioplasty to CABG in patients with diabetes suggested higher rates of revascularization and mortality with the former particularly in patients with multivessel disease. Early trials of PCI with stenting, including those using drug-eluting stents (DES), showed similar survival rates but a persistent increased need for revascularization. The large FREEDOM trial published in 2012 found a lower combined rate of all-cause death, myocardial infarction, and stroke with CABG compared to stenting using DES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Balloon angioplasty versus CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous coronary intervention (PCI) is almost always performed with stenting in patients with and without diabetes to avoid the complications associated with balloon angioplasty such as",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    closure and restenosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=see_link\">",
"     \"General principles of the use of intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, prior to the routine use of stenting, some studies compared balloon angioplasty to CAGB. In the general population no difference in survival has been shown between balloon angioplasty and CABG except in patients in the subgroup of patients with multivessel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/78\">",
"     78",
"    </a>",
"    ]. Although the BARI trial and a meta-analysis (discussed below) suggested better outcomes with CABG in patients with diabetes, their current applicability is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/26,78-81\">",
"     26,78-81",
"    </a>",
"    ]. Stents, particularly drug-eluting stents, and other therapies such as glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors and platelet P2Y12 receptor blockers prior to stenting and long-term statin therapy, were not used in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Stenting versus CABG in multivessel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population of patients who require coronary revascularization, CABG is preferred to PCI with stenting in many, but not all, patients with multivessel coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence to guide the choice between stenting and CABG in patients with diabetes was limited (as is discussed below) prior to the publication of the international FREEDOM trial, which showed a clear benefit in favor of CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/77\">",
"     77",
"    </a>",
"    ]. In FREEDOM, 1900 patients with diabetes and multivessel CAD (83 percent three-vessel disease) were randomly assigned to either PCI with drug-eluting stents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ) or CABG. Both groups received optimal medical therapies for the secondary prevention of cardiovascular disease. The median follow-up among survivors was 3.8 years. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary composite outcome of death from any cause, nonfatal myocardial infarction, or nonfatal stroke occurred significantly more often in the PCI group at five years (26.6 versus 18.7 percent; absolute difference of 7.9 percent, 95% CI 3.3-12.5). The benefit from CABG existed in all SYNTAX score subgroups. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link\">",
"       \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With regard to the individual components of the composite end point, all-cause mortality and myocardial infarction were significantly higher with PCI (16.3 versus 10.9 and 13.9 versus 6.0 percent, respectively), whereas stroke occurred significantly less often (2.4 versus 5.2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At one year, there was a higher rate of repeat revascularization in the PCI group (12.6 versus 4.8 percent; hazard ratio 2.74, 95% CI 1.91-3.89).",
"   </p>",
"   <p>",
"    Very early studies evaluated outcomes in patients treated with either bare metal stents (BMS) or CABG in patients with diabetes. Subset analyses from two smaller randomized trials, ARTS-I and AWESOME, showed a higher rate of repeat revascularization with BMS. Mortality was not significantly different, but these studies were severely underpowered to assess mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/82-85\">",
"     82-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first evidence comparing drug-eluting stents (DES) to CABG was observational and suggested that DES diminished the advantage of CABG compared to PCI seen when BMS are used in diabetic patients. This hypothesis was evaluated in the ARTS II study, which was a single-arm study of 607 patients (including 159 with diabetes) who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    eluting stents; the outcomes were compared to the CABG arm in the ARTS I trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/86\">",
"     86",
"    </a>",
"    ]. At three years, the incidence of the primary combined endpoint of death, stroke, MI and repeat revascularization with DES was not significantly different from the CABG arm of ARTS I after adjustment for independent predictors (27.7 versus 17.7 percent for CABG).",
"   </p>",
"   <p>",
"    More evidence comparing DES to CABG came from the CARDia and SYNTAX trials, which came to similar conclusions. CARDia randomly assigned 510 patients with diabetes and symptomatic, multivessel, or complex single vessel CAD to either stenting (31 percent were bare metal stents) or CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/87\">",
"     87",
"    </a>",
"    ]. At a mean follow-up of one year, stenting was not found to be noninferior to CABG for the primary composite outcome of all-cause mortality, MI, and stroke (13.0 versus 10.5 percent respectively; hazard ratio 1.25, 95% CI 0.75-2.09). Repeat revascularization was significantly more frequent with DES (11.8 versus 2.0 percent). However, the strength of the observations in this study is reduced, as it was underpowered due to early termination of enrollment and limited duration of follow-up.",
"   </p>",
"   <p>",
"    In a prespecified subgroup analysis of the 452 patients with diabetes in SYNTAX, which compared CABG to DES in patients with multivessel or left main coronary artery disease, the primary outcome of major adverse cardiac and cerebrovascular events occurred significantly more often in patients treated with DES (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting stents) (26.0 versus 14.2 percent), attributable primarily to a significantly higher rate of repeat revascularization (20.3 versus 6.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/88\">",
"     88",
"    </a>",
"    ]. There was no significant difference in the composite rate of death, stroke, or MI. At three-year follow-up of patients with diabetes, the primary outcome occurred significantly more often with stenting than with CABG (37.0 versus 22.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/89\">",
"     89",
"    </a>",
"    ]. Diabetes increased the rate of the primary outcomes among DES treated patients, but had little impact on the CABG group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Post-CABG angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the optimal revascularization approach in diabetic patients with post-CABG angina. The general approach to the management of post-CABG angina is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24536?source=see_link&amp;anchor=H4#H4\">",
"     \"Late recurrent angina pectoris after coronary artery bypass graft surgery\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data are limited and patients were treated before the widespread use of standard therapies such as statins, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, coronary artery stents (only 25 percent received a stent), and improvements in surgical technique. The largest reported series consisted of over 1700 diabetic patients with prior CABG who underwent revascularization for recurrent angina with PCI (1123 patients) or CABG (598 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/90\">",
"     90",
"    </a>",
"    ]. Repeat CABG was associated with an increased incidence of in-hospital mortality (11.2 versus 1.6 percent), stroke (4.7 versus 0.1 percent), and ST elevation MI (3.2 versus 1.3 percent). Patient survival was similar in the two groups by four years and was not significantly different at 10 years (26 versus 32 percent with PCI). There was a trend toward worse outcomes with PCI in patients who also had heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24536?source=see_link&amp;anchor=H4#H4\">",
"     \"Late recurrent angina pectoris after coronary artery bypass graft surgery\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that PCI is reasonable first choice for most patients with diabetes and unacceptable angina (with appropriate anatomy). Re-CABG should be considered for patients with multigraft failure or no prior placement of a left internal thoracic artery graft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer CABG to PCI with stenting (with either bare metal or drug eluting stents) in most patients with diabetes and multivessel disease based on the results of the FREEDOM trial, as well as the consistent results from older balloon angioplasty and bare metal stent trials and the observation of better outcomes with CABG in the SYNTAX trial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"    </a>",
"    .) For patients with single or two-vessel disease, we believe that PCI is a reasonable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline for CABG made a weak recommendation to prefer CABG to PCI in patients with multivessel disease with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/91\">",
"     91",
"    </a>",
"    ]. This recommendation was made prior to the publication of the FREEDOM trial. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Stenting versus CABG in multivessel disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     IMPACT OF LATE-ONSET HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the unfavorable long-term prognosis after revascularization in diabetics has been ascribed to progressive atherosclerotic disease, plaque instability, and a higher restenosis rate, progressive heart failure may be another factor. This was illustrated in a report of 363 patients who were followed for 13 years after balloon angioplasty or CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/92\">",
"     92",
"    </a>",
"    ]. The cumulative incidence of hospitalizations for heart failure was higher in diabetics (25 versus 11 percent for nondiabetics), with a rapidly increasing incidence after five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/92\">",
"     92",
"    </a>",
"    ]. Both long-term survival (43 versus 78 percent) and survival free of heart failure (33 versus 71 percent) were reduced in patients with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28569?source=see_link\">",
"     \"Heart failure in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     STRATEGIES TO IMPROVE OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the procedure chosen, all patients with diabetes and coronary artery disease should be treated with aggressive risk factor reduction including blood pressure control, statin therapy, exercise, and smoking cessation when indicated. In addition, as mentioned above, strict glycemic control (HbA1c &le;7 percent) may lower the rate of target vessel revascularization after PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/55,93\">",
"     55,93",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Glycemic control'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The multiple benefits associated with multifactorial risk factor reduction were demonstrated in the Steno-2 trial. The details of the protocol and overall results of this study are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Multifactorial risk factor reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those patients undergoing CABG, maintenance of strict glycemic control (serum glucose &lt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    with a continuous insulin infusion during the perioperative period is useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In addition to improving cardiac outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], a continuous insulin infusion also may reduce the rate of postoperative mediastinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Perioperative glycemic control'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, the use of arterial conduits, preferably internal thoracic grafts, particularly to anastomoses to the left anterior descending artery are advantageous. As noted above, the improved outcomes with CABG in BARI were only seen in patients receiving at least one internal thoracic graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/15/30970/abstract/26\">",
"     26",
"    </a>",
"    ]. Long-term internal thoracic artery graft patency may contribute to this benefit by reducing the mortality from late myocardial infarctions by providing a better alternative source of perfusion in hypoperfused areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outcomes after revascularization are generally worse in patients with diabetes than those without. However, the approach to revascularization is for the most part similar, including a preference for medical therapy to revascularization therapy unless it will improve survival or lessen unacceptable symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link\">",
"       \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical therapy versus revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with diabetes and stable angina that is not significantly interfering with the quality of life and who do not have silent myocardial ischemia involving at least a moderate sized territory or an indication for revascularization associated with mortality benefit, we suggest intensive medical therapy as initial strategy rather than immediate revascularization (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical therapy versus revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with multivessel disease with a proximal LAD lesion &ge;70 percent, we recommend CABG rather than PCI (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link\">",
"       \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H24\">",
"       'PCI versus CABG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with diabetes undergoing CABG, we suggest placement of bilateral, rather than single, internal thoracic artery (ITA) grafts (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It is reasonable to not perform bilateral ITA grafting in individuals older than 70 to 75 years, as the survival benefit from bilateral ITA may be small in older individuals. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Internal thoracic artery grafts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For diabetic patients with recurrence of unacceptable angina after CABG, we suggest repeat revascularization with PCI for appropriate lesions (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Post-CABG angina'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Irrespective of the method of revascularization chosen, all patients should receive non-revascularization therapies known to be associated with better outcomes in patients with diabetes and coronary artery disease. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Strategies to improve outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/1\">",
"      Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 2000; 36:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/2\">",
"      Boden WE, Taggart DP. Diabetes with coronary disease--a moving target amid evolving therapies? N Engl J Med 2009; 360:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/3\">",
"      BARI 2D Study Group, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/4\">",
"      Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009; 120:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/5\">",
"      Brooks MM, Chaitman BR, Nesto RW, et al. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 2012; 126:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/6\">",
"      Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/7\">",
"      Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/8\">",
"      Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996; 94:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/9\">",
"      Suero JA, Marso SP, Jones PG, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol 2001; 38:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/10\">",
"      Mehran R, Dangas GD, Kobayashi Y, et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 2004; 43:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/11\">",
"      Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/12\">",
"      Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997; 96:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/13\">",
"      Rensing BJ, Hermans WR, Vos J, et al. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group. Circulation 1993; 88:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/14\">",
"      West NE, Ruygrok PN, Disco CM, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004; 109:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/15\">",
"      Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993; 118:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/16\">",
"      Schofer J, Schl&uuml;ter M, Rau T, et al. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol 2000; 35:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/17\">",
"      Tada T, Kimura T, Morimoto T, et al. Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulin-treated diabetic, and non-diabetic patients from j-Cypher registry. Am J Cardiol 2011; 107:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/18\">",
"      Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997; 95:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/19\">",
"      Moreno PR, Fallon JT, Murcia AM, et al. Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients. J Am Coll Cardiol 1999; 34:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/20\">",
"      Ahmed JM, Hong MK, Mehran R, et al. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. J Am Coll Cardiol 2000; 36:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/21\">",
"      Mick MJ, Piedmonte MR, Arnold AM, Simpfendorfer C. Risk stratification for long-term outcome after elective coronary angioplasty: a multivariate analysis of 5,000 patients. J Am Coll Cardiol 1994; 24:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/22\">",
"      Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/23\">",
"      Salomon NW, Page US, Okies JE, et al. Diabetes mellitus and coronary artery bypass. Short-term risk and long-term prognosis. J Thorac Cardiovasc Surg 1983; 85:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/24\">",
"      Higgins TL, Estafanous FG, Loop FD, et al. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. JAMA 1992; 267:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/25\">",
"      Whang W, Bigger JT Jr. Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from The CABG Patch Trial database. The CABG Patch Trial Investigators and Coordinators. J Am Coll Cardiol 2000; 36:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/26\">",
"      Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997; 96:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/27\">",
"      Morris JJ, Smith LR, Jones RH, et al. Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation 1991; 84:III275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/28\">",
"      Lawrie GM, Morris GC Jr, Glaeser DH. Influence of diabetes mellitus on the results of coronary bypass surgery. Follow-up of 212 diabetic patients ten to 15 years after surgery. JAMA 1986; 256:2967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/29\">",
"      Smith LR, Harrell FE Jr, Rankin JS, et al. Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery. Circulation 1991; 84:III245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/30\">",
"      Cohen Y, Raz I, Merin G, Mozes B. Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Am J Cardiol 1998; 81:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/31\">",
"      Thourani VH, Weintraub WS, Stein B, et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999; 67:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/32\">",
"      DeBakey ME, Glaeser DH. Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up. Am J Cardiol 2000; 85:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/33\">",
"      Sprecher DL, Pearce GL. How deadly is the \"deadly quartet\"? A post-CABG evaluation. J Am Coll Cardiol 2000; 36:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/34\">",
"      Barzilay JI, Kronmal RA, Bittner V, et al. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged &gt; or = 65 years (report from the Coronary Artery Surgery Study [CASS] Registry). Am J Cardiol 1994; 74:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/35\">",
"      Borger MA, Rao V, Weisel RD, et al. Deep sternal wound infection: risk factors and outcomes. Ann Thorac Surg 1998; 65:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/36\">",
"      Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/37\">",
"      Peterson MD, Borger MA, Rao V, et al. Skeletonization of bilateral internal thoracic artery grafts lowers the risk of sternal infection in patients with diabetes. J Thorac Cardiovasc Surg 2003; 126:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/38\">",
"      Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol 1993; 22:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/39\">",
"      Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol 2011; 57:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/40\">",
"      Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/41\">",
"      Baumgart D, Klauss V, Baer F, et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol 2007; 50:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/42\">",
"      Jim&eacute;nez-Quevedo P, Sabat&eacute; M, Angiolillo DJ, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007; 28:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/43\">",
"      Kirtane AJ, Ellis SG, Dawkins KD, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 2008; 51:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/44\">",
"      Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008; 337:a1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/45\">",
"      Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/46\">",
"      Sabat&eacute; M, Jim&eacute;nez-Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005; 112:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/47\">",
"      Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/48\">",
"      Mahmud E, Bromberg-Marin G, Palakodeti V, et al. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol 2008; 51:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/49\">",
"      Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol 2008; 52:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/50\">",
"      Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial. JACC Cardiovasc Interv 2011; 4:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/51\">",
"      Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/52\">",
"      Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 2012; 345:e5170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/53\">",
"      Marso SP, Ellis SG, Tuzcu M, et al. The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. J Am Coll Cardiol 1999; 33:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/54\">",
"      Reeder GS, Holmes DR, Lennon RJ, et al. Proteinuria, serum creatinine, and outcome of percutaneous coronary intervention in patients with diabetes mellitus. Am J Cardiol 2002; 89:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/55\">",
"      Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/56\">",
"      Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006; 29:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/57\">",
"      Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/58\">",
"      Kastrati A, Mehilli J, Sch&uuml;hlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/59\">",
"      Sch&ouml;mig A, Schmitt C, Dibra A, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J 2005; 26:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/60\">",
"      Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/61\">",
"      Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 1999; 100:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/62\">",
"      O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002; 287:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/63\">",
"      Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/64\">",
"      Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/65\">",
"      Lincoff AM. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation 2003; 107:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/66\">",
"      Mehilli J, Kastrati A, Sch&uuml;hlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110:3627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/67\">",
"      Adler DS, Goldman L, O'Neil A, et al. Long-term survival of more than 2,000 patients after coronary artery bypass grafting. Am J Cardiol 1986; 58:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/68\">",
"      Leavitt BJ, Sheppard L, Maloney C, et al. Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery. Circulation 2004; 110:II41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/69\">",
"      Marso SP, Ellis SG, Gurm HS, et al. Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. Am Heart J 2000; 139:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/70\">",
"      Momin AU, Deshpande R, Potts J, et al. Incidence of sternal infection in diabetic patients undergoing bilateral internal thoracic artery grafting. Ann Thorac Surg 2005; 80:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/71\">",
"      Agrifoglio M, Trezzi M, Barili F, et al. Double vs single internal thoracic artery harvesting in diabetic patients: role in perioperative infection rate. J Cardiothorac Surg 2008; 3:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/72\">",
"      Dorman MJ, Kurlansky PA, Traad EA, et al. Bilateral internal mammary artery grafting enhances survival in diabetic patients: a 30-year follow-up of propensity score-matched cohorts. Circulation 2012; 126:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/73\">",
"      Puskas JD, Sadiq A, Vassiliades TA, et al. Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients. Ann Thorac Surg 2012; 94:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/74\">",
"      Puskas JD. Why did you not use both internal thoracic arteries? Circulation 2012; 126:2915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/75\">",
"      Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/76\">",
"      Lazar HL, Chipkin SR, Fitzgerald CA, et al. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004; 109:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/77\">",
"      Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/78\">",
"      Hoffman SN, TenBrook JA, Wolf MP, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 2003; 41:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/79\">",
"      Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996; 335:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/80\">",
"      Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000; 35:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/81\">",
"      BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 2007; 49:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/82\">",
"      Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/83\">",
"      Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001; 104:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/84\">",
"      Legrand VM, Serruys PW, Unger F, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004; 109:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/85\">",
"      Sedlis SP, Morrison DA, Lorin JD, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol 2002; 40:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/86\">",
"      Daemen J, Kuck KH, Macaya C, et al. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. J Am Coll Cardiol 2008; 52:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/87\">",
"      Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010; 55:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/88\">",
"      Banning AP, Westaby S, Morice MC, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010; 55:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/89\">",
"      Mack MJ, Banning AP, Serruys PW, et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg 2011; 92:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/90\">",
"      Cole JH, Jones EL, Craver JM, et al. Outcomes of repeat revascularization in diabetic patients with prior coronary surgery. J Am Coll Cardiol 2002; 40:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/91\">",
"      Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/92\">",
"      Halon DA, Merdler A, Flugelman MY, et al. Late-onset heart failure as a mechanism for adverse long-term outcome in diabetic patients undergoing revascularization (a 13-year report from the Lady Davis Carmel Medical Center registry). Am J Cardiol 2000; 85:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/15/30970/abstract/93\">",
"      Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005; 293:1501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1581 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30970=[""].join("\n");
var outline_f30_15_30970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL THERAPY VERSUS REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OUTCOMES COMPARED TO PATIENTS WITHOUT DIABETES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      With PCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Restenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Event-free survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      With CABG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Nonfatal adverse events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OUTCOMES AFTER PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Stent type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diabetes-related factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nephropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Glycoprotein IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUTCOMES AFTER CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Internal thoracic artery grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Perioperative glycemic control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PCI VERSUS CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Balloon angioplasty versus CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Stenting versus CABG in multivessel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Post-CABG angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      IMPACT OF LATE-ONSET HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      STRATEGIES TO IMPROVE OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1581\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1581|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/29/32221\" title=\"figure 1\">",
"      Survival stenting in diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1581|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/39/11901\" title=\"table 1\">",
"      Coronary artery stents approved in the United States",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=related_link\">",
"      Comparison of drug-eluting intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=related_link\">",
"      Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24536?source=related_link\">",
"      Late recurrent angina pectoris after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4426?source=related_link\">",
"      Management of left main coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29081?source=related_link\">",
"      Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39609?source=related_link\">",
"      Systematic review and meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_15_30971="TEE in chronic MR";
var content_f30_15_30971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Transesophageal echocardiography (TEE) in patients with chronic mitral regurgitation (MR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that TEE is indicated in patients with chronic MR in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; If transthoracic echocardiography does not provide diagnostic information about left ventricular function and/or the severity or mechanism of MR.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; When surgery is recommended, before or during surgery to establish the anatomic basis for severe MR to assess the feasibility of and guide mitral valve repair.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of TEE in patients with chronic MR in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; In asymptomatic patients with severe MR who are considered for surgery, before surgery to assess the feasibility of mitral valve repair.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that TEE is not useful in patients with chronic MR in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Routine follow-up of patients with asymptomatic MR in a native valve.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30971=[""].join("\n");
var outline_f30_15_30971=null;
var title_f30_15_30972="Indications for upper gastrointestinal endoscopy";
var content_f30_15_30972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for upper gastrointestinal endoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Signs/symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper abdominal symptoms that fulfill any of the following criteria:",
"        <br/>",
"        <ul>",
"         <li>",
"          Are unresponsive to empiric therapy",
"         </li>",
"         <li>",
"          Are associated with alarm symptoms",
"         </li>",
"         <li>",
"          Occur in a patient greater than 45 years of age",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysphagia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Odynophagia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent or recurrent esophageal reflux despite therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active or recent upper GI bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presumed chronic blood loss and iron deficiency anemia if any of the following are present:",
"        <br/>",
"        <ul>",
"         <li>",
"          There is clinical suspicion of an upper GI source",
"         </li>",
"         <li>",
"          Colonoscopy is negative",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lesion seen on upper GI tract imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute caustic ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Screening/surveillance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysplasia surveillance in patients with Barrett's esophagus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric cancer screening in selected patients*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screening for upper GI malignancies in patients with polyposis syndromes or Lynch syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screening for esophageal varices in patients with portal hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screening for squamous cell carcinoma in patients with a history of caustic ingestions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Therapeutic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment of bleeding upper GI tract lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prophylactic variceal banding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Removal of foreign bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placement of feeding or drainage tubes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Removal of selected polypoid lesions*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilation of stenotic lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Management of achalasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palliation of&nbsp;stenoses due to neoplasms",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GI: gastrointestinal.",
"     <br>",
"      * See text for details.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data for table collected from: Appropriate use of gastrointestinal endoscopy. Gastrointest Endosc 2000; 52:831.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30972=[""].join("\n");
var outline_f30_15_30972=null;
var title_f30_15_30973="Muscles of the posterior compartment of the forearm";
var content_f30_15_30973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Muscles of the posterior compartment of the forearm",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Muscle",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proximal attachment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Distal attachment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Innervation*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Superficial layer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brachioradialis",
"       </td>",
"       <td>",
"        Proximal two thirds of supraepicondylar ridge of humerus",
"       </td>",
"       <td>",
"        Lateral surface of distal end of radius proximal to styloid process",
"       </td>",
"       <td>",
"        Radial nerve (C5,",
"        <strong>",
"         C6",
"        </strong>",
"        , C7)",
"       </td>",
"       <td>",
"        Relatively week flexion of forearm, maximal when forearm is in midpronated position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extensor carpi radialis longus (ECRL)",
"       </td>",
"       <td>",
"        Lateral supraepicondylar ridge of humerus",
"       </td>",
"       <td>",
"        Dorsal aspect of base of 2nd metacarpal",
"       </td>",
"       <td>",
"        Radial nerve (C6, C7)",
"       </td>",
"       <td rowspan=\"2\">",
"        Extend and abduct hand at the wrist joint; ECRL active during fist clenching",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extensor carpi radialis brevis (ECRB)",
"       </td>",
"       <td rowspan=\"3\">",
"        Lateral epicondyle of humerus (common extensor origin)",
"       </td>",
"       <td>",
"        Doral aspect of base of 3rd metacarpal",
"       </td>",
"       <td>",
"        Deep branch of radial nerve (",
"        <strong>",
"         C7",
"        </strong>",
"        , C8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extensor digitorum",
"       </td>",
"       <td>",
"        Extensor expansions of medial four fingers",
"       </td>",
"       <td rowspan=\"3\">",
"        Posterior interosseous nerve (",
"        <strong>",
"         C7",
"        </strong>",
"        , C8), continuation of deep branch of radial nerve",
"       </td>",
"       <td>",
"        Extends medial four fingers primarily at metacarpophalangeal joints, secondarily at interphalangeal joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extensor digiti minimi (EDM)",
"       </td>",
"       <td>",
"        Extensor expansion of 5th finger",
"       </td>",
"       <td>",
"        Extends 5th finger primarily at metacarpophalangeal joint, secondarily at interphalangeal joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extensor carpi ulnaris (ECU)",
"       </td>",
"       <td>",
"        Lateral epicondyle of humerus; posterior border of ulna via a shared aponeurosis",
"       </td>",
"       <td>",
"        Dorsal aspect of base of 5th metacarpal",
"       </td>",
"       <td>",
"        Extends and adducts hand at wrist joint (also active during fist clenching)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Deep layer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Supinator",
"       </td>",
"       <td>",
"        Lateral epicondyle of humerus; radial collateral and anular ligaments; supinator fossa; crest of ulna",
"       </td>",
"       <td>",
"        Lateral posterior, and anterior surfaces of proximal third of radius",
"       </td>",
"       <td>",
"        Deep branch of radial nerve (C7,",
"        <strong>",
"         C8",
"        </strong>",
"        )",
"       </td>",
"       <td>",
"        Supinates forearm; rotates radius to turn palm anteriorly or superiorly (if elbow is flexed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extensor indicis",
"       </td>",
"       <td>",
"        Posterior surface of distal third of ulna and interosseous membrane",
"       </td>",
"       <td>",
"        Extensor expansion of 2nd finger",
"       </td>",
"       <td>",
"        Posterior interosseous nerve (C7,",
"        <strong>",
"         C8",
"        </strong>",
"        ), continuation of deep branch of radial nerve",
"       </td>",
"       <td>",
"        Extends 2nd finger (enabling its independent extension); helps extend hand at wrist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Outcropping muscles of deep layer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abductor pollicis longus (APL)",
"       </td>",
"       <td>",
"        Posterior surface of proximal halves of ulna, radius, and interosseous membrane",
"       </td>",
"       <td>",
"        Base of 1st metacarpal",
"       </td>",
"       <td rowspan=\"3\">",
"        Posterior interosseous nerve (C7,",
"        <strong>",
"         C8",
"        </strong>",
"        ), continuation of deep branch of radial nerve",
"       </td>",
"       <td>",
"        Abducts thumb and extends it at carpometacarpal joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extensor pollicis longus (EPL)",
"       </td>",
"       <td>",
"        Posterior surface of middle third of ulna and interosseous membrane",
"       </td>",
"       <td>",
"        Dorsal aspect of base of distal phalanx of thumb",
"       </td>",
"       <td>",
"        Extends distal phalanx of thumb at interphalangeal joint; extends metacarpophalangeal and carpometacarpal joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extensor pollicis brevis (EPB)",
"       </td>",
"       <td>",
"        Posterior surface of distal third of radius and interosseous membrane",
"       </td>",
"       <td>",
"        Dorsal aspect of base of proximal phalanx of thumb",
"       </td>",
"       <td>",
"        Extends proximal phalanx of thumb at metacarpophalangeal joint; extends carpometacarpal joint",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The spinal cord segmental innervation is indicated (eg, \"",
"     <strong>",
"      C7",
"     </strong>",
"     , C8\" means that the nerves supplying the extensor carpi radialis brevis are derived from the seventh and eighth cervical segments of the spinal cord). Numbers in boldface (",
"     <strong>",
"      C7",
"     </strong>",
"     ) indicate the main segmental innervation. Damage to one or more of the listed spinal cord segments or to the motor nerve roots arising from them results in paralysis of the muscles concerned.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30973=[""].join("\n");
var outline_f30_15_30973=null;
var title_f30_15_30974="Food impaction CPC Endosc";
var content_f30_15_30974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Food impaction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the distal esophagus showing a round food bolus, which was successfully extracted using a basket and an overtube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Helen M. Shields, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30974=[""].join("\n");
var outline_f30_15_30974=null;
var title_f30_15_30975="Typical carcinoid CXR";
var content_f30_15_30975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Typical carcinoid radiographic imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Posterior-anterior (PA) chest radiograph demonstrating a nodular opacity (white arrow) in the right middle lobe with volume loss on the right. The nodule is better visualized on the axial CT image of the chest (Panel B) just below the level of the carina (black arrow). At surgical resection the nodule proved to be a typical carcinoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles F Thomas, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_15_30975=[""].join("\n");
var outline_f30_15_30975=null;
